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ABSTRACT
Objective: The purpose of this study was to investigate the effects of two different prophylactic
behavioral swallowing exercise regimens performed by head and neck cancer/s (HNC) patients
during radiation therapy with/without chemotherapy (RT/C) on swallowing physiology, function,
quality-of-life (QOL) and weight outcomes at the completion of RT/C. Feeding tube (PEG)
status at 3 months post-treatment was also compared.
Methods: This study was conducted via a prospective design. 50 patients diagnosed with HNC
who were to undergo RT/C were recruited at pre-treatment based on the inclusion criteria:
functional swallowing abilities; without prophylactic PEG tubes; ability to comprehend and
perform therapy tasks and signed informed consent. Patients were assigned to the exercise group
(EX: n=26) or repetitive swallow group (SW: n=24), by alternate assignment as well as matching
for age, tumor site and stage. A no treatment group (NTx) of patients (n=23) was recruited
retrospectively from co-facilities during identical timelines as the prospective cohort. The EX
and SW treatment groups attended therapy sessions once a week and completed two different
intensive exercise regimens throughout RT with maintenance of a daily home program.
Outcome measures: All patients in the EX and SW treatment groups, underwent pre and posttreatment MBS studies. The following outcomes were reported: physiological (aspiration and
Penetration Aspiration Scale scores); functional (PEG tube dependence and Functional Oral
Intake Scale scores); QOL (MD Anderson Dysphagia Inventory Scale scores) and weight loss. At
3 months post-treatment, PEG tube dependence was assessed and compared. PEG tube
dependence and weight loss in patients in the treatment and no treatment groups were compared
at post-treatment and 3 months post-treatment.
Results: The EX and SW groups did not statistically significantly differ on any outcomes at posttreatment. The NTx group also did not differ from the EX and SW groups in terms of PEG tube
xiv

dependence and weight loss at post-treatment. However, the EX group exhibited a significantly
higher rate of PEG tube elimination than the SW group at 3 months post-treatment (i.e. 16% vs.
50%). Among patients who received both radiation and chemotherapy, patients in the EX group
exhibited significantly lower PEG tube dependence rates at post-treatment and 3 months posttreatment, compared to the SW and NTx groups. The EX group‟s post-treatment aspiration (i.e.
18%) and PEG tube dependence (16%) rates at 3 months post-treatment were among the lowest
reported in the literature.
Conclusions: Performing swallowing exercises prophylactically, resulted in significantly
improved rates of PEG tube elimination and oral intake abilities. Findings indicated substantial
benefits of the EX group‟s exercise regimen, encouraging its utility in the clinical setting.
Although statistically non-significant, the SW group exhibited better outcomes than no therapy,
warranting future investigations to explore the benefits of the SW exercise regimen.

xv

CHAPTER 1: INTRODUCTION
1.1. Statement of the Problem
The last two decades have led to a dramatic alteration in the treatment of head and neck
cancers (HNC). Landmark studies such as the VA study (i.e. Veteran‟s Administration)
the RTOG-9111 (i.e. Radiation Therapy Oncology Group)

3

1, 2

and

among many others have altered

head and neck oncologists‟ opinions of the management of HNC. Chemotherapy (ChT) and
radiation therapy (RT) as concomitant therapies, have become the standard of care for even the
most advanced stage tumors in the head and neck. While these changes have demonstrated
significant advantages in patient survival and organ-preservation, their impact on function and
quality-of-life (QOL) measures were initially not sufficiently monitored. Recognition of
significantly detrimental functional impairments on voice and particularly swallowing, have not
gone unnoticed

4-12

and a subsequent interest in QOL assessment both from voice and

swallowing function standpoints has emerged in the field.
Literature findings suggest that dysphagia may develop as a primary complication of
head and neck tumors itself

13-18

or as a result of surgical and non-surgical interventions.

14, 19-26

Serious complications resulting from dysphagia include aspiration pneumonia, malnutrition and
impaired QOL.

27, 28

Dysphagia rates at one year following radiation therapy with/without

chemotherapy (RT/C) a have been recognized to range from 15%

29

to 100%

9

with frequent

reports of significant long-term silent aspiration 8, 30-33 up to 44%. 8 Wide ranges in these reports
are indicative of methodological differences between studies.

14

Studies have reported the need

for alternative modalities of feeding during and after the completion of cancer treatments, to
support maintenance of nutrition and hydration statuses.
a

34

Rieger, Zalmanowitz and Wolfaardt

Throughout this document, the abbreviation RT/C will indicate radiation therapy with/without chemotherapy, as
this is common practice. Wherever a differentiation is required, RT will indicate radiation therapy and ChT will
indicate chemotherapy.

1

(2006) 35 conducted a review of the literature and reported evidence of feeding tube dependence
(percutaneous endoscopic gastrostomy/ PEG tube) of 61% during RT/C;
post-treatment;

37

50% at five months;

38

20%

39, 40

to 60%

41

36

86% at four months

at one year and 8% to 18% long-

term dependence in surviving patients. 36, 37, 40, 42-44 In a recent review of the literature, Locher et
al., (2011)

45

have reported PEG tube dependence rates of 4% to 18.7% before the initiation of

RT/C, 29.6% to 40.8% during treatment, 18% at one month, 40% to 45% at three months, 9% to
36% at six months and 8% to 60% at 12 months post-RT/C.

32, 40, 41, 44, 46-51

QOL impairments

related to PEG tube placements have been described in the literature previously.52-63 In addition,
diet restrictions and social dining difficulties have also been reported as negatively impacting
patients‟ QOL post-cancer treatments.

20, 38-40, 42, 46, 64-70

At least 10% weight loss post-RT/C is

typically reported in the literature, 44 increasing patients‟ risk of dehydration and malnutrition.
Biomechanical and functional swallowing impairments resulting from RT are known to
be related to short-term toxicities including but not limited to significant inflammation, edema,
erythema and long-term tissue fibrosis, which is characterized by scar-tissue formation within
irradiated structures.

24

Although, it has been reported that induction ChT alone, may not affect

swallowing physiology or function in patients with HNC,

71

its pathophysiological impacts on

impairing salivary function, resulting in the development of painful oral mucositis is well known.
72

Since HNC are almost never treated using ChT alone, except for palliative treatment, most all

studies describe the effects of combined RT/C on swallowing changes. 71
Speech-language pathologist/s (SLP) perform the critical role of assessing and managing
cancer treatment-induced dysphagia.

24, 28

The primary goals of dysphagia treatment and

management are to maintain efficient and safe swallowing function and to prevent aspiration.

14

Several postural strategies, 73, 74 bolus volume and consistency modifications 75 and rehabilitation
exercises

76-82

are employed by SLPs to alter patients‟ physiology of swallowing to reduce or
2

eliminate the risk of aspiration and maintain safe swallow function.

14

Pauloski (2008) has

reviewed currently employed behavioral swallowing therapy procedures including postural
strategies, swallow maneuvers, bolus size and consistency modifications and exercises in
managing dysphagia following treatment of HNC, along with their impact on patients‟
swallowing outcomes. 83 Medical treatments mainly for the management of proximal esophageal
strictures,

84

have also been successfully employed more commonly to reduce or eliminate

oropharyngeal and/or pharyngoesophageal swallowing impairments in this patient population.
Additionally, advances in radiation-oncology treatment techniques, such as the introduction of
intensity-modulated radiotherapy (IMRT) have offered the potential to spare anatomical
structures involved in swallowing, while continuing to treat tumors effectively.

85

Currently,

most clinicians and centers typically treat dysphagia at the completion of RT/C (i.e. reactively),
if and when patients present with swallowing difficulties.24 While the positive impacts of such
swallowing therapy on patients‟ swallowing physiology, function and QOL are evident clinically
and supported by SLPs and Oncologists, there is much paucity of objective data in the literature
to support these benefits.

14

Hence, standardized behavioral dysphagia care protocols to be

generalized to clinical practice, are currently not available. Emerging literature continues to
focus on fully delineating standardized treatments in terms of establishing the most optimal
exercises, their frequency and intensity and the timing of onset of therapy, to optimize the return
of function in this challenging patient population. 14, 83
Recent advances in the understanding of radiation fibrosis and the application of exercise
physiology to the reintegration of radiated tissue have further resulted in the conceptualization of
a highly aggressive approach to swallowing rehabilitation in patients with HNC. Proactive or
prophylactic swallowing therapy, which is essentially introduced with an intention of potentially
preventing or minimizing the known post-treatment swallowing impairments, has been one of
3

the most vital changes introduced to patients‟ therapeutic regimens. Few studies have
demonstrated significant benefits of prophylactic swallowing therapy in swallowing physiology,
function, QOL and weight outcomes.

86-92

Although evident, literature elaborating on these

benefits is sparse and hence a standardized exercise program with a recommended intensity and
frequency schedule of the most optimal exercises, is not available at this time. Systematic
observations of the effects of swallow maneuvers on healthy and disordered swallowing, have
laid the impetus for many of the swallowing strategies and exercises that are currently employed
routinely in the management of dysphagia, post-RT/C. Advances in the understanding of the
roles of neural plasticity and exercise physiology in the establishment of evidence-based,
effective treatment protocols, have led researchers to further evaluate the adherence of
swallowing strategies and maneuvers to the principles of neural plasticity and exercise
physiology.

93

Complex dysphagia exercises have been introduced with the assumption of their

superiority over the target activity of swallowing behavior itself, in impacting muscle structure
and function. It is clinically known that patients undergoing RT/C for HNC often suffer
treatment toxicities, negatively impacting oral intake and causing a sharp reduction in the use of
swallowing muscles. Prolonged lack of swallowing may potentially cause atrophy in the muscles
of swallowing.

85, 94-97

Although the importance of continuing to swallowing through RT/C has

been acknowledged in the literature, no study has systematically evaluated the relative
advantages of performing intensive, complex swallowing exercises over encouraging patients to
perform simple, yet intensive repetitive swallows as the therapeutic task itself, on swallowing
outcomes. The strenuous nature of behavioral swallowing exercises may be considered
challenging to the swallowing muscles undergoing RT/C, beyond the already occurring side
effects of cancer treatment, evidently reducing patient-compliance with exercises. Given, the
simplicity and saliency of „repetitive swallowing‟ over performing relatively complicated
4

exercises in achieving the desired goal of safe swallowing, this area deserves much research.
Therefore, based on the current understanding of the available literature on prophylactic
behavioral swallowing rehabilitation in the HNC patient population, this study aims to
investigate:
Primary Research Questions
 If performing intensive evidence-based „behavioral swallowing exercises‟ during radiation
therapy with or without chemotherapy (RT/C) will result in better post-treatment swallowing
physiology, function, quality-of-life (QOL) and weight outcomes than performing an intensive
number of „swallows‟ as the therapeutic task.
 If behavioral dysphagia therapy when initiated during RT/C, will reduce the number of reactive
PEG tube placements in the HNC patient population, compared to that in patients who received
no behavioral dysphagia therapy (NTx)
 If physiological swallowing alterations will directly influence alterations in swallowing function,
quality-of-life (QOL) and weight, post-RT/C.
 If patient demographics, tumor characteristics or cancer-treatment related characteristics affect
aspiration and PEG tube dependence outcomes in the treatment group of patients.
Secondary Research Questions
 How the severity of radiation toxicities including xerostomia, mucositis, pain, odynophagia,
nausea/vomiting, dysgeusia, trismus and reduced appetite progress through RT/C
 How the severity of dysphagia symptoms including choking with solids and liquids, nasal/ oral
regurgitation, reflux, difficulty initiating a swallow, globus sensation, foods sticking in the
throat, gagging, NPO status, hoarseness and wet/gurgly voice quality progress through RT/C
 Patient-compliance with the exercise regimens.

5

1.2. Research Hypotheses
The research hypotheses of this study, based on previous literature findings are:
1. The „behavioral swallowing exercise (EX)‟ treatment group will exhibit significantly better
swallowing outcomes post-RT/C than the „repetitive swallowing (SW)‟ treatment group in
terms of,
a) Physiological outcomes determined by aspiration and Penetration Aspiration Scale
(PAS) scores
b) Functional outcomes determined by PEG tube dependence and Functional Oral Intake
Scale (FOIS) scores
c) Quality-of-life (QOL) outcomes determined by the MD Anderson Dysphagia Inventory
(MDADI) scores
d) Weight outcomes determined by weight loss post-RT/C
2. Swallowing intervention during RT/C will result in a significant reduction in PEG tube
dependence when compared to a No Treatment (NTx) group.
3. Severity of physiological outcomes (aspiration and PAS scores) will correlate with severity
of functional outcomes (FOIS scores and PEG dependence), QOL outcomes (MDADI
scores) and weight outcomes (weight loss) post- RT/C.

6

CHAPTER 2: LITERATURE REVIEW
Advances in the understanding of the pathophysiological changes occurring in tissuestructure post-RT/C, have led to a new prophylactic perspective to swallowing rehabilitation in
patients with HNC. The foundation of this new perspective continues to be guided by evidence
on the known impacts of several behavioral interventions on healthy and disordered swallowing
outcomes. The principles of neural plasticity and exercise physiology have gained increased
importance in current research undertaking the establishment of a therapeutic standard of care in
patients with HNC. This chapter elaborates the available literature in each of these areas, vital to
the current investigation.
2.1. Pathophysiological Impacts of Radiation Therapy with/without Chemotherapy (RT/C)
on Structures of the Swallowing Mechanism
Radiation affects body cells through a small number of events, sometimes only one
event.98 Cells that are mainly affected are those that replicate or reproduce. It has been
established that the DNA (DeoxyriboNucleic Acid) is the radiosensitive component within cells,
as it has the ability to replicate cell function. When exposed to ionizing radiations, DNA
molecules physically break into two and its bases on both complementary strands are destroyed.
This breakage or base-loss interferes with the continuity of the existence of DNA.

98

DNA

damage occurs in both diseased as well as healthy tissues with subsequent apoptosis or mitotic
cell death.

99

Along with damaging DNA, radiation promotes several mechanisms in the body

including inflammation, epithelial regeneration, activation of the coagulation system and remodeling of tissues, which is caused by the interaction of cytokines, chemokines and growth
factors.

99

Thus, the mechanisms of radiation-induced tissue injury begins with apoptosis of the

cells in the endothelium, which in turn increases endothelium permeability and results in the
attraction of adhesion molecules and chemokines. This causes reduced fibrinolysis, increased
tissue factor and con Willebrand factor, reduced prostacyclin and thrombomodulin and
7

eventually reduced thrombi-resistance of blood vessels.

99

Subsequently increased vascular

permeability causes an increase in tissue factor and thrombin formation intravascularly and also
in the extracellular matrix and perivascular areas. Thrombin accumulation in the intravascular
and perivascular areas is what causes continued increase in fibrotic sclerosis of tissues and is
termed as radiation fibrosis. 99 Radiation fibrosis can occur in all tissues including skin, muscle,
ligament, tendon, nerve, viscera and bone.

100

Radiation fibrosis induced in the swallowing

musculature after exposure during the treatment of HNCs, is a known clinical complication. It
may occur from early on during treatment to several years after treatment and is described as an
irreversible phenomenon.

101

As blood vessels in tissues are exposed to radiation, fibrosis

continues; it changes muscle fibers to connective tissue and this process may continue to occur
for years.

82

A more serious form of long-term radiation fibrosis is osteoradionecrosis, which is

essentially permanent damage to bone and vessels from exposure to radiation.

102

Progressive

osteoradionecrosis can lead to severe pain or even fractures, requiring jaw resection.

102

From

the swallowing perspective, radiation fibrosis interferes with the smooth transit of food and
liquid boluses, causing clinically life-threatening aspiration of foods and liquids before, during
and/or after swallowing, often silent in nature. 24, 103
Chemotherapy (ChT), which is typically used in combination with radiation therapy
(RT), is associated with additional reduction in salivary gland function. Induction-ChT alone has
been found to not cause any impairment in oropharyngeal swallowing efficiency or speech
intelligibility.

71

However, its impact on altered salivary function may have significant negative

bearings on patients‟ abilities to swallow. Chemotherapeutic agents adversely affect cells with
high turnover rates, such as the epithelium within the oral cavity.

102

Oral mucositis, along with

saliva underproduction and taste dysfunction induced by ChT is reportedly much more
aggressive than that resulting from RT.

102, 104

Oral ulcerations may occur due to direct cellular
8

cytotoxicity from chemotherapeutic agents as injured tissues are more susceptible to infections
due to neutropenia, trauma or a combination of factors. 102 These significantly impact eating and
speech functions in patients.

102

Significant nausea and vomiting are also highly specific

reactions of chemotherapeutic agents, further reducing oral intake.

105

Recently, Sullivan (2005)

explained the effects of RT/C on salivary glands including the processes of: acinar cell loss along
with salivary duct metaplasia, ductal proliferation, increased fibrosis, chronic inflammation,
nuclear atypia and cytoplasmic vacuolization. 106 Since HNC are almost never treated using ChT
alone, except for palliative treatment, most all studies describe the effects of combined RT
with/without ChT on swallowing changes. 71 24
Thus, along with desirable eradication of cancer cells, RT/C causes significant
undesirable changes in normal tissue, resulting in dysphagia. Permanent tissue changes make the
process of rehabilitation of swallowing function quite challenging. This renders greater
importance to a need for techniques to prophylactically prevent and/or maintain a safe and
efficient swallow function in these patients. The following section presents a review of the
RT/C-induced toxicities in patients.
2.1.1. Toxicities Associated with Radiation Therapy with/without Chemotherapy (RT/C)
and Their Management in Head and Neck Cancers (HNC)
Patients undergoing RT/C exhibit several physical toxicities during and after the
completion of treatment due to treatment-induced pathophysiological alterations described in the
previous section. Short-term toxicities including edema (i.e. swelling), xerostomia (i.e. dry
mouth), mucositis (i.e. sores in the mouth and throat), nausea, odynophagia (i.e. pain on
swallowing), reduced appetite, fatigue and dysgeusia (i.e. loss of taste), and long-term radiation
fibrosis (i.e. tissue scarring) are the most commonly presented side-effects of RT/C.

67, 103, 107-109

Clinically, these toxicities are known to directly result in swallowing difficulties during
treatment, including choking, difficulty initiating a swallow, foods sticking in the throat, loss of
9

appetite and subsequently diminished oral intake, particularly of solid foods.

103

Patients may

even begin to spit their own secretions due to the pain associated with swallowing. This may
cause a significant reduction in the use of swallowing muscles. Prolonged muscle inactivity is
associated with a serious risk of atrophy.

85, 97

Despite intact swallowing physiology, associated

toxicities impacting oral intake, may result in severe weight loss.

109

Rademaker et al., (2003)

reported that at pre-treatment, oral intake for 7% patients was ≤ 50%.48 Immediately posttreatment, 39% consumed ≤ 50% of their nutrition and hydration orally. Thin liquids were best
tolerated by patients at any timeline, and crunchy foods the hardest.48 Weight loss can result in
malnutrition and has also been associated with a sharp increase in morbidity and mortality.

110

A

PEG tube may have to be considered to meet the patient‟s nutrition and hydration needs during
treatment.

24

It is not uncommon for some patients to exhibit reduced tolerance of PEG tube

feedings, necessitating total parenteral nutrition (TPN) dependence, which in turn is not
complication-free either. Alternative modalities of nutrition and hydration further reduce the use
of swallowing muscles, prolonging the duration of avoidance of swallowing. This may have
significant bearings on return of swallowing function. 97
Several medical interventions have been employed to manage radiation-induced
toxicities. Eilers and Million (2011) have evaluated the literature to present the evidence for
various interventions for oral mucositis in patients undergoing RT/C. Cryotherapy, keratinocyte
growth factor (palifermin®) and sucralfate have been shown to benefit in the reduction of oral
mucositis.

111

Rodriguez-Caballero, et al., (2011) have presented a summary of intensive oral

care protocols, antimicrobial agents, anti-inflammatory agents, cytoprotective agents, nutritional
supplements, bio-stimulants, low-energy laser therapy and natural and homoeopathic agents that
have been employed to treat and manage RT/C-induced oral mucositis.

104

Shenoy, Shenoy,

Rodrigues and Shetty (2007) have reviewed the management of oral health in patients who
10

underwent RT for HNC, including: timely dental evaluations and treatments both during and
following the completion of RT; use of oral prophylaxis, fluoride treatments and patient
education to maintain oral hygiene; topical and systemic antifungals to prevent and treat
infections of the oral cavity; use of saliva substitutes, moisturizers, sugarless gums and candies to
manage xerostomia; employment of coating agents, topical analgesics and anesthetics to treat the
pain associated with mucositis and daily mouth opening exercises to manage trismus (i.e.
reduced jaw opening) occurring as a result of fibrosis.

112

Delanian and Lefaix (2007) have

described the use of various medical treatments in managing radiation-induced fibrosis
including: anti-inflammatory treatments, vascular therapies and anti-oxidant treatments.

113

O‟Sullivan and Levin, (2003) have discussed the use of pharmacological therapies, hyperbaric
oxygen treatments and microcurrent therapies in the management of post-radiation fibrosis.

114

Clinical trials assessing the impacts of various pharmacological therapies continue in the field, to
reduce treatment-related toxicities.
Oral, pharyngeal and/or esophageal phase dysphagia in varying degrees, frequently occur
during and after the completion of RT/C.

103

The resultant oropharyngeal dysphagia is

characterized by reduced tongue range-of-motion (ROM) and strength, inadequate bolus
formation and anterior-posterior transit, prolonged oral transit time, increased oral cavity residue,
reduced tongue-base retraction to make contact with the posterior pharyngeal wall,
velopharyngeal sphincteric closure abnormalities, delayed pharyngeal swallow response trigger,
reduced pharyngeal contraction and peristalsis, reduced hyolaryngeal excursion and reduced
laryngeal closure. Additionally, reduced opening of the upper esophageal segment (UES) may
result in inadequate bolus clearance from the pharynx, leaving residue at the tongue-base,
valleculae, pyriform sinuses or throughout the pharynx. This residue can result in aspiration,
typically after the swallow, often silent in nature.
11

10, 82, 103, 115, 116

Cricopharyngeal (CP) strictures

are not uncommon, and usually occur later after the completion of RT/C.

85, 117

CP strictures may require medical interventions, such as dilating the area

84

Management of

to allow smoother

transit of foods and liquids into the esophagus.
Standard radiation for most head and neck primary tumors is delivered at a dose of 1.8 to
2 Gy, once daily, 5 days a week. 118 Two modifications to this schedule exist: hyperfractionation
and accelerated fractionation”. Hyperfractionation involves the delivery of two treatments in a
day, ≥ 6 hours apart, each treatment‟s dosage being slightly lower than the standard dosage, yet
allowing delivery of a slightly higher total dosage per day.

118

Accelerated fractionation on the

other hand, allows the delivery of treatments more than 5 days a week, including the weekends
and/or delivering two or more fractions on some days of the week.

118

Swallowing impairments

arising from acute radiation toxicities may sometimes last only temporarily when relatively
smaller radiation doses are employed in the treatment of smaller tumors. However, larger doses
of RT employed to treat more advanced cancers may cause significant oropharyngeal and
pharyngoesophageal dysphagia, not uncommonly permanent in nature.

85

Tables 2.1 and 2.2

present literature reviews of the rates of aspiration and PEG tube dependence within 3 months
post-completion of RT/C. None of these studies report the employment of any behavioral
swallowing interventions.
Carnaby-Mann, Crary, Schmalfuss and Amdur (2012) recently conducted the only
existing study to investigate the impact of performing behavioral swallowing exercises during
RT/C, on muscle size and composition, assessed by T2-weighted Magnetic Resonance Imaging
(MRI) at 6 months post-treatment.

91

The study indicated that although all patients who

underwent RT/C exhibited significant deterioration of muscle composition through treatment,
patients who performed swallowing exercises exhibited greater preservation of three prime
swallowing muscles: genioglossus, mylohyoid and hyoglossus. Current dysphagia clinical
12

Table 2.1: Literature reports of aspiration rates (%) within 3 months of completion of radiation therapy with/without chemotherapy
(RT/C) for head and neck cancers (HNC)
Authors & RT/C protocol

N

Age (years)

Sex

T site (%)

T stage (%)

Aspiration@ < 3
mos.

Agarwal et al (2011)
66-70 Gy RT + CC

47

Median: 51
Range: 40-65

40M
7F

53% OPhx
13% Lx

76% III/IV

23%

Nguyen et al (2009)
(TL patients excluded)
59.4-66 Gy RT post-surgery

37

Median: 58
Range: 45-78

37M

19% OC
22% Lx

19% OPhx
40% O

3% I
8% II
35% III 51% IV
3% R

24%

Nguyen et al (2006)
66-70.2 Gy RT + CC

63

Median: 64
Range: 49-86

62M
1F

2% OC
3% NPhx
27% Lx

56% OPhx
12% HPhx

3% II 32% III
62% IV 3% R

49%
(21% trace,
28% severe)

Logemann et al (2006)
67 to 72.75 Gy + CC

53

Median: 56
Range 38-78

41M
12F

41% OPhx 6% NPhx
26% Lx
8% HPhx
19% O

66% III/IV

23%

Eisbruch et al (2002, 2004)
70 Gy RT + CC

26

≥ 18

NR

8% OC
15% NPhx
4% HPhx

54% OPhx
8% Lx
11% O

100% III/IV

65%

Kotz et al (2004)
69.3- 72.3 Gy + CC

12

Mean: 50
Range: 31-72

9M
3F

8% OC
25% Lx

59% OPhx
8% O

100% III/IV

33%

Newman et al (2002)
2 protocols of RT + CC

30
(I=14
II=16)

Mean: 61

64 & 56% M
34 & 44% F

0 & 6%II
14 & 13%III
86 & 81%IV

At least 40%

34% HPhx

21 & 6% Oral
64 & 81% Phx
14 & 13% Lx

RT/C= radiation therapy with or without chemotherapy; N= number of patients; T= tumor; mos: months; @= at; RT= radiation therapy; CC= concomitant
chemotherapy; M= male; F= female; OC= oral cavity; OPhx= oropharynx; NPhx= nasopharynx; Lx= larynx; HPhx= hypopharynx; O= other; R: recurrence;
NR= not reported
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Table 2.2: Literature reports of PEG tube dependence (%) within 3 months of completion of radiation therapy with/without chemotherapy
(RT/C) for head and neck cancers (HNC)
Authors & RT/C protocol

N

Age (years)

Sex

T site (%)

T stage (%)

PEG @ <3 months

Ackerstaff et al (2009)
70 Gy RT + CC

207

Mean: 55

73%M
27%F

19% OC
62% OPhx
18% HPhx

100% III/IV

86%
at post-treatment
some PEGs were placed before treatment

Murphy et al (2009)
Several RT ± CC ± surgery
protocols employed

1877

Mean: 59
Range: 19-97

76%M
24%F

41% OPhx
20% Lx
16% OC
4% NPhx
4% HPhx
15% O

9% I
10% II
19% III
63% IV
8% missing

40% academic centers
30% community centers
during treatment
additional PEGs were placed before treatment

Nguyen et al (2009)
(TL patients excluded)
59.4-66 Gy RT post-surgery

37

Median: 58
Range: 45-78

37M

19% OC
19% OPhx
22% Lx
40% O

3% I
8% II
35% III
51% IV
3% R

10%
at post-treatment

Hutcheson et al (2008)
66 to 77 Gy RT ± CC

40

Mean: 59
SD: 11

75%M
25%F

97.5% Lx
2.5% O

75% ≥T3

78%
at some point during treatment
some patients underwent TL, not evaluated
exclusively

Salama et al (2008)
8 Primary surgery
72-75 Gy RT + CC

95

Median: 58
Range: 35-77

NR

8% OC
52% OPhx
4% NPhx
5% HPhx
23% Lx
7% O

57% ≥ T3
86% ≥ N1

38%
during treatment

Lazarus, et al (2007)
58.5 to 75.78 Gy RT ± CC

46

Mean: 59
Range: 29 to 78

76%M
24%F

85% OPhx
15% OC

6% II
11% III
83% IV

22%
at 1 month post-treatment

14

(Table 2.2 continued)
Authors & RT/C protocol

N

Age (years)

Sex

T site (%)

T stage (%)

PEG @ <3 months

Oates et al (2007)
60 to 70 Gy RT + CC

14

Range: 27 to 71

NR

100% NPhx

86% III/IV

93%
at post-treatment

Goguen et al (2006)
70-74 Gy RT + CC

59

Mean: 54
Range: 38-75

73%M
27%F

5% OC
71% OPhx
19% Lx
5% HPhx

14% III
86% IV

73%
at 3 months post-treatment

Logemann et al (2006)
67 to 72.75 Gy RT ± CC

53

Median: 56
Range: 38 to 78

77%M
23%F

6% NPhx
41% OPhx
26% Lx
8% HPhx
19% O

66% ≥T3

40%
at post-treatment
small number of PEG tubes were placed prior
to treatment

Shiley, Hargunani, Skoner,
Holland & Wax (2006)
71 Gy RT (mean) + CC

27

Mean: 57
Range: 45-80

96%M
4%F

96% OPhx
4% HPhx

7% III
93% IV

81%
prior to or during treatment

Ahmed, Samant & Vieira (2005)
68-74 Gy RT + CC

477

Range: 18-86

220M
257F

16% OC
41% OPhx
19% Lx
10% HPhx
8% NPhx
6% O

100% III/IV

Rademaker et al (2003)

255

Mean: 59
Range: 24-80

77%M
23%F

46% OPhx
23% Lx
10% OC
9% HPhx
5% NPhx
7% unknown

6% II
19% III
73% IV

70 Gy (median) (30-75.5 Gy) RT
± CC

15

45%
at 3 months post-treatment
46%
at post-treatment
small number of PEGs were placed before
treatment

48%
at 1 month post-treatment
36%
at 3 months

(Table 2.2 continued)
Authors & RT/C protocol

N

Age (years)

Sex

T site (%)

T stage (%)

PEG @ <3 months

Kies et al (2001)

64

Median: 57
Range: 33-78

84%M
16%F

27% OC
2% NPhx
33% OPhx
9% HPhx
14% Lx
16% O

98% IV

78%
at post-treatment

47

Mean: 56.5
Range: 38-83

34M
13F

13% HPhx
30% Lx
9% OC
49% OPhx

91% ≥T3
60% ≥N1

26%
at post-treatment
small number of PEGs were placed before
treatment

73.5 Gy RT (median) + CC

Newman, et al (1998)
63-70 Gy RT + CC

RT/C= radiation therapy with or without chemotherapy; N = number of patients; T= tumor; @= at; RT= radiation therapy; CC= concomitant chemotherapy; M=
male; F= female; OC= oral cavity; OPhx= oropharynx; NPhx= nasopharynx; Lx= larynx; HPhx= hypopharynx; O= other; NR= not reported
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practice in the HNC population employs various ROM exercises and behavioral swallowing
maneuvers, which reportedly alter and/or improve the functional ability of impaired structures. 83
The support for this practice comes from a limited number of studies, described in the following
sections of the document. Additionally, literature investigating the specific role of exercises in
minimizing radiation fibrosis and its effects on swallowing function is emerging, and requires
further investigations. Physiotherapy as a behavioral management modality is frequently
employed in reducing post-RT fibrosis. Only a few reports currently exist to support the use of
physical therapy in the rehabilitation of irradiated tissues.

114

Benefits of physical exercise in

reducing risks of impaired shoulder movements following surgical and RT for breast cancer have
been reported in the literature. 119-121 In particular, the irreversibility of radiation fibrosis assessed
by relative maintenance of range-of-motion (ROM) at least partially in breast cancer patients has
been demonstrated medically by Delanian and Lefaix, (2007). 113 However, there appears a need
for confirmatory studies to evaluate the efficacies of such medical interventions specific to HNC.
113, 114

Such encouraging reports of the positive impacts of behavioral therapy in preserving

and/or reducing muscle fibrosis, encourage the future potential of swallowing therapy in
efficiently minimizing the occurrence of dysphagia associated with irradiated tissue.
In summary, the effects of RT/C and its toxicities on swallowing physiology may result
in inefficient and unsafe swallowing, frequently evidenced on post-treatment Modified Barium
Swallow (MBS) studies.24 Radiation fibrosis frequently may cause aspiration, increased risk of
aspiration as well as inadequate oral intake to meet the nutritional and hydration needs of the
HNC patient-population. Reduced pharyngeal peristalsis which impairs the transit of foods and
liquids into the esophagus, has direct impacts on oral intake and nutritional adequacy. Due to the
permanent nature of RT-induced tissue fibrosis, a prophylactic approach targeting tissue while it
is still healthy has emerged.

91

The rationale of this approach is to minimize reductions in the
17

range-of-motion of these tissues and muscles, prior to and during exposure to RT/C, rather than
attempting the same, once RT damage has already been induced. Future studies expanding on
this significant finding are highly warranted. The following section reviews current clinical
practice in dysphagia rehabilitation in patients diagnosed with and treated for HNC.
2.2. Review of Current Clinical Practice in Dysphagia Rehabilitation of the Head and Neck
Cancer (HNC) Patient Population- Reactive Behavioral Swallowing Therapy
Current clinical practice utilizes a wide variety of postural strategies,
volume and consistency modifications

75

73, 74, 122

bolus

and rehabilitation exercises 76-82 to manage swallowing

impairments following RT/C. The following is a summary of the behavioral swallowing
exercises routinely employed, along with the evidence supporting their benefits in post-RT/C
swallowing impairments.
Range-of-Motion (ROM) Exercises
ROM of the lips, jaw, tongue and larynx are often disrupted following HNC treatments,
typically from RT/C-induced fibrosis. ROM exercises involve stretching target structures in the
desired direction, holding the position for a few seconds followed by relaxation.

82

ROM

exercises can be used for the lips, jaw, oral tongue, tongue-base, larynx and the hyolaryngeal
musculature.

83

A standardized treatment schedule for these exercises has not yet been

determined. However, most commonly 5-10 repetitions of each exercise 5-10 times per day have
been recommended in several studies. 21, 82, 123
 Jaw Exercises
HNC treatments have been reported to cause trismus (reduced jaw opening) due to RTinduced fibrosis in 5% to 38% patients.

124

ROM exercises for the jaw are employed in patients

with a restricted mouth opening, which may result from surgical removal of pertinent muscles of
RT/C-induced fibrosis. Unassisted practice of ROM of the jaw, finger-assisted stretching,
stacked tongue depressors and mechanical assistance with devices such as the Therabite® (Atos
18

Medical AB, Horby, Sweden), which is a hand held device assisting in improving jaw opening
for increased flexibility, motility and function, are currently utilized in treating reduced ROM of
the jaw.

83

All of these techniques have proved effective in relieving some of the trismus and

increasing jaw opening in HNC patients treated with surgery or RT/C.

125-127

Unassisted jaw

opening exercises have recently been reported to result in a significant increase in suprahyoid
muscle strength in healthy elderly subjects. 128
Patients are instructed to open their mouths as widely as possible without causing pain,
holding this open position for two seconds with or without assisted/ mechanical devices, then
moving the jaw to the left side as much as possible, holding this position for two seconds and
then relaxing. 83 The exercise is then repeated for the right side. Finally, the patient is encouraged
to move the jaw in a circular pattern and relax after every full circle.
 Tongue Exercises
ROM exercises of the tongue are applicable in oral tongue and tongue-base movement
impairments.

82

ROM exercises for tongue function in bolus manipulation include tongue-

cupping, side-to-side tongue movements and posterior tongue movements. These exercises
intend to facilitate chewing, bolus formation and bolus transport functions of the tongue. 82
Tongue-extension involves protrusion of the tongue as far past the lips as possible
without pain, sustaining the stretch for two seconds followed by relaxation.

82

Tongue-

lateralization involves moving the tongue to either the left or right corner of the mouth, tightly
sustaining the stretch for 2 seconds followed by relaxation. The exercise is repeated on the other
corner of the mouth. Oral tongue-elevation requires that the tongue be lifted in the mouth with
the tip of the tongue touching the alveolar ridge, sustaining the stretch for two seconds followed
by relaxation. Tongue-base elevation can be performed by raising the back of the tongue to
produce a /k/ or /g/ sound, holding the position for two seconds followed by relaxation. Tongue19

retraction involves pulling the tongue back in the mouth as far as possible, holding the stretch for
two seconds followed by relaxation. Tongue-cupping involves holding a piece of gauze soaked
in water or a licorice stick or a lollipop on the middle of the tongue such that the sides of the
tongue are cupped against the palate and the tip of the tongue rests on the alveolar ridge. The
position is sustained for five seconds followed by relaxation. A soaked gauze piece may be
employed to perform oral bolus retrieval, bolus manipulation, anterior-posterior bolus transit and
swallowing tasks. Once the patient exhibits improved ability to handle a soaked gauze piece,
harder textures such as hard candy may be introduced. Tongue-retraction and pretending to yawn
and gargle have been shown to improve tongue-base retraction.

82

However, gargling as a

tongue-base retraction exercise was found to be more effective in approximating the base of the
tongue closest to the posterior pharyngeal wall than yawn exercises in a study of 20 patients with
various diagnoses including some treated HNC patients. 81
Tongue Resistance and Strengthening Exercises
White, Cotton, Hind, Robbins and Perry (2009) reported significant differences in orolingual swallowing pressures recorded in HNC patients vs. healthy adults.

129

Tongue

strengthening exercises involve pushing the tongue against resistance and sustaining the resisted
push for a few seconds followed by relaxation. 82 Tongue protrusion, lateralization at the corners
of the mouth or inside the cheek may be employed against resistance applied by a wooden
tongue depressor or the back of a spoon. Isometric tongue pressure increases have been reported
in healthy subjects with lingual resistance exercise programs. Resistance training exercises have
also shown to improve isometric tongue-strength in healthy older adults as well as those with
stroke-related dysphagia. 130, 131 Van Nuffelen, Vanderwegen, Van den Steen and De Bodt (2012)
recently reports benefits of a tongue strengthening exercise protocol in improving tongue
strength in patients with dysphagia post-RT/C.
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20

The IOWA Oral Pressure Instrument (IOPI)

helps to monitor pressure during tongue strengthening exercises;

133

however, no significant

differences in physiological outcomes using a tongue depressor or the IOPI have been reported in
normal subjects. 134 Whether improvements in strength with tongue-resistance exercises translate
into functional improvements in swallowing are yet to be investigated. 135, 136
Weakening of the tongue muscles in older adults has been demonstrated in the
literature.137-139 Bond, Dietrich and Murphy (2011) have reported that advanced age may
therefore further increase the burden of toxic symptoms to patients undergoing RT/C.
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Given

the increasing percentage of older adults, which may potentially increase the prevalence of HNC,
establishment of a standard of care to keep treatment-related dysphagia to the minimum possible,
is warranted in this high-risk age group of patients. Employment of objectively assessed tongue
strength and ROM exercises in the HNC patient population (young and especially older adults) is
therefore suggested.
 Laryngeal Range-of-Motion (ROM) Exercises
ROM exercises for the larynx are employed to improve laryngeal elevation in patients
who exhibit reduced laryngeal movement typically following RT for HNCs. 83
The Falsetto Voice or Pharyngeal Squeeze Maneuver
The falsetto voice is a simple maneuver produced by gliding up the pitch scale as high as
possible until a high-pitched squeaky voice is reached and sustaining phonation at this pitch for
as long as able. Manual assistance may be provided initially but should be eliminated gradually.
Rodrigues, Roth, Rees and Belafsky (2007) conducted an investigation to assess the reliability of
the pharyngeal squeeze maneuver on 40 individuals undergoing the Fiberoptic Endoscopic
Evaluation of Swallowing (FEES) procedure for various reasons.
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The investigation revealed

reliable differentiation of a normal vs. abnormal pharyngeal squeeze; but not between a
diminished vs. absent pharyngeal squeeze. Fuller, Leonard, Aminpour and Belafsky (2009)
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conducted an investigation to validate the pharyngeal squeeze maneuver by conducting
simultaneous Videofluoroscopic Swallowing Study (VFSS) and endoscopic evaluation of
swallowing procedures on patients with dysphagia.

142

Their findings suggested that the

pharyngeal squeeze maneuver is a valid measure of pharyngeal strength and “motor integrity”.
Patients with dysphagia affecting hyolaryngeal excursion, often exhibit reduced pharyngeal
strength and diminished or absent ability to perform the maneuver.

82

Setzen et al., (2003) have

shown that impairments in laryngopharyngeal sensation and pharyngeal motor function associate
with high risk of aspiration. 143 Aviv et al., (2009) have also reported in their study consisting of
patients with dysphagia from varied causes including some HNC that, patients who have a
diminished or impaired pharyngeal squeeze are at greater risk for penetration and aspiration.
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Emerging evidence supports the pharyngeal squeeze technique in the swallowing rehabilitation
of structural dysphagia, such as that post-RT/C, where in tissue fibrosis can cause a reduction in
hyolaryngeal ROM. The current study therefore includes the pharyngeal squeeze maneuver as
one of the exercises targeting the pharyngeal phase of swallowing aimed to potentially minimize
post-RT swallowing impairments.
The Shaker Exercise
The Shaker exercise consists of three one-minute sustained neck -lifts in a supine position
with a one-minute rest period between each lift. Following this, the patient is required to lift the
neck 30 times in the same position without sustaining each lift and without any rest period
between the lifts.
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The Shaker exercise is considered as an isometric/isokinetic exercise and

has been reported to improve the strength of the suprahyoid musculature resulting in both
improved hyolaryngeal movement and UES opening in healthy adults and some patients post-RT
for HNCs. 145-147 Logemann, et al., (2009) found that the Shaker exercise resulted in significantly
reduced post-swallow aspiration compared to traditional eclectic swallowing therapy in a small
22

group of patients with varied diagnoses including post-RT/C for HNC.

148

Thus, although

limited, the evidence is encouraging in applying the Shaker exercise to swallowing rehabilitation
of the irradiated swallowing mechanism, which commonly involves impairments in UES
opening.

83

The current study employs the Shaker exercise prophylactically based on two vital

reasons: 1) it is one of the few evidence-based exercises shown to improve UES opening postRT/C 83 and 2) it has been shown to improve UES opening in the tissues of healthy older adults
as well as previously treated HNC. 145-147 Given the known UES opening impairments commonly
occurring post-RT/C, these explanations justify employment of the Shaker exercise in the
prophylactic rehabilitation of swallowing in HNC patients.
Swallowing Maneuvers
 The Mendelsohn’s Maneuver
The Mendelsohn maneuver was designed to prolong the extent and duration of
hyolaryngeal elevation and cricopharyngeal opening. 76 Therefore it may be employed in patients
with dysphagia who exhibit reduced laryngeal movement, delayed or reduced CP opening and/or
a less coordinated swallow.83 Three HNC patients treated with organ preservations therapies with
or without surgery exhibited significantly improved mean pressure amplitude at the tongue baseposterior pharyngeal wall contact, longer duration of contact and reduced pharyngeal residue
using the Mendelsohn maneuver.

149

In fact, the Mendelsohn maneuver resulted in the longest

duration of tongue base to posterior pharyngeal wall contact when compared to other maneuvers.
In a patient who underwent right composite resection for cancer of the right retromolar trigone,
the Mendelsohn maneuver improved tongue base retraction to the posterior wall in relation to
both laryngeal closure and CP opening, improved the coordination and timing of events of the
pharyngeal phase of swallowing and eliminated aspiration. 77
The Mendelsohn maneuver requires that the patient initiates a swallow normally, then
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grabs the voice box using the throat muscles as it is felt elevating, holding the position for a
count of three and then completing the swallow.

76

Typically training of this maneuver begins

without food and gradually as the patient is able to demonstrate the maneuver accurately, food
may be introduced.83 Difficulty to comprehend and inability to monitor accuracy of its
performance without the use of an external monitoring tool, have been two primary concerns
with the employment of this maneuver in swallowing therapy. These may influence patient
compliance and negatively impact the clinician‟s ability to provide accurate feedback.
 Masako Maneuver
The Masako or tongue-hold maneuver involves protruding the tongue and holding the
anterior tongue between the central incisor teeth while swallowing. 150 The Masako technique is
shown to improve contact between the tongue base and the posterior pharyngeal wall,

150

which

is thought to be essential for bolus transit by inducing necessary pressure on the bolus. In a
study by Lazarus et al., (2002) three HNC patients treated with organ-preservation therapies with
or without surgery exhibited improved pressure at tongue base- posterior pharyngeal wall and
improved duration of contact.

149

The improvement remained limited to the structure‟s ROM

without functional changes in the overall swallowing of patients. However, if appropriate
swallowing exercises, which have been shown to address deficiencies in specific physiologic
events during the swallow, are combined, the outcome of the therapy could lead to an overall
improvement of swallowing function. This holds especially true for HNC patients, who exhibit
dysphagia at multiple levels of the structural pathway.
 The Supraglottic and Super-supraglottic Swallow Maneuvers
The aim of the super-supraglottic swallow is to forcefully close the vocal folds both
before and during the swallow thus preventing aspiration.

79, 82

Prolonged airway closure in

normal and treated HNC patients has been demonstrated with the use of both, supraglottic and
24

super-supraglottic maneuvers on MBS studies and Fiberoptic Endoscopic Evaluation of
Swallowing (FEES) procedures.

77, 151

The super-supraglottic swallow has been shown to result

in earlier CP opening, prolonged pharyngeal swallow, initiation of laryngeal closure to an extent,
prior to the swallow and altered extent of hyolaryngeal elevation prior to the swallow, than the
supraglottic swallow.

151

The super-supraglottic maneuver provides additional airway protection

as compared to the supraglottic swallow in that it involves anterior arytenoid tilting to contact the
base of the epiglottis or base of tongue in case the epiglottis is resected. 79 In patients with HNC
treated with RT/C, the super-supraglottic maneuver results in early laryngeal closure,
improved tongue-base retraction,

149

149

improved hyolaryngeal elevation at the time of UES

opening and improved maximum hyolaryngeal displacement. 21
The super-supraglottic swallow involves taking a deep breath and holding it tightly,
bearing down and swallowing while continuing to hold the breath and coughing when finished.83
Although the supraglottic and super-supraglottic maneuvers have been shown to improve
hyolaryngeal elevation and laryngeal closure, these maneuvers are designed for patients who
mainly aspirate before or during the swallow and/or who have undergone a surgical procedure
such as a partial laryngectomy or supraglottic laryngectomy, to help compensate for some loss of
structure. In addition these swallow maneuvers are considered as compensatory techniques rather
than behavioral exercises and they need to be performed prior to each swallow of a bolus.
 Effortful Swallow
By forcing the bolus through the pharynx and the UES, the effortful swallow helps to
reduce the amount of residue in the pharynx after the swallow.

82

The effortful swallow may be

employed in patients treated for HNC who exhibit diminished tongue strength, reduced
pharyngeal contraction, reduced hyolaryngeal elevation, reduced laryngeal closure and
dysmotility of the CP sphincter.

83

In healthy normal subjects, an effortful swallow results in
25

significantly increased oral pressure, reduced oral residue, prolonged laryngeal closure, increased
hyoid excursion and elevation,

152

prolonged pharyngeal pressure duration, prolonged UES

relaxation duration 153 and increased peristaltic amplitude in the distal esophagus. 154 Three HNC
patients treated with organ preservations therapies with or without surgery exhibited highest
mean pressure amplitudes at the tongue base- posterior pharyngeal wall contact, with the use of
an effortful swallow.

149

Also, a longer duration of tongue base contact with the posterior

pharyngeal wall was evident with the use of an effortful swallow versus no maneuver in all three
patients. The effortful swallow maneuver requires that patients swallow by squeezing hard with
all their throat muscles thus increasing tongue base retraction, pharyngeal pressure and bolus
transit from the vallecular spaces.

82

On the downside, particularly in HNC patients, it has been

reported that the effortful swallow may result in fatigue causing a reduction in the accuracy of its
performance. 14 The McNeil Dysphagia Therapy Program (MDTP) 155 employs the hard swallow
maneuver intensively (1 hour daily for 3 weeks in therapy), in conjunction with bolus
consistency and volume modifications and gradual increases in eating rate and amount of oral
intake. The program has been shown to result in the following physiological and functional
improvements in patients with persistent dysphagia (>12 months) post- HNC treatments and/or
neurological injury: improvements in scores on the Mann Assessment of Swallowing Ability
(MASA), improved FOIS scores, improves scores on the Visual Analog Scale (VAS)- a measure
of patient perception of swallowing ability, reduction in PEG tube dependence (from 78% to
33%), biomechanical swallowing improvements with at least one consistency (hyolaryngeal
elevation,

lingual-palatal

pressure,

pharyngeal

manometric

measures,

sEMG

mean

amplitude).155, 156 Most gains were statistically significant; most gains were maintained at the 3month follow-up.
Table 2.3 provides a summary of the studies investigating the impacts of behavioral
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swallowing exercises that have been employed in swallowing rehabilitation of HNC patients,
post-RT/C. Research continues to be warranted to address specific benefits of exercises to
irradiated tissue. Limitations of the available literature in concluding the impact of reactive
swallowing therapy include but are not limited to: 1) small sample sizes, limiting generalization
of findings, 2) employment of different combinations of exercises between studies, 3) mixed
subject pool with various diagnoses, 4) lack of reports of correlation of physiological outcomes
to function and QOL, 5) failure to include control groups, 6) failure to include comparison
groups, 7) use of non-standardized assessment tools and outcome measures, 8) sham treatment
groups or crossover of treatment groups to identify placebo effects, 9) majority non-experimental
or quasi-experimental designs raising questions regarding reported outcomes, 10) lack of
collection of baseline data to address natural variability among individuals‟ performance, 11)
lack of control of confounding factors, and 12) employment of convenience samples rather than
randomization and lack of assessor blinding.

157

Methodological inadequacies and differences

within and between studies; make objective conclusions regarding the effectiveness of
swallowing therapy in patients quite difficult.

14

This results in much reliance on the clinician‟s

knowledge, judgment and clinical experience in the management of structurally induced
dysphagia. Therefore research addressing these gaps in dysphagia treatment for the HNC
population is warranted to achieve an evidence-based standard of care. Amidst continued
investigations of the effects of behavioral swallowing techniques on swallowing outcomes postRT/C, an aggressive, prophylactic approach to swallowing therapy is underway, and currently
appears to already be influencing the assessment and management approaches employed by
clinicians to rehabilitate this group of patients.
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Table 2.3: Summary of studies investigating the impacts of behavioral swallowing exercises in
improving swallowing biomechanics and function following radiation therapy with/without
chemotherapy (RT/C) for head and neck cancers (HNC)
Target

Exercise

Findings

Jaw ROM

Unassisted ROM

Improved jaw opening 126, 127

Stacked tongue
depressors

Improved jaw opening 127

Therabite®

Improved jaw opening 125, 127

Unassisted ROM

Improved tongue-base retraction 81

Masako

Improved pressure at the tongue base- posterior pharyngeal wall
contact 77, 149
Longer duration of contact 149

Tongue ROM

Tongue strength

Laryngeal
ROM

Maneuvers

Tongue-depressor/spoon

N/A

IOPI

N/A

Pharyngeal squeeze

N/A

Mendelsohn

Improved pressure at the tongue base- posterior pharyngeal wall
contact 77, 149
Longer duration of contact 149
Reduced pharyngeal residue 149
Improved coordination & timing of pharyngeal phase events of
swallowing 77
Eliminated aspiration 77

Shaker exercise

Improved UES opening 145
Improved anterior laryngeal excursion 145
Eliminated aspiration after the swallow 145, 148
Resumed oral feeding 145

Supraglottic swallow

Prolonged airway closure 77, 151

Super-supraglottic
swallow

Prolonged airway closure 77, 151
Anterior arytenoid tilting to contact the base of the epiglottis or base
of tongue in case the epiglottis is resected 79
Early laryngeal closure 149
Improved tongue-base retraction 149
Improved hyolaryngeal elevation at the time of UES opening 21
Improved maximum hyolaryngeal displacement 21

Effortful swallow

Highest mean pressure amplitudes at the tongue base- posterior
pharyngeal wall contact 149
Longer duration of tongue base contact with the posterior pharyngeal
wall 149

*ROM: range-of-motion; N/A: not available
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2.3 Review of Current Clinical Practice in Dysphagia Rehabilitation of the Head and Neck
Cancer (HNC) Patient Population- Prophylactic Behavioral Swallowing Therapy
Recent advances in neural plasticity and exercise physiology sciences, and the
applications of their principles to reintegration of fibrotic tissue post-RT/C, have resulted in the
emergence of proactive or prophylactic swallowing therapy, which is essentially introduced with
an intention of potentially preventing or minimizing the known post-RT/C swallowing
impairments. This has been one of the most vital changes in patients‟ therapeutic regimens in the
last decade. Experts in the field have promoted the concept of prophylactic swallowing exercises
for HNC patients, for several years.

80, 82, 96, 103, 158

However, it wasn‟t until recently that this

approach to swallowing rehabilitation attracted the focus of several experts in the field. Only five
studies have been conducted to evaluate the impacts of introducing swallowing exercises prior to
or during RT/C on post-RT/C swallowing outcomes.

86, 88-91

Their research protocols and

findings are summarized in Table 2.4.
In summary, the five investigations that have been conducted so far have addressed the
impacts of prophylactic swallowing exercises on swallowing biomechanics,
preservation,
functions,

91

91

PEG tube dependence,

weight loss,

89, 90

QOL,

86, 89, 91

88, 90

eating ability,

89-91

86, 89, 91

muscle

salivary, taste and smell

and compliance with swallowing exercises.89,

91

Additionally, Retel et al., (2011) have demonstrated the cost-effectiveness of prophylactic
swallowing therapy (Netherlands‟ healthcare costs and currency) over usual patient care in
terms of tube dependency at 12 months and number of days of hospital admission upto 1 year
post-RT/C.

159

Unfortunately, all studies report the employment of highly varied exercise

protocols, making clinical generalization difficult. Nonetheless, this is necessary in obtaining the
most beneficial exercise protocol (i.e. type of task, frequency and intensity). Not all interventions
employed by the above studies yielded significantly better outcomes than control or sham
groups; hence continued research to investigate the most optimal exercise schedule is warranted.
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Table 2.4: Summary of the available literature investigating the impacts of prophylactic swallowing therapy on swallowing
outcomes post- radiation therapy with/without chemotherapy (RT/C)
STUDY & PROTOCOL

SUBJECTS & METHODS

OUTCOMES

FINDINGS

LIMITATIONS

Kulbersh et al., 2006

Experimental (2)  Control 

QOL
-MDADI score

MDADI scores:

-Not randomized

Mailed survey to patients
1) h/o RT + ChT
2) h/o University of Alabama
(UAB) dysphagia therapy
protocol

Experimental Group 1: n=25
Mean age: 55.1 years
Gender (%): 76M: 24F
Tumor size: T1-2 = 29.2%; T3-4 = 70.8%
T site: OPhx = 92%; Lx = 8%
Therapy 2 wks before RT; f/u at 2 & 6 wks

Group 1 sig > than Group 2
-overall, global, emotional &
physical scores

-Varied accrual
times of Groups

Exercise Protocol: Mendelsohn,
tongue-hold & tongue resistance
(5 sets of 10 rep); Shaker (5
sets); Falsetto phonation (few
patients)

Experimental Group 2: n=12
Mean age: 60.3 years
Gender (%): 75M: 25F
T size: T1-2 = 50%; T3-4 = 50%
T site: OPhx = 58.3%; Lx = 25%;
NPhx = 8.3%; Neck = 8.3%
Therapy 1st wk of RT; f/u at 2 & 6 wks

Carroll et al., 2008

Experimental  Control 

Retrospective case-control
design
1) III/IV cancers
2) h/o RT/C
3) Dose ≥ 70 Gy

Experimental Group (EG): n=9
Mean age: 57.5 years
Gender (%): 78M: 22F
T site: OPhx= 78%; Lx= 22%
Therapy ~ 2 wks prior to RT/C

Exercise Protocol:
Mendelsohn, tongue-hold,
tongue resistance & effortful
swallow (5 sets of 10 rep);
Shaker (1 set)

Control Group (CG): n=9
Mean age: 60.7 years
Gender (%): 56M: 44F
T site: OPhx= 78%; Lx= 11%;
HPhx= 11%
Therapy post-treatment as is typical

Group 1 f/u:
6-12 mos
(median= 9 mos)
Group 2 f/u:
6-20 mos
(median=14 mos)

No sig diff in:
-Functional score
Concurrent chemotherapy:
No impact on scores

-MDADI completed
at different f/u times
-Did not report raw
scores
-Not assessed:
Physiological
Functional 
Weight
Compliance

Physiological
-MBS study @ 3 mos
post-RT/C
Functional
- Rate of PEG tube
d/c @ 12 mos

All patients had PEG tubes
placed prophylactically

-Not randomized
EG- sig > than CG:
-Tongue base position
-Epiglottis inversion
No significant difference:
-Hyoid elevation
-Tongue base movement
-CP opening
-Aspiration score
-PEG tube elimination
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-Small sample size

-Not assessed:
QOL
Weight
Compliance

(Table 2.4 continued)
van der Molen et al., 2011

Experimental (2)  Control 

Prospective randomized trial
1) III/IV cancers
2) RT +ChT
3) Dose 70 Gy

Experimental Group (EG): n=24
Mean age: 56 years
Gender(%): 96M: 4F
T site: OC= 6%; OPhx= 43%; HPhx= 35%
Lx= 2%; NPhx= 14%
Therapy ~ 2 wks prior to RT/C

EG Exercise protocol:
TheraBite® (Atos Medical AB,
Horby, Sweden) (Stretch
exercises 3 times & strength
exercises 10 times daily)
SG Exercise protocol:
Logopedic strengthening
exercises including jaw ROM (3
sets daily) & effortful swallow,
Masako maneuver & supraglottic
swallow (5 sets daily)

Standard Group (SG): n=25
Mean age: 57
Gender(%): 64M: 36F
T site: OC= 12%; OPhx= 36%;
HPhx= 32%; Lx= 4%; NPhx= 16%
Therapy ~ 2 wks prior to RT/C

Physiological
-MBS studies
-mouth opening
-Pain scale
Functional
-FOIS scores
-PEG tube
Weight & Body Mass
Index
Compliance
- Familiarity
- # Practice days
- Reason for quitting

Ahlberg et al., (2011)

Experimental  Control 

Prospective non-randomized trial
1) Mean RT EG= 65 Gy
2) Mean RT CG= 63 Gy
3) ± surgery pre/post
4) ± ChT

Experimental Group (EG): n=84
Mean age: 63.6
Gender(%): 67M:33F
T stage: I= 11%; II= 19%; III= 14%;
IV= 45%; Missing= 11%
T site: OC= 36%; OPhx= 33%; HPhx= 7%
Lx= 10%; O= 14%
Therapy prior to the initiation of RT.

EG Exercise protocol:
Mendelsohn‟s maneuver (10 rep
x 2 daily); tongue ROM
exercises (5 rep each x 2 daily)
Received PT & nutrition
counseling prior to RT

Baseline & 10 wks
post-RT/C

Control group (CG): n=121
Mean age= 64.1
Gender: 68M: 32F
T stage: I= 14%; II= 16%; III=19%;
IV= 37%; Missing= 14%
T site: OC= 30%; OPhx= 31%
No SLP or PT

Pre-treatment and 3
mos post-treatment
Physiological
-Bedside swallow
-Weight loss
QOL
-EORTC-QOLO-C30
-EORTC-H&N35
-HADS
-Project specific

Post-RT/C physiology:
- 18% aspiration
- decreased residue
- decreased mouth opening
- weight loss (6.1 kg)
- no decrease in BMI
- decrease FOIS scores
(35% scores 1, 2 or 3)
- SG < residue than EG

-Not assessed
QOL 

Post-RT/C Function:
PEG post-RT/C: 38/49 (78%)
PEG at 10 weeks: 17/49 (35%)
Compliance:
-57% “very familiar with the
exercises” (as a group)
- SG complied > EG
- Females complied > Males
EG = CG:
-physiology
-weight loss
(5.9 kg EG vs. 6.2 kg CG)
-QOL assessment
All consistencies po:
- EG: 35% vs. CG: 58%
- CG returned to work at a
higher rate than the EG
- 61% dysphagia
- 92% xerostomia
At 6mos
- 61% chewing problems
- 51% less mouth opening
- 70% stiffness in neck
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-Lack of a control
group

-EG & CG were
recruited at different
centers
-No instrumental
evaluations were
used to report
physiology of
dysphagia 
-Patients were seen
by SLP only once
prior to RT.
-Not assessed
Functional 

(Table 2.4 continued)
Carnaby-Mann et al., (2011)
Randomized, controlled trial
1) OPhx cancers
2) RT (38) ± CC (22) ± neck
dissection
3) no h/o PEG for cancer
CG Exercise regimen:
Supervision for feeding & safe
swallow precautions if at all.
Weekly phone calls to monitor
SG Exercise regimen:
Buccal extension maneuver (10
reps in 4 sets, each 10 mins) +
diet modifications, twice daily in
a 45 min session
Pharyngocise Exercise regimen:
falsetto, tongue press, hard
swallow, Therabite (10 reps in 4
sets, each 10 mins) + diet
modifications, twice daily in a 45
min session

Experimental Control Sham 

Exercise Group (Pharyngocise): n= 20
Mean age= 59
Gender(%): 90M:10F
T stage median (range): 2 (1 to 4)
T site: Base of tongue, Tonsil
Mean RT dosage: 72.5 Gy
Control group (CG): n= 20
Mean age: 54
Gender (%): 75M: 25F
T stage median (range): 2 (0-4)
Tumor site: Base of tongue, Tonsil
Mean RT dosage: 67.5 Gy
Sham group (SG): n=18
Mean age: 60
Gender (%): 61M:39F
T stage median (range): 2 (1-4)
Tumor site: Base of tongue, Tonsil
Mean RT dosage: 69.2 Gy

Baseline & postRT/C
Physiology
- T2-weighted MRI
(change in muscle
size & composition)
- MBS study
- Mouth opening
- Saliva production
Function
- FOIS scores
- PEG
- Mann assessment of
swallowing ability
(MASA)
- Smell & taste
- Nutrition exam
- Weight loss
- QOL questionnaires

Overall
- 14% aspiration
- 21% PEG (4/6 in CG)
- 23% maintained normal diet
- 31% reduced MASA scores
- 6.69 kg weight loss
- 65% mucositis
- 14% oral yeast infection

Only 31/58 patients
had a 6 month f/u
hence no data on f/u
after post-treatment

Pharyngocise exhibited:
- more genioglossus,
mylohyoid & hyoglossus
muscle preservation vs. CG &
SG
- less decline in mouth
opening than SG & CG
- more preservation of saliva
- better maintenance of PO
intake (i.e. 42% vs. 14% CG)
- Median FOIS (5 post-RT/C)
(not sig vs. CG & SG)
- less PEG (25%)
- less deterioration in MASA
scores vs. CG & SG
- more preservation of taste
- more preservation of smell
- weight loss
Compliance
- overall 68%
- SG > Pharyngocise

OC: oral cavity; NPhx: nasopharynx; OPhx: oropharynx; HPhx: hypopharynx; Lx: larynx; O: other; M: male; F: female; T: tumor; mos: months;
SLP: speech language pathology; PT: physical therapy; QOL: quality-of-life; EG: experimental group; CG: control group; SG: Sham group or
Standard group; RT: radiation therapy; ChT: Chemotherapy; RT/C: radiation therapy with/ without chemotherapy; f/u: follow-up; wks: weeks;
MDADI: MD Anderson Dysphagia Inventory; MBS: Modified Barium Swallow; d/c discharged; rep: repetitions; MRI: Magnetic Resonance
Imaging; mins: minutes
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The current study therefore hypothesizes that a clinically feasible, evidence-based prophylactic
exercise protocol will result in better swallowing outcomes in its patient group, compared with a
no treatment group and with literature at post-treatment and at 3 months-post treatment.
2.4. Application of the Principles of Exercise Physiology and Neural Plasticity to
Swallowing Rehabilitation Post-Radiation Therapy with/without Chemotherapy (RT/C) for
Head and Neck Cancers (HNC)
Recent advances in the study of neural plasticity and exercise physiology have provided a
new scientific direction to research in the rehabilitation of dysphagia. This is especially true of
structurally-induced dysphagia from irradiation, which is particularly challenging to restore.
RT/C is known to cause significant muscle change leading to edema and fibrosis as elaborated
earlier. Further, the reduction in the use of swallowing muscles by patients going through
treatment is postulated to result in muscle weakness and sometimes atrophy. Skeletal muscle
exhibits notable plasticity in response to functional demands.

160

Swallowing exercises are

performed prior to/ during/ after RT/C to facilitate muscle function and maintain or restore
swallowing function. The evidence of the employment of behavioral exercises for these purposes
is largely derived from the sciences of neural plasticity and exercise physiology.
Kent (2004) described speech as one of the fastest discrete-rate human motor behaviors
and “speech muscles have distinctive lifespan patterns, functional properties and molecular
phenotypes.”

161

Kent‟s (2004) and Kent and Robbins‟ (2011) review of the literature has

indicated that oropharyngeal musculature significantly varies in structure and function from all
other muscles of the human body.

161, 162

Oropharyngeal muscles are capable of not only causing

a constriction in the aerodigestive tract to allow smooth downward passage of the bolus; but
these muscles also dilate the same tract during inhalation.

93, 161

Animal studies have indicated

that the tongue in rats has motor units that are fatigue-resistant.
speaking, speech muscles are not easily fatigued.
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161

163

Even after prolonged

According to Stal and Lindman (2000),

palatal muscles including the levator veli palatini and the tensor veli palatini have high aerobic
capacity and a rich supply of capillaries making these muscles highly fatigue-resistant.

164

Fatigue in speech muscles is evident typically in cases of pathologies such as Myasthenia Gravis,
impairing the continuous muscular demands of speaking.
The structural and functional differences between speech muscles and the remaining
muscles of the body have also been shown to translate into differences in treatment options. For
example, many medical interventions that are employed for non-speech muscle groups, such as
the limbs either do not affect speech motor control desirably or result in worse outcomes.

161

Even within neurological disorders, interventions highly vary and one intervention cannot be
employed for every neurological condition, due to the differential manners in which muscles are
affected.

161

Therefore, McComas (1998) has highlighted the importance of avoiding

generalization of research findings from one group of muscles to the other.

161

The principles of

exercise physiology, which have been established primarily from experiments involving large
muscles such as limb muscles, should not be extrapolated for speech and swallowing muscle
groups without conducting thorough investigations and experiments with these highly unique
groups of muscles. Further, the unique nature of irradiated tissue is sufficient to question the
applicability of rehabilitation adapted from the principles of exercise physiology employed
mainly in other muscle groups or similar muscle groups with varied nature of impairments.
However, these principles should serve as the foundation in initiating specific research in
dysphagia.
In reviewing the science of exercises, Burkhead (2009) has indicated that any muscle
disease, injury, disuse or even normal aging causes reduced use of the particular muscle and
resultant deconditioning.

93

Under deconditioning, muscles atrophy, become less efficient and

easily fatigued. Such structural adaptations are accompanied by changes in nervous system
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activation as well. When exercise training of muscles is initiated, typically neural changes begin
to occur and precede structural changes.

93

Gradually, the role of neural adaptation decreases as

the muscle fibers begin to enlarge and exhibit improved endurance. 165 Again, these processes of
deconditioning and adaption have been explored only in larger muscles of the body, and not in
the muscles specific to the swallowing mechanism . Therefore, when applying these principles to
the muscles of swallowing, it is vital to first identify the treatment objective of strength training
in dysphagia. 93 The clinician must determine whether the goal of therapy is to increase strength,
improve coordination and/or improve speed of movement. Establishment of treatment goals are
generally achieved following assessment via an instrumental evaluation of the individual‟s
swallowing with various volumes of liquid and food consistencies. Based on the impairments
identified, therapeutic tasks should be selected to build a therapeutic regimen for each individual
patient. This concept is especially important in dysphagia treatment following treatments for
HNC. Irradiated tissue is likely to exhibit reductions in muscle strength, coordination as well as
speed of movement, and subsequent muscle atrophy.
Neural plasticity has been defined as the ability of the brain to make alterations.

166, 167

There is emerging evidence to show that following injury to the brain, neural plasticity is
responsible for re-modeling of target functions.

166

The ten principles of neural plasticity168 as

applied to dysphagia therapy166 include: use it or lose it; use it and improve it; plasticity is
experience-specific; intensity matters; repetition matters; time matters; salience matters; age
matters; transference and interference. In selecting therapeutic tasks, the principles of saliency
and intensity of exercises are vital.

93

The principle of specificity/ saliency suggests that the

training task should resemble the target activity as much as possible to make maximum gains.
Thus, general strengthening exercises alone may not improve activity or muscle function.
According to the principle of intensity of exercises, any activity that does not result in working a
35

muscle beyond its capacity (i.e. increased activity) may not result in neuromuscular adaptation.169
Burkhead (2009) has recommended that it may be best to work a muscle until fatigue is reached
rather than performing each exercise for a specific number of repetitions in a specific number of
sets.

93

The intensity of the activity must then be increased both within a session and over a

period of time to cause adaptations. In exercise sciences, this practice is referred to as
93

progressive resistance.

Sapienza, Wheeler-Hegland, Stewart, and Nocera (2008) have

proposed that no less than 2 weeks of direct treatment delivered 3-5 times per week may be
recommended to expect improvements specific to dysphagia.

170

However again, these

recommendations are not specific to cancer treatment-induced dysphagia and hence are not part
of the standard of care in the field. Emerging studies
Mann et al., (2012)

91

86, 88-90

particularly the one by Carnaby-

has demonstrated the positive effects of exercises on muscle size and

composition. These effects potentially reflect at least partially the adequacy of the type of
therapeutic task, its intensity and frequency employed by the researchers. However, no research
has established optimal treatment dosage at this time. Future investigations are recommended to
derive optimal clinical decisions as well as provide insights into the much needed evidence to
guide optimal standard of care for irradiated tissue.
In dysphagia exercise literature, several strengthening exercises and swallowing
maneuvers have been employed in multiple repetitions and sets, demonstrating the application of
the principle of intensity in clinical practice. One of the high intensity exercises employed in the
treatment of dysphagia is the Shaker exercise. 93 Shaker exercises employed in dysphagia include
a frequency and intensity adapted from exercise physiology literature.

170

The Shaker exercise

when performed over six weeks has been shown to result in improvements in the UES opening in
the anterior-posterior direction, anterior laryngeal excursion, bolus clearance and safety and
efficiency of oral intake.

145

Another high intensity and high effort exercise regimen, the Lee
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Silverman Voice Therapy (LSVT) when employed for four weeks by patients with Parkinson‟s
disease, has been shown to improve oral, pharyngeal and laryngeal swallowing measures.

171

Healthy progressive lingual muscle strength training for eight weeks has been shown to improve
the force generating capacity of the tongue, oral pressure generation and airway protection in
patients with dysphagia post-stroke.

131

Muscle hypertrophy i.e. increased lingual volume was

also evident in two patients in this study. Expiratory Muscle Strength Training (EMST)
employed for four weeks has been shown to improve expiratory pressure generations and airway
protection in patients with Parkinson‟s disease.

172

Authors have reported that the use of the

EMST to exhale against 75% load of respective patients‟ maximal expiratory pressure, elicits
notable neuromuscular activity in the suprahyoid muscles responsible for hyolaryngeal excursion
and airway protection. Progressive resistive lingual strength training and EMST reportedly force
adaptations in one or more muscle groups, which carry over to the function of swallowing. 93 25
to 30 repetitions of lingual exercises per day and 3 sustained and 30 repetitive Shaker exercises
per day, 3-5 days a week for 4-8 weeks have been recommended. Set frequency and intensity
schedules are not available for other exercises and a clinically based intensity is often used. 170
Similarly, although without direct reference, therapeutic tasks employed in dysphagia
practice closely abide by the principles of saliency and specificity. It is noteworthy however, that
most strength training exercises in dysphagia have been employed in patients with neurological
impairments. Rehabilitation of the unique irradiated tissue which results in impairments in
muscle strength, coordination and speed of movement, requires more specific exercise
investigations focused towards resolving muscle fibrosis. For instance, the effortful swallow
although helpful in some oropharyngeal dysphagia may require increased muscle effort, which in
turn may cause fatigue to irradiated fibrotic tissue as well as fatigue to the person and affect its
execution over time.

14

Yet, other studies have demonstrated the benefits of a hard swallow
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incorporated into an exercise program, on swallowing outcome.

155, 156

This appears to warrant

the evaluation/ redefinition of principles which may be specific to irradiated tissue structure and
function. Robbins (2012) has reported that strength training alone may not be sufficient in
improving swallowing function, sensorimotor stimulation involving a stimulus-response pattern
may be essential.

173

Emerging literature focuses towards establishing an optimal prophylactic

swallowing therapy protocol for HNC patients. Future studies are needed to determine which
swallowing exercises are most appropriate at what intensities and frequencies to potentially
minimize or resolve the effects of RT/C on irradiated muscle physiology and function.
The current investigation aims at determining how prophylactic exercises based on the
principles of exercise physiology and neural plasticity, (in particular, use it or lose it; intensity
matters; repetition matters; and salience matters)

166

influence swallowing physiology and

function outcomes following HNC treatments. This investigation is hypothesized to improve the
understanding of the differential impacts of a combination of currently employed behavioral
exercises vs. a swallow-specific intense therapeutic task, on swallowing outcomes. The „exercise
group‟ of this study performed the Masako maneuver, the pharyngeal squeeze exercise and the
Shaker exercises. The „repetitive swallow group‟ performed an intense number of repetitive
swallows of saliva with sips of water as needed. The rationale for employing these therapeutic
tasks is presented in the Procedures section of Chapter 3- Design and Methods, which follows.
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CHAPTER 3: DESIGN AND METHODS
To evaluate the proposed hypotheses, a prospective study was conducted at the Mary
Bird Perkins Cancer Center (MBPCC) in Baton Rouge, Louisiana. Institutional Review Board
(IRB) approvals to conduct the study at the MBPCC, were obtained from the Louisiana State
University (LSU) in Baton Rouge, Louisiana State University Health Sciences Center
(LSUHSC) in New Orleans, Earl K Long (EKL) Medical Center in Baton Rouge and Our Lady
of the Lake (OLOL) Regional Medical Center (RMC) in Baton Rouge.
3.1. Recruitment of Patients in the Experimental Groups
All newly diagnosed HNC patients who were to undergo radiation therapy with/without
chemotherapy (RT/C) between December 1, 2010 and January 30, 2012, at the MBPCC, were
referred to the OLOL-Voice Center (VC) in Baton Rouge, for a routine, baseline MBS study, and
were subsequently recruited upon eligibility. The MBS study protocol employed at the OLOLVC is described in Appendix A. Following the MBS study, patients were screened for
qualification in the current study. The inclusion and exclusion criteria for patient recruitment in
the experimental groups of the study are presented in Table 3.1. If patients met these inclusion
criteria, a short recruitment session was conducted with the patient with/without their family
members. During the session, the study coordinator briefly explained the objectives and
procedures of the current study, fully outlined in the Informed Consent (Appendix B). If the
patient expressed interest in participating in the study, he/she along with the family members
were encouraged to read the Informed Consent. On obtaining patient-agreement to participate in
the study, he/she was requested to sign the LSU-approved Informed Consent, the LSUHSCapproved Informed Consent and the LSUHSC-approved Health Insurance Portability and
Accountability Act (HIPAA) Statement.
Neo-adjuvant (prior to RT) or concurrent (alongwith RT) chemotherapy (ChT) is typically
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Table 3.1: Inclusion criteria and exclusion criteria for patient-recruitment to the experimental
groups of this study
Inclusion criteria

Exclusion criteria

i) Diagnosis of cancers of the oral cavity, i) Evidently or reportedly with diminished
oropharynx,
nasopharynx,
hypopharynx, ability to comprehend and perform therapy
larynx and/or nodal disease
tasks, due to any reasons
ii) Evidence of functional swallowing abilities ii) Dysphagia warranting PEG tube placement
assessed using a baseline MBS study, prior to prior to the initiation of RT/C
the initiation of RT/C
iii) Without prophylactic PEG tube placement
iv) Signed Informed Consent
PEG: feeding tube; MBS: Modified Barium Swallow; RT/C: radiation therapy with/without chemotherapy

employed in the treatment plan of advanced head and neck tumors vs. smaller tumors. 102 Not all
patients received ChT in this study. As described in detail earlier, ChT by itself minimally affects
patients‟ swallowing abilities; its toxicities co-exist with those of RT when used in combination.
71, 24

Therefore irrespective of whether patients received ChT prior to or during RT or not, as

long as they continued with functional swallowing abilities without any indication for the need of
a PEG tube prior to initiating RT, they qualified for recruitment in this study. Similarly, some
patients in this study underwent pre-RT surgeries when considered appropriate. As long as these
patients did not exhibit any swallowing impairments on their post-surgery MBS evaluation, they
qualified for recruitment in the study.
A total of 50 consecutively referred patients who met the inclusion criteria of the study
were prospectively recruited in two groups: i) the exercise group i.e., EX and ii) the swallow
group i.e. SW. The first 25 patients were recruited in the two groups by alternate-assignment;
however the next 25 patients were recruited in the respective groups with the intention of
matching the groups for age, tumor size (T size) and tumor site (T site), as possible. Twenty-six
patients constituted the EX group and 24 patients constituted the SW group.
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3.2. Recruitment of Patients in the ‘No Treatment’ Group
Only patients who underwent RT/C at the Baton Rouge site of the MBPCC were
recruited in the study‟s experimental groups. Therefore patients who underwent RT/C at the
other sites of the MBPCC i.e. Gonzalez, Hammond, Houma and Covington, did not receive any
swallowing intervention prior to or during RT/C, and constituted the study‟s no treatment (NTx)
group, upon qualification. The inclusion and exclusion criteria for patient recruitment are
presented in Table 3.2. All patients in the NTx group underwent RT/C within the same timeline
as the patients in the experimental groups of this study, i.e. December 1, 2010 to September 30,
2011.
Patients in the NTx group were recruited in a retrospective manner. Since these nonBaton Rouge MBPCC treating sites do not have an onsite SLP or a nearby SLP with expertise in
the HNC patient-population, these patients were not referred for SLP services. Recruiting
patients prospectively after being referred from their doctors at the Baton Rouge site would pose
ethical issues, given the emerging literarture on benefits of prophylactic therapy; hence this
retrospective method appeared to allow recruitment of the most representative no treatment
(NTx) group in this study.
Table 3.2: Inclusion criteria and exclusion criteria for patient-recruitment to the no treatment
(NTx) group of this study
Inclusion criteria

Exclusion criteria

i) Diagnosis of cancers of the oral cavity, i) Any doctor‟s reports of diminished patientoropharynx, hypopharynx, larynx and/or nodal ability to follow commands or comprehend
disease
information due to any reasons
ii) Indication of no dysphagia in doctor‟s ii) Dysphagia warrantying PEG tube placement
consult notes, prior to the initiation of RT/C
prior to the initiation of RT/C
iii) Without prophylactic PEG tube placement
RT/C: radiation therapy with/without chemotherapy; PEG: feeding tube
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3.3. Pre-treatment Assessment of Group Differences in Demographic, Cancer-Related,
Swallowing-Related and Cancer Treatment-Related Characteristics
Chapter 2 of this document explained the influence of advanced age, tumor sites and
tumor stage on swallowing outcomes. Since the methods of recruitment in the study could not
ensure matched treatment and non-treatment groups, it was considered necessary to utilize
statistical analyses to determine if at pre-treatment, the three study groups were similar in these
characteristics, and prevent an influence of potential confounding factors on the outcomemeasures proposed in this study. Table 3.3. lists the pre-treatment variables compared between
the EX, SW, EX+SW and/or the NTx groups.
Table 3.3: List of pre-treatment variables compared between the exercise (EX), swallow (SW)
and/or no treatment (NTx) groups
Pre-treatment Variables
(level of measurement)

Test Statistic

Age (continuous)

Mann-Whitney U test

Gender (nominal, 2 levels)

Fisher‟s exact test

Tumor site (nominal, 5 levels)

Pearson chi square

Tumor stage (nominal, 4 levels)

Mann-Whitney U test

Aspiration (nominal, 2 levels)

Fisher‟s exact test

PAS scores (ordinal, 1 to 8)

Mann-Whitney U test

Swallowing function

FOIS scores (ordinal, 1 to 8)

Mann-Whitney U test

Swallowing-related QOL

MDADI scores (continuous)
Overall (1 to 100)
Global (1 to 5)
Emotional (1 to 30)
Functional (1 to 25)
Physical (1 to 40)

Mann-Whitney U test

Cancer treatment-related

Pre-treatment surgeries (nominal, 2 levels) Pearson chi square

Patient demographic

Tumor-related

Swallowing physiology

PAS: Penetration Aspiration Scale; FOIS: Functional Oral Intake Scale; QOL: quality-of-life; MDADI: MD
Anderson Dysphagia Inventory
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Non-parametric test statistics were employed to assess pre-treatment between-group
differences for dichotomous and ordinal level variables appropriately. Additionally, due to
normality issues, non-parametric tests were also employed to compare groups on the basis of
continuous level variables. To compare nominal level variables between groups, the Pearson chi
square test was employed. If a cell count has less than the expected count of 5, the Fisher‟s exact
test was used. To compare ordinal level variables between groups, the Mann-Whitney U test was
utilized. Due to evidence of non-normal distributions, the Mann-Whitney U test was also
employed to assess group differences on continuous variables. The type I error rate was set at α =
.05.
Patient Demographics (Age and Gender)
Table 3.4 summarizes the demographic characteristics, including age (years) and gender
of patients in the EX (exercise) and SW (swallow) treatment groups and of patients in the NTx
(no treatment) group. At the time of recruitment to the treatment groups, patients were alternately
assigned to the EX and SW groups, matching for age as possible. The Mann-Whitney U test and
Fisher‟s exact test analyses revealed no statistically significant differences between the treatment
groups in age (p=.217) and gender distribution (p=.294), respectively. Also, the NTx group did
Table 3.4: Demographics of patients, including age and gender, in the exercise (EX) and swallow
(SW) treatment groups and no treatment group (NTx)
Demographics

EX
(N=26)

SW
(N=24)

NTx
(N=23)

p value

Age (years)

Mean
(range)
Median
Mode

64
(24 to 90)
61
60

60
(43 to 85)
56.5
53

62
(39 to 79)
60
60

Mann-Whitney U
EX vs SW, p=.217
EX+SW vs. NTx, p=.849

Gender # (%)

Males
Females

19 (73)
7 (27)

21 (87.5)
3 (12.5)

19 (83)
4 (17)

Fisher‟s exact test
EX vs SW, p=.294
EX+SW vs. NTx, p=1.0

#: number; EX: exercise group; SW: swallow group; NTx: no treatment group; No statistically significant
differences between groups evident.
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not statistically significantly differ from the treatment groups (EX+SW) in age (Mann-Whitney U
test, p=.849) and gender (Fisher‟s exact test, p=1.0).
Tumor Characteristics
Table 3.5 summarizes the tumor characteristics, including tumor site (i.e. oral cavity,
nasopharynx, oropharynx, hypopharynx, larynx or unknown primary tumors), tumor size (i.e. T1,
T2, T3 or T4, T4 being the worst), nodal disease category (i.e. N0, N1, N2 or N3, N3 being the
worst) and tumor stage (i.e. I, II, III or IV, IV being the worst) of patients in the EX and SW
treatment groups and of patients in the NTx group. At the time of recruitment to the treatment
groups, patients were alternately assigned to the EX and SW groups, matching for these
characteristics at best possible. There were no statistically significant differences between the EX
and SW treatment groups in the distribution of tumor site (χ2(5)= 2.048, p=.842) and tumor
stage (Mann-Whitney U test, p=.762). The NTx group also did not statistically significantly
differ from the treatment groups (EX+SW) in terms of either tumor site (χ2(5)= 7.631, p=.178)
or tumor stage (Mann-Whitney U test, p=.260).
Pre-treatment Swallowing Physiology, Function and Quality-of-Life (QOL) Assessments
Pre-treatment swallowing assessment of all patients in the EX and SW treatment groups
revealed physiological and functional swallowing abilities to be within functional limits (i.e.
absence of any physiological impairments affecting patients‟ abilities to tolerate a full oral diet
safely) on a baseline MBS study, as outlined by the inclusion criteria. Although the intention was
the perform all pre-treatment MBS studies prior to the initiation of any RT, miscellaneous factors
resulted in unexpected delays, and 23 of 50 MBS studies had to be performed within the first
week of RT. These 23 patients did not self-report experiencing any dysphagia or RT related
toxicities and demonstrated functional swallowing abilities on the MBS study. Table 3.6 presents
pre-treatment aspiration (%), PAS scores (mean), FOIS scores (mean) and MDADI scores
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Table 3.5: Tumor characteristics including tumor site, tumor size, nodal disease category and tumor stage, of patients in the exercise
(EX) and swallow (SW) treatment groups and no treatment (NTx) group.
EX (N=26)

SW (N=24)

NTx (N=23)

Tumor site
No. of patients (%)

Oral cavity
Nasal cavity
Oropharynx
Hypopharynx
Larynx
unknown

2 (8%)
1 (4%)
9 (34%)
2 (8%)
7 (27%)
5 (19%)

Oral cavity
Nasal cavity
Oropharynx
Hypopharynx
Larynx
unknown

2 (9%)
1 (4%)
12 (50%)
1 (4%)
6 (25%)
2 (8%)

Oral cavity
Nasal cavity
Oropharynx
Hypopharynx
Larynx
unknown

2 (9%)
1 (4%)
6 (26%)
2 (9%)
12 (52%)
0

Tumor size
No. of patients (%)

T0
T1
T2
T3
T4
unknown

3 (12%)
6 (23%)
5 (19%)
6 (23%)
1 (4%)
5 (19%)

T0
T1
T2
T3
T4
unknown

1 (4%)
4 (17%)
9 (37%)
4 (17%)
4 (17%)
2 (8%)

T0
T1
T2
T3
T4
unknown

0
6 (26%)
8 (35%)
8 (35%)
0
1 (4%)

Nodal disease
No. of patients (%)

N0
N1
N2
N3
unknown

4 (15%)
8 (31%)
9 (35%)
3 (11%)
2 (8%)

N0
N1
N2
unknown

8 (33%)
3 (13%)
11 (46%)
2 (8%)

N0
N1
N2
N3
unknown

12 (52%)
2 (9%)
8 (35%)
1 (4%)
0

Tumor stage
No. of patients (%)

I
II
III
IV
unknown

2 (8%)
1 (4%)
10 (38%)
12 (46%)
1 (4%)

I
II
III
IV
unknown

3 (12%)
5 (21%)
4 (17%)
11 (46%)
1 (4%)

I
II
III
IV
unknown

6 (26%)
2 (9%)
6 (26%)
9 (39%)
0

p value

Pearson chi square
EX vs. SW,χ2(5)= 2.048, p=.842
EX+SW vs. NTx, χ2(5)= 7.631,p=.178

N/A

N/A

Mann-Whitney U test
EX vs. SW, p=.762
EX+SW vs. NTx, p=.260

EX: exercise group; SW: swallow group; NTx: no treatment group; N/A: not applicable No statistically significant differences between groups evident

45

Table 3.6: Pretreatment aspiration (%), Penetration Aspiration Scale (PAS) scores and
Functional Oral Intake Scale (FOIS) scores estimated from Modified Barium Swallow (MBS)
studies, and pretreatment MD Anderson Dysphagia Inventory (MDADI) scores- overall, global,
emotional, functional and physical domains, of patients in the exercise (EX) and swallow (SW)
treatment groups
EX (N=26)

SW (N=24)

p value

Aspiration

(%)

2/26 (8%)
(trace instance,
eliminated
spontaneously)

1/24 (4%)
(trace instance,
eliminated
spontaneously)

Fisher‟s exact test
p=1.0

PAS scores

Mean (range)
Median
Mode

2 (1 to 8)
1
1

1.8 (1 to 8)
1.5
1

Mann-Whitney U test
p=.915

FOIS scores*

Mean (range)
Median
Mode

6.5 (5 to 7)
7
7

6.6 (5 to 7)
7
7

Mann-Whitney U test
p=.551

MDADI scores
Overall

Mean (range)
Median
Mode

94.85 (64 to 100)
100
100

91.25 (57 to 100)
97.5
100

Mann-Whitney U test
p=.234

Global

Mean (range)
Median
Mode

4.85 (2 to 5)
5
5

4.67 (1 to 5)
5
5

p=.197

Emotional

Mean (range)
Median
Mode

28.5 (21 to 30)
30
30

28.67 (20 to 30)
30
30

p=.695

Functional

Mean (range)
Median
Mode

23.73 (15 to 25)
25
25

23.17 (15 to 25)
25
25

p=.505

Physical

Mean (range)
Median
Mode

37.69 (21 to 40)
40
40

34.83 (19 to 40)
38
40

p=.095

EX: exercise group; SW: swallow group; No statistically significant differences between the groups evident
*A recommended FOIS score of 5 and 6 were always related to patients‟ inability to take certain tough solid
consistencies due to dental treatments or extractions in preparation for RT

(mean) obtained from the swallowing assessment of patients in both EX and SW treatment
groups. Appendix D presents the PAS, FOIS and MDADI tools.
 Physiological assessment: The EX and SW groups did not differ in % aspiration (Fisher‟s exact
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test, p=1.0) and PAS scores (Mann-Whitney U test, p=.915) at pre-treatment. Two patients in the
EX group and one patient in the SW group aspirated at pre-treatment, however these were only
single instances of aspiration, were not repeated, eliminated spontaneously and did not warrant
any dietary or behavioral intervention. Most importantly there was no indication of a need for a
PEG tube for patients to meet their nutritional and hydration statuses safely.
 Functional assessment: The EX and SW groups did not differ in FOIS scores (Mann-Whitney U
test, p=.551). Scores of 5 and 6 (i.e. modified, full oral diets) were always related to patients‟
inability to take certain tough solid consistencies due to dental treatments or extractions in
preparation for RT.
 QOL assessment: The Mann-Whitney U test did not reveal any statistically significant
differences between the treatment groups on the pre-treatment MDADI-overall scores (p=.234),
global domain scores (p=.197), emotional domain scores (p=.695), functional domain scores
(p=.505) and physical domain scores (p=.095).
Patients in the NTx group were recruited in a retrospective manner and did not undergo
pre-treatment, baseline swallowing evaluations. However, as per the consultation notes in
patients‟ charts, none of these patients exhibited any dysphagia, impairing eating ability at pretreatment.
Cancer Treatment-Related Characteristics
 Pre-treatment Surgeries: 13/26 (50%) patients in the EX group, 6/24 (25%) patients in the SW
group and 4/23 (17.39%) patients in the NTx group underwent pre-treatment surgeries beyond a
diagnostic biopsy to treat their tumors. These were not statistically significantly different
between the EX and SW groups (χ2(1)= 3.311, p=.069) and between the EX+SW and the NTx
groups (χ2(1)= 3.1, p=.078). Incisional biopsies were not considered as surgeries since all
patients undergo these for staging and treatment planning. Surgeries performed included, wide
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local excisions of tumors, laser excisions of tumors, excisions of glands and/or lymph nodes,
parotidectomy, partial cordectomy, partial glossectomy, partial mandibulectomy, modified neck
dissections and flap reconstructions. All MBS studies in patients, who underwent pre-RT/C
surgeries, were performed post-surgery and these revealed functional oropharyngeal and
pharyngoesophageal swallowing abilities.
3.4. Rationale for Selecting Therapeutic Tasks
The therapeutic tasks for the EX group were: the Masako exercise performed at a
frequency and intensity of 10 repetitions in each of 7 sets daily; the Pharyngeal Squeeze exercise
performed at a frequency and intensity of 10 repetitions in each of 7 sets daily and the Shaker
exercise performed at a frequency and intensity of 3 sets daily. The therapeutic task for the SW
group was: 34 swallows of saliva and/or water in each of 7 sets daily. These exercise protocols
are described in detail in Table 3.7.
Significant impairments in tongue-base retraction, hyolaryngeal elevation and UES
opening have been shown to occur most commonly in the oral, pharyngeal and esophageal
phases of swallowing, post-RT/C.

82, 174

The Masako technique has been shown to improve

tongue-base retraction, without functional changes in overall swallowing, in a highly limited
group of HNC patients.

149

The Shaker exercise is one of the few evidence-based exercises

shown to improve UES opening in the tissues of healthy older adults as well as previously
treated, limited number of HNC patients.

83, 145-147

The pharyngeal squeeze maneuver has been

considered as a valid measure of pharyngeal strength and “motor integrity”.

142

All three

exercises have been employed in isolation or in combination of twos in previous investigations
of prophylactic swallowing exercises; however, a combination of the three exercises known to
physiologically benefit all three phases of swallowing has not been investigated in an outcomestudy previously. The review of current clinical practice and the recommendations of exercise
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Table 3.7: Exercise protocols performed by patients in the exercise (EX) and swallow (SW)
treatment groups
Group Therapeutic task
EX

Repetitions/Set Sets/Day Total/Day

Masako maneuver:
Stick out your tongue, hold it between your
lips or front teeth and swallow. You may
take water as needed, but do not do the
exercise while holding a sip in your mouth.

10

7

70

Pharyngeal Squeeze exercise:

10

7

70

3

3

9

30

3

90

34

7

238

Glide up the pitch scale on the “ee” sound
and hold the highest pitch for several
seconds
Shaker exercise (Part A):
Lie down on your back on the bed or
floor
Do not use a pillow
Keep your shoulders flat against the
bed or floor
Lift up your head, bringing your chin
forward until you can see your toes
Keep your head lifted for 60 seconds,
and then lower your head and rest for
60 seconds.
Shaker exercise (Part B):
Lie down on your back on the bed or
floor
Do not use a pillow
Keep your shoulders flat against the
bed or floor
Lift up your head, bringing your chin
forward until you can see your toes.
Then immediately lower your head.
SW

Swallow your saliva. Count each swallow as
one repetition of the exercise. You may take
tiny sips of water as and when needed,
however, please try to do as many swallows
with saliva only as you can.
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physiology, justify the scientific adequacy of such a program in hypothesizing improved
outcomes. The frequency and intensity of the Masako and pharyngeal squeeze exercises were
determined by estimating an average number of ROM exercises reported in other studies and
clinical protocols as described earlier. The frequency and intensity of the Shaker exercise has
been recommended in the literature as described earlier.
Clinically, when patients are unable to perform exercises due to toxicities, they are
instructed to continue to swallow and use the swallowing muscles. Therefore to objectively
assess this task with ensured intensity, it was selected as the therapeutic task for the SW
treatment group. The number of repetitive swallows performed by patients in the SW group was
determined by adding the total number of Masako maneuvers (i.e. 70) + pharyngeal squeeze
exercises (i.e. 70) + neck lifts in the Shaker exercise (i.e. 99) performed by patients in the
exercise group. Since repetitive swallowing has not been employed as a therapeutic task in
dysphagia previously, its intensity could be estimated most appropriately by this method. As
described earlier, the principle of specificity of exercise physiology suggests that the training task
should resemble the target activity as much as possible to make maximum gains.

93

In addition,

the authors of this study confirmed that by performing 234 additional swallows (i.e. 34 x 7),
patients would achieve a 40% increase in the average use of the swallowing musculature, beyond
regular swallowing accomplished when eating, drinking and saliva swallows. Therefore this
number was thought to clinically significantly increase patients‟ use of the muscles of
swallowing.
Lear, Flanagan, and Moorrees (1965) have investigated the average frequency of
swallowing over 24 hours in 20 healthy adults.

175

They reported that on an average, humans

swallow 585 times per day; the range being 203 to 1008. Lear et al., (1965) expressed that this
number actually appeared to be notably less than expected.
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Swallowing occurred most

frequently during meals and least during sleep. Sato and Nakashima (2006) have reported a mean
of 2.9 ± 1.3 swallows per hour in eight normal human adults during sleep.176 Performing normal
activity at a highly increased capacity is a necessary aspect of exercise as per Pollock et al.,
(1998).
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A 40% increase in normal activity was hypothesized to be therapeutic in this study,

since this intensity corresponded with the intensity of behavioral exercises, which appear intense,
from literature reports and clinical practice.
Each patient in both the EX and SW treatment groups was instructed to attend
swallowing therapy sessions once every week for 45 minutes, throughout the duration they were
undergoing RT/C. During the session, patients partially completed their therapeutic tasks (50%)
for the day under the study coordinator‟s supervision, reported current diet and severity of
treatment toxicities and clarified any questions regarding their swallowing. In addition, patients
filled out the M D Anderson Dysphagia Inventory (MDADI) questionnaire on each weekly visit
with the speech pathologist. Appendix C displays the weekly progress note employed in this
study and the IRB-approved MDADI questionnaire appears in Appendix D. The first swallowing
therapy session was conducted during the first week of RT and the last session was conducted
during the last week of RT. Following the completion of RT/C, MBS studies were completed for
each patient. Patients whose studies indicated the need for structured swallowing therapy were
referred for these services promptly.
3.5. Data Collection
Experimental Groups i.e. EX (exercise) and SW (swallow) groups
 Pre RT
The following data was obtained from patients‟ electronic medical records (EMR) prior
to the initiation of RT: age (years), gender, tumor site, TNM classification, tumor stage, any
previous surgical interventions beyond a diagnostic biopsy, ChT or RT for HNC and baseline
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weight (lbs.) Information obtained from patients‟ baseline MBS studies included: PAS scores,
FOIS scores and diet consistencies tolerated. In addition, patients filled the MDADI
questionnaire, scores of which were obtained.
 During RT
On a weekly basis during RT, the following information was obtained from patients: diet
consistencies tolerated, PEG placement, weight, MDADI scores, RT toxicity (i.e., xerostomia,
mucositis, soreness or pain in the mouth, odynophagia, nausea and/or vomiting, dysgeusia,
trismus and reduced appetite), and changes in swallowing (i.e. choking with solids and/or
liquids, nasal regurgitation, oral regurgitation, reflux, difficulty initiating a swallow, globus
sensation, feeling of foods sticking in the throat, gagging, oral intake, hoarseness and wet or
gurgly voice quality). Additionally, patients were requested to return a daily log indicating the
frequency and intensity of exercises completed. At the completion of treatment, the total
numbers of days from the beginning to the end of RT was calculated and reported as the total
duration of RT.
 Post RT
Following the completion of RT, the following information was obtained from patients‟ post
treatment MBS studies: PAS scores, FOIS scores and diet consistencies tolerated. In addition,
patients filled the MDADI questionnaire.
No Treatment i.e NTx Group
The following data was obtained from patients‟ EMR: age (years), gender, tumor site,
TNM classification, tumor stage, previous surgical interventions beyond a diagnostic biopsy,
ChT or RT for HNC, duration of RT, baseline weight (lbs), post-treatment weight and PEG tube
placement if at all during RT.
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3.6. Standardized Dependent Measures
In the HNC-dysphagia literature, one of the most frequent methodological limitations is
that researchers do not consistently use standardized tools to evaluate patient outcomes.

14

This

results in the inability to compare study findings and to interpret findings of combined studies to
generalize to clinical patient care. Fortunately, the World Health Organization‟s International
Classification of Functioning, Disability and Health (ICF) has encouraged communication
professionals around the world to adopt standardized outcome measures,
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and to shift focus

from the impaired structure alone, to its direct impact on function, activity and participation. 178,
179

In addition, the importance of recognizing environmental and personal facilitators and

barriers, which affect patients‟ participation and activities, is encouraged. Specific to HNC, there
is limited research related to cancer interventions‟ impact on patients‟ functioning.
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The ICF

has established an initial core set of structures and functions specific to HNC, however
standardizing outcome measures to use with the ICF framework is only now underway.180, 181
The current prospective investigation therefore attempts to adopt the ICF approach to outcomes
evaluation by utilizing the PAS to assess physiology, 182 FOIS to assess function 183 and MDADI
to assess QOL,

184

which are valid and reliable outcome measures. Assessment of prophylactic

behavioral swallowing therapy as a facilitator and lack of compliance as a barrier are undertaken
in this study, consistent with the recommendations of the ICF model.
The Penetration Aspiration Scale (PAS)
The development of the PAS (Appendix D1), originally a 9-point scale, reduced to an 8item scale, has been described by Rosenbek, Robbins, Roecker, Coyle and Wood (1996), and has
been assessed for validity, inter-judge and intra-judge reliability. 182 The scale was designed to be
useful to both clinical researchers and clinicians. Score 1 represents no penetration or aspiration,
scores 2 through 5 represent laryngeal penetration with increasing depth and scores 6 through 8
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represent aspiration and sensation response to aspiration. In the current investigation, the PAS
was utilized to objectify the baseline and post-treatment MBS findings of penetration and
aspiration of food and/or liquid boluses.
The Functional Oral Intake Scale (FOIS)
Crary, Carnaby Mann and Groher (2005) described the development and psychometric
assessment of the FOIS (Appendix D2) in 302 acute stroke patients.183 Originally, a 10-point
rating scale, reduced to a final 7-point rating scale, the scale has been shown to indicate changes
in oral intake of acute stroke patients over time. Levels 1 through 3 indicate non-oral feeding i.e.
PEG tube dependence, levels 4 to 6 indicate limited, yet full oral feedings and level 7 indicates a
regular oral diet intake. Inter-rater reliability, consensual validity, criterion validity and cross
validation of the scale have been adequately established. Scores can be reported by the clinicians
or patients themselves to reflect diets tolerated, demonstrating its ease of employment. In the
current study, the FOIS was employed to indicate the feeding status of each individual patient at
baseline and post-RT/C. At the completion of RT/C, patients reported a FOIS score, based on
their oral intake at that time. At the post-treatment follow-up MBS study, the clinician assigned
FOIS scores to patients based on the physiology of swallowing exhibited. Both scores were
included in data analyses.
M D Anderson Dysphagia Inventory (MDADI)
Chen, Frankowski, Bishop-Leone, Hebert, Leyk, Lewin and Goepfert (2001) described
the development of the MDADI instrument (Appendix D3).184 The MDADI has been reported as
a valid and reliable tool, which allows HNC patients‟ reports of their swallowing-related QOL. It
constitutes four domains: global, emotional, functional and physical. The global domain (1 to 5)
is scored separately; however the emotional (1 to 30), functional (1 to 25) and physical (1 to 40)
domains together estimate the overall score.
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3.7. Data Analyses
The test statistics employed to analyze group differences in hypothesis 1 (EX vs. SW)
and hypothesis 2 (EX+SW vs. NTx) are presented in Table 3.8. Group differences between
Table 3.8: List of hypotheses 1 and 2 variables compared between or within the exercise (EX),
swallow (SW) and/or no treatment (NTx) groups, their level of measurement and test statistic
employed for analyses.
Hypotheses

Post-treatment Variables
(level of measurement)

Test statistic

Hypotheses 1a

Aspiration (nominal)

Pearson Chi square

PAS scores (ordinal)

Mann-Whitney U

Pre vs. post-treatment aspiration (nominal)

McNemar‟s

Pre vs. post-treatment PAS scores (ordinal)

Wilcoxon‟s signed rank

PEG (nominal)

Pearson Chi square

FOIS scores (ordinal)

Mann-Whitney U

Pre vs. post-treatment PEG (nominal)

McNemar‟s

Pre vs. post-treatment FOIS scores (ordinal)

Wilcoxon‟s signed rank

MDADI (continuous)

Mann-Whitney U

Pre vs. post-treatment MDADI (continuous)

Wilcoxon‟s signed rank

Hypotheses 1d

Weight (continuous)

Mann-Whitney U

Hypotheses 2

PEG (nominal)

Pearson chi square

Hypotheses 1b

Hypotheses 1c

PAS: Penetration Aspiration Scale; PEG: feeding tube; FOIS: Functional Oral Intake Scale; MDADI: MD
Anderson Dysphagia Inventory

nominal level outcome variables were assessed using the Pearson chi square test. If a cell count
had less than the expected count of 5, the Fisher‟s exact test was used. Group differences
between ordinal level outcome variables were assessed using the Mann-Whitney U test. Due to
evident non-normal distributions of continuous variables, the non-parametric Mann-Whitney U
test was also utilized to assess group differences between continuous variables.185 To assess
within-group differences between pre-treatment and post-treatment outcomes within groups, the
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McNemar test was applied for nominal level variables and the Wilcoxon‟s ranked test for ordinal
level variables. Again, due to non-normal distributions of continuous variables, the Wilcoxon‟s
ranked test was also use to assess within-group differences between pre-treatment and posttreatment continuous level outcomes. The type I error rate was set at α = .05.
To assess the correlations between physiological and functional, QOL and weight
outcomes as outlined in hypothesis 3 of this study, the following test statistics185 were used
(Table 3.9): nominal variables (Phi correlation), one nominal and another ordinal or continuous
variable (Point biserial correlation) and two ordinal or continuous level variables (Kendall‟s
tau). No statistical analyses were conducted for the secondary research questions proposed in this
study; graphical representation of the data was presented.

Table 3.9: List of hypothesis 3 variables employed in correlation analyses, along with the level
of measurement and test statistic employed to conduct analyses.
Hypotheses

Correlated Variables
(level of measurement)

Test statistic

Hypothesis 3

Aspiration (nominal) vs. PEG (nominal)

Phi correlation

Aspiration (nominal) vs. FOIS scores (ordinal)

Point biserial

Aspiration (nominal) vs. MDADI (continuous)

Point biserial

Aspiration (nominal) vs. Weight (continuous)

Point biserial

PAS scores (ordinal) vs. PEG (nominal)

Point biserial

PAS scores (ordinal) vs. FOIS scores (ordinal)

Kendall‟s tau

PAS scores (ordinal) vs. MDADI (continuous)

Kendall‟s tau

PAS scores (ordinal) vs. Weight (continuous)

Kendall‟s tau

PAS: Penetration Aspiration Scale; PEG: feeding tube; FOIS: Functional Oral Intake Scale; MDADI: MD
Anderson Dysphagia Inventory
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CHAPTER 4: RESULTS
The IBM SPSS Statistics v19.0.1 (SPSS, Inc., Chicago, IL) software was employed to
conduct the statistical analyses of all data in this study. Descriptive statistics, nonparametric
statistics and correlation analyses were utilized to test the proposed hypotheses as explained in
the Data Analyses section of Chapter 3: Design and Methods.
4.1. Cancer Treatment-Related Characteristics
At post-treatment, the EX, SW and NTx groups were assessed and compared in terms of
cancer-treatment related characteristics including, radiation dosage employed (continuous, nonnormal), duration of RT (continuous, non-normal) and % employment of ChT (nominal, 2 levels).
The Mann-Whitney U test was employed to assess group-differences on the continuous, nonnormal variables and the Pearson chi square test was utilized to assess group-differences in %
ChT employed (Table 4.1)
Table 4.1: Cancer treatment-related characteristics including, neo-adjuvant or concomitant ChT
(% patients), radiation dosage (mean, range, median and mode) and radiation therapy duration
(mean, range, median and mode) employed in the cancer treatment of patients in the exercise
(EX) and swallow (SW) treatment groups and no treatment (NTx) group
GROUPS 

EX (n=26)

SW (n=24)

NTx (n=23)

p value

% Chemotherapy
(Neo-adjuvant
and/or concomitant)

20/26 (77%)

16/24 (67%)

11/23 (47.83%)*

Pearson chi square
EX vs. SW, χ2(1)= 0.651, p=.420
EX+SW vs. NTx, χ2(1)=4.015, p=.045*

Radiation Dosage
(Gy)

Mean= 66.61
Range= 31 to 74
Median= 70
Mode= 70

Mean= 64.92
Range= 30 to 70
Median= 70
Mode= 70

Mean= 67.17
Range= 60 to 75
Median= 70
Mode= 70

Mann-Whitney U test
EX vs. SW, p=.496
EX+SW vs. NTx, p=.547

Duration of RT
(days)

Mean= 46
Range 23 to 58
Median= 48
Mode= 47

Mean= 48
Range= 15 to 64
Median= 51
Mode= 53, 52

Mean= 48
Range= 39 to 71
Median= 48
Mode= 49

Mann-Whitney U test
EX vs. SW, p=..311
EX+SW vs. NTx, p=.326

EX: exercise group; SW: swallow group; NTx: no treatment group; RT: radiation therapy; *Chemotherapy
utilization in NTx group vs. EX+SW groups (p=.045*)
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Chemotherapy (ChT): The EX and SW treatment groups did not differ statistically significantly
in the number of patients who received neo-adjuvant and/or concomitant ChT (χ2(1)=0.651,
p=.420). However, the NTx group received ChT, statistically significantly less frequently than
patients in the treatment groups (EX+SW) (χ² (1) = 4.015, p=.045*).
RT Dosage & Duration: Radiation dosage employed in the treatment of HNC did not differ
statistically significantly between the EX and SW treatment groups (Mann-Whitney U test,
p=.496) and between the NTx group and treatment groups (EX+SW) (Mann-Whitney U test,
p=.574). The mean number of days from the initiation to the completion of RT was also not
significantly different between the EX and SW groups and between the EX+SW and NTx
groups.(Mann-Whitney U test, p=.311 and .326 respectively)
4.2. Hypotheses Testing
Hypothesis 1a: Physiological outcomes in exercise (EX) vs. swallow (SW) treatment groups
 Aspiration
Post-treatment MBS studies could be completed in only 42 of the total 50 patients. One
patient died prior to the MBS study, 2 patients‟ insurances refused to cover the cost of the test.
Five other patients failed to follow-up for the test. Although the intention was to complete MBS
studies within 3 weeks following the completion of RT/C; miscellaneous conflicts resulted in
unexpected delays. The mean duration of post-treatment MBS studies from RT completion, was
rounded down to 4 weeks (median= 3 weeks; mode= 2, 3 weeks). However, 39/42 MBS studies
were performed within 6 weeks post-treatment, and the remaining 3 were performed beyond this
timeline. 4/22 (18%) patients in the EX group and 6/20 (30%) patients in the SW group exhibited
post-treatment aspiration. These differences were not statistically significant (Fisher‟s exact test,
p=.477) (Table 4.2). Further, differences between pre-treatment vs. post-treatment aspiration
were not statistically significant within the EX group (McNemar test, p=.625); however they
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Table 4.2: Pre-treatment and post-treatment physiological (aspiration % and Penetration
Aspiration Scale scores), functional (PEG tube dependence % and Functional Oral Intake Scale
scores), quality-of-life (MD Anderson Dysphagia Inventory scores) and weight loss in the
exercise (EX) vs. swallow (SW) treatment groups
EX Group

SW Group

Outcomes

Pre

Post

Pre

Post

p value

Physiology:
Aspiration (%)

2/26
(8%)

4/22
(18%)

1/24
(4%)

6/20
(30%)

Fisher‟s exact test, EX vs. SW, p=.477
McNemar‟s test
Pre vs. post EX, p=.625
Pre vs. post SW, p=.031*

PAS (Mean)

2

3.14

1.8

3.7

Mann-Whitney U testEX vs. SW, p=.594
,
Wilcoxon‟s signed rank test
Pre vs. post EX, p=.022*
Pre vs. post SW, p=.002*

Function:
PEG (%)

0

8/26
(31%)

0

13/24
(54%)

Pearson chi square
EX vs.SW, χ2(1)=2.805, p=.094

FOIS (Mean)

6.5

3.8

6.6

3.7

Mann-Whitney U test, EX vs. SW, p=.571
Wilcoxon‟s signed rank test
Pre vs. post EX, p <.001*
Pre vs. post SW, p <.001*

QOL: MDADI (Mean)

Mann-Whitney U test
(between/within groups)
Between EX vs. SW, p=.627
Within EX & SW p<.001*

Overall (1-100)

94.85

63.1

91.25

62.3

Global (1-5)

4.85

2.1

4.67

2.2

Between EX vs. SW, p=.410
Within EX & SW p<.001*

Emotional (1-30)

28.5

21.7

28.67

21.9

Between EX vs. SW, p=.977
Within EX & SW p<.001*

Functional (1-25)

23.73

16

23.17

16.2

Between EX vs. SW, p=.854
Within EX & SW p<.001*

Physical (1-40)

37.69

22.1

34.83

22.3

Between EX vs. SW, p=.454
Within EX & SW p<.001*

Weight Loss (Mean)

Post-pre

Post-pre

-13.5 lbs

-13.9 lbs

Mann-Whitney U test (post-pre)
EX vs. SW, p=.719

EX: exercise group; SW: swallow group; PAS: Penetration Aspiration Scale; PEG: feeding tube; FOIS: Functional
Oral Intake Scale; MDADI: MD Anderson Dysphagia Inventory; post: post-treatment; pre: pre-treatment
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were significant in the SW group (McNemar test, p=.031*).
 Penetration-Aspiration Scale (PAS) Scores
The mean post-treatment PAS scores for patients in the EX and SW groups were 3.14 and
3.7 respectively (Table 4.2). These differences were not statistically significant (Mann-Whitney
U test, p=.594). However, differences in pre-treatment vs. post-treatment PAS scores were
statistically significant within each group: EX (Wilcoxon signed rank test, p=.022*) and SW
(Wilcoxon signed rank test, p=.002*). Silent aspiration i.e. a PAS score of 8, was evident in 3
(14%) and 4 (20%) patients in the EX and SW groups, respectively (Table 4.3). Ten patients who
aspirated in this study can be categorized based on the severity of aspiration as follows: 4 trace,
highly inconsistent (2 EX and 2SW); 2 mild, inconsistent, eliminated completely by using
compensatory strategies (2 EX); 3 mild, consistent, reduced but not eliminated by using
compensatory strategies (1 EX and 2 SW) and 1 severe, frank aspiration, unable to eliminate by
using compensatory strategies (1 SW). Thus, only 4 patients (8%) as a group and 1 patient (4%)
in the EX group exhibited significant aspiration post-RT/C.
Table 4.3: Distribution of Penetration Aspiration Scale (PAS) scores among patients in the
exercise (EX) and swallow (SW) groups at pre-treatment and post-treatment
PAS scores

Normal

EX Group
Pre-treatment Post-treatment
(N=26)
(n=22)

SW Group
Pre-treatment
Post-treatment
(N=24)
(n=20)

1

14 (54%)

8 (36%)

12 (50%)

7 (35%)

2

7 (27%)

6 (27%)

10 (42%)

3 (15%)

3

3 (11%)

1 (4.5%)

1 (4%)

2 (10%)

4

0

0

0

1 (5%)

5

0

3 (14%)

0

1 (5%)

6

0

0

0

0

7

1 (4%)

1 (4.5%)

0

2 (10%)

8

1 (4%)

3 (14%)

1 (4%)

4 (20%)

Penetration

Aspiration

EX: exercise group; SW: swallow group; PAS: Penetration Aspiration Scale; MBS: Modified Barium Swallow
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 Characteristics of Aspirating vs. Non-Aspirating Patients in the Treatment Groups (EX+SW)
Table 4.4 characterizes patients who exhibited post-treatment aspiration (n=10) vs. those
who did not aspirate post-treatment (n=32), in terms of demographics (age and gender), tumor
characteristics (tumor site and tumor stage) and cancer treatment-related characteristics (surgery,
ChT, radiation dosage and treatment duration). Patients who aspirated post-treatment exhibited
statistically significantly longer RT duration as compared to the non-aspirating group (MannWhitney U test, p=.027*)
Table 4.4: Comparison of patient demographics (age and gender), tumor characteristics (tumor
site and stage) and cancer treatment-related characteristics (pre-RT surgery, use of chemotherapy
and radiation dosage), in aspirating vs. non-aspirating patients in the treatment groups, at posttreatment.
n=42

Aspiration (n=10)

No Aspiration (n=32)

p value

Age (years)

Mean ± SD

63 (SD=12)

61 (SD=14.5)

Mann-Whitney U, p=.506

Gender

Females
Males

3
7

30%
22%

7
25

70%
78%

Fisher‟s exact p=.678

Tumor site

OC
NPhx
OPhx
HPhx
Lx
U

0
0
9
0
1
0

0
0
45%
0
10%
0

3
2
11
1
9
6

100%
100%
55%
100%
90%
100%

Tumor stage

I
II
III
IV

1
0
2
7

25%
0
17%
35%

3
5
10
13

75%
100%
83%
65%

Mann-Whitney U, p=.149

Surgery

Yes
No

1
9

6%
35%

15
17

94%
65%

Fisher‟s exact p=.061

Chemotherapy

Yes
No

8
2

26%
18%

23
9

74%
82%

Fisher‟s exact p=1.0

RT Dosage

Mean
< 70
≥ 70

69.6 Gy
1
8%
9
31%

63.91 Gy
12
92%
20
69%

χ2(5)=9.752, p=.083

Mann-Whitney U, p=.121

Mean(Range)
51.6 (47 to 54)
45.59 (15 to 64)
Mann-Whitney U, p=.027*
Median
53
49
Mode
53
52
SD= standard deviation; χ2= Pearson‟s chi square; df= degrees of freedom; OC= oral cavity; NPhx= nasopharynx;
OPhx= oropharynx; HPhx= hypopharynx; Lx= larynx; U= unknown primary; RT= radiation therapy; PAS=
Penetration-Aspiration Scale; FOIS= Functional Oral Intake Scale
Duration of RT
(days)
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Hypothesis 1b: Functional outcomes in exercise (EX) vs. swallow (SW) treatment groups
 PEG tube dependence
8/26 patients in the EX group vs. 13/24 patients in the SW group relied on a PEG tube to
meet their nutrition and hydration requirements at the completion of treatment (Table 4.2). These
differences were not detected as statistically significant (χ2(1)=2.805, p=.094); however, within
the EX and SW groups, post-treatment PEG tube dependence was statistically significant
(McNemar test, p=.008* and .000* respectively). Table 4.5 provides information regarding the
timing of reactive (during or after cancer treatment) PEG tube placements in patients of the EX
and SW treatment groups based on radiation dosage completed. Within the first four weeks of
RT/C, 5/8 patients in the EX group vs. 10/13 patients in the SW group received PEG tubes. The
remaining three PEG tube dependent patients in each group received PEG tubes towards the
latter half of treatment or immediately at the completion of treatment.
Table 4.5: PEG tube placements in patients of the exercise (EX) and swallow (SW) groups,
categorized based on of radiation treatment (RT) dosage completed
RT dosage completed

EX group

SW group

≤ 10 Gy

2

1

11 to 20 Gy

-

3

21 to 30 Gy

-

5

31 to 40 Gy

3

1

41 to 50 Gy

1

-

51 to 60 Gy

-

-

61 to 70 Gy

2

3

RT: radiation dosage; EX: exercise group; SW: swallow group; Gy: unit or RT

 Functional Oral Intake Scale (FOIS) scores
The mean post-treatment FOIS scores of patients in the EX and SW groups were 3.8 and
3.7 respectively. These differences were not statistically significant (Mann-Whitney U test,
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p=.571). However, both EX and SW treatment groups reported significantly worse FOIS scores
at post-treatment, compared to pre-treatment (Wilcoxon signed rank test, p=.000* and p=.000*
respectively). 77% and 62% patients in the EX and SW groups respectively, continued to tolerate
a full oral diet (FOIS scores 4 to 7) post-treatment, as compared to 100% at pre-treatment (Table
4.6). 38.5% and 33% patients in the EX and SW groups respectively, tolerated only liquids
(FOIS score 4) at post-treatment.
Table 4.6: Distribution of Functional Oral Intake Scale (FOIS) scores among patients in the
exercise (EX) and swallow (SW) groups at pre-treatment and post-treatment


EX Group (N=26)

FOIS scores
PEG tube

Full oral diet
(modified)

SW Group (N=24)

Pre-treatment

Post-treatment

Pre-treatment
0

1

0

4 (15%)

2

0

2 (8%)

0

3 (13%)

3

0

0

0

3 (13%)

4

0

10 (38.5%)

0

8 (33%)

5

5 (19%)

10 (38.5%)

5 (21%)

5 (21%)

6

3 (12%)

0

0

0

19 (79%)

2 (8%)

7
18 (69%)
0
Full oral diet
(Normal)
EX: exercise group; SW: swallow group; FOIS: Functional Oral Intake Scale

Post-treatment
3 (12%)

 Characteristics of PEG Tube vs. Non-PEG Tube Dependent Patients in the Treatment Groups
of This Study (EX+SW)
Table 4.7 characterizes patients who exhibited post-treatment PEG tube dependence
(n=21) vs. non-PEG tube dependent patients (n=29), in terms of demographics (age and gender),
tumor characteristics (tumor site and tumor stage) and cancer treatment-related characteristics
(surgery, ChT, radiation dosage and treatment duration). Patients who required PEG tubes in this
study, appeared to have underwent significantly less frequent pre-RT surgeries (χ2(1)=5.52,
p=.019*), higher radiation dosage (Mann-Whitney U test, p=036*) and longer duration to RT
completion (Mann-Whitney U test, p=.028*).
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Table 4.7: Comparison of patient demographics (age and gender), tumor characteristics (tumor
site and stage) and cancer treatment-related characteristics (pre-RT surgery, use of
chemotherapy, radiation dosage and treatment duration) in PEG tube dependent vs. non-PEG
tube dependent patients at post-treatment.
N=50

PEG tube (n=21)

No PEG tube (n=29)

64 (13)

61 (15)

p value

Age (years)

Mean (SD)

Gender

Females
Males

7
14

70%
35%

3
26

30%
65%

Tumor site

OC
NPhx
OPhx
HPhx
Lx
U

0
1
11
2
4
3

0%
50%
52%
67%
31%
43%

4
1
10
1
9
4

100%
50%
48%
33%
69%
57%

Tumor stage
*not staged (n=1)

I
II
III
IV

1
2
6
11

20%
29%
46%
46%

4
5
7
13

80%
71%
54%
54%

Mann-Whitney U, p=.298

Surgery

Yes
No

4
17

21%
55%

15
14

79%
45%

χ2 (1)=5.52, p=.019*

Chemotherapy

Yes
No

18
3

50%
21%

18
11

50%
78%

χ2(1)=3.39, p=.066

RT Dosage

Mean
< 70
≥ 70

67.67 Gy
3
20%
18
51%

64.45 Gy
12
17

80%
49%

Duration of RT
(days)

Mean
Range
Median
Mode

49.86
23 to 64
52
53

Mann-Whitney U, p=.672
Fisher‟s exact p=.073

χ2 (5)=5.30, p=.380

Mann-Whitney U, p=.036*

45.45
15 to 58
47
47

Mann-Whitney U, p=.028*

SD= standard deviation; χ2= Pearson‟s chi square; df= degrees of freedom; OC= oral cavity; NPhx= nasopharynx;
OPhx= oropharynx; HPhx= hypopharynx; Lx= larynx; U= unknown primary; RT= radiation therapy; PAS=
Penetration-Aspiration Scale; FOIS= Functional Oral Intake Scale

Hypothesis 1c: Quality-of-life (QOL) in exercise (EX) vs. swallow (SW) treatment groups
Mean post-treatment MDADI scores of patients in the EX vs. SW groups were: overall
63.1 vs. 62.3, global 2.1 vs. 2.2, emotional 21.7 vs. 21.9, functional 16 vs. 16.2 and physical 22.1
vs. 22.3, respectively. Between groups, no statistically significant differences were obtained in
changes in post-treatment MDADI scores (from pre-treatment) including, overall scores (MannWhitney U test, p=.627), global scores (Mann-Whitney U test, p=.410), emotional scores (Mann64

Whitney U test, p=.977), functional scores (Mann-Whitney U test, p=.854) or physical scores
(Mann-Whitney U test, p=.454). However, within the EX and SW groups, pre-treatment vs. posttreatment MDADI scores statistically significantly differed for the overall scores and scores of
each domain: global, emotional, functional and physical (Wilcoxon signed rank test, p<.001*,
each difference).
Hypothesis 1d: Pre-treatment to post-treatment weight loss in exercise (EX) vs. swallow
(SW) treatment groups
The mean weight loss post-treatment exhibited by the EX and SW treatment groups was
-13.5 lbs. and -13.9 lbs. respectively (Table 4.2). These differences were not statistically
significantly (Mann-Whitney U test, p=.719).
 Physiological, Functional, Quality-of-Life (QOL) and Weight Outcomes in Patients Who
Exhibited Post-Treatment Aspiration and/or PEG Tube Dependence
Of the 10 patients who aspirated in the current study, seven (70%) required reactive PEG
tube placements (i.e. during or at the completion of RT/C) (Table 4.8). Three of these 10 patients
(1 EX group; 2 SW group) eliminated aspiration with postural and/or dietary changes without
warranting PEG tube placement. Of the 21 patients who received PEG tubes, only 7 aspirated on
the post-treatment MBS study.
Table 4.8: Number of patients who exhibited aspiration and/or PEG tube dependence in the
exercise (EX) and swallow (SW) treatment groups
Groups 

Aspiration
+ PEG

No aspiration
+ PEG

Total PEG

3 (75%)

5 (62.5%)

8

SW group
(# aspiration =6 & # PEG = 13)

4 (67%)

9 (69%)

13

Total
(# aspiration = 10; # PEG = 21)

7 (70%)

14 (67%)

21

EX group
(# aspiration =4 & # PEG = 8)

EX: exercise group; SW: swallow group; PEG: feeding tube; #: number
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Tables 4.9 and 4.10 characterize patients who aspirated (vs. non aspirating patients) or
required a PEG tube at post-treatment (vs. non-PEG tube dependent patients), respectively.
Patients who exhibited aspiration on the post-treatment MBS study were assigned significantly
worse FOIS scores by the clinician, at the post-treatment MBS study (Table 4.9), which is
expected, since aspiration can result in dietary and behavioral alterations in eating (MannWhitney U test, p=.009*). PEG tube dependent patients exhibited significantly worse PAS scores
at the post-treatment MBS study (Mann-Whitney U test, p=.042*), were assigned worse FOIS
scores by the clinician (Mann-Whitney U test,p=.000*) and had significantly lower MDADIoverall and emotional scores (Mann-Whitney U test, p=.040* and .017* respectively) as
compared to the non-PEG tube dependent patient-group (Table 4.10).
Table 4.9: Comparison of physiological outcomes (PAS scores), functional outcomes (PEG tube
dependence and FOIS scores), quality-of-life (QOL) outcomes (MDADI scores) and weight loss
in aspirating vs. non-aspirating patients at post-treatment (EX+SW)

n=42

Aspiration (n=10)

No Aspiration (n=32)

p value

2.1 (1-5)

Not applicable

11 (34%)
21 (66%)

Fisher‟s exact p=.070

3.7 (1-7)
5.6 (3-7)

Mann-Whitney U, p=.927
Mann-Whitney U, p=.009*

-29.34
-2.59
-6.13
-7.59
-14

Mann-Whitney U, p value
.779
.717
.181
.240
.848

PAS scores
Mean (range)
7.7 (6-8)
PEG tube
Yes
No

7 (70%)
3 (30%)

FOIS scores
Mean (range)
Post-RT/C
MBS (n=42)

3.8 (1-7)
4 (1-5)

MDADI Mean
- Overall
- Global
- Emotional
- Physical
- Functional

-29.7
-2.7
-7.9
-5.9
-14.3

Mann-Whitney U, p=.848
Weight loss
-13.2(-21.5 to -0.5)
-13.5 (-46 to +6)
Mean (range)
EX: exercise group; SW: swallow group; PAS: Penetration Aspiration Scale; FOIS: Functional Oral Intake Scale;
MDADI: MD Anderson Dysphagia Inventory; RT/C: radiation therapy with/without chemotherapy; MBS: Modified
Barium Swallow; χ2: Chi square; df: degrees of freedom; SD: Standard deviation
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Table 4.10: Comparison of physiological outcomes (aspiration and PAS scores), functional
outcomes (FOIS scores), quality-of-life (QOL) outcomes (MDADI scores) and weight loss in
PEG tube dependent vs. non-PEG tube dependent patients at post-treatment (EX+SW)
N=50
Aspiration (n=42)
Yes
No
PAS scores (n=42)
Mean (range)
FOIS scores Mean (range)
Post-RT/C
MBS (n=42)
MDADI Mean
- Overall
- Global
- Emotional
- Functional
- Physical
Weight loss
Mean (range)

PEG tube (n=21)

No PEG tube (n=29)

p value

7 (70%)
11 (34%)

3 (30%)
21 (66%)

Fisher‟s exact p=.070

4.4 (1 to 8)

2.7 (1 to 8)

2.5 (1 to 5)
4.3 (1 to 7)

4.6 (4 to 7)
6 (5 to 7)

Mann-Whitney U, p=.000*
Mann-Whitney U, p=.000*

-34.81
-2.90
-8.57
-8.43
-15.95

-27.21
-2.38
-5.48
-6.62
-13.59

Mann-Whitney U, p value
.040*
.398
.017*
.076
.211

-15.6 (-41 to -0.5)

-12.3 (-46 to +6)

Mann-Whitney U, p=.201

Mann-Whitney U, p=.042*

EX: exercise group; SW: swallow group; PAS: Penetration Aspiration Scale; FOIS: Functional Oral Intake Scale;
MDADI: MD Anderson Dysphagia Inventory; RT/C: radiation therapy with/without chemotherapy; MBS: Modified
Barium Swallow; χ2: Chi square; df: degrees of freedom; SD: Standard deviation

Hypothesis 2: PEG tube outcomes between the treatment and no treatment groups
At post-treatment, 8/26 (31%) patients in the EX group, 13/24 (54%) patients in the SW
group and 10/23 (43.5%) patients in the NTx group exhibited PEG tube dependence (Table
4.11). The NTx group‟s post-treatment PEG tube dependence rate did not statistically
significantly differ from that of the EX group (χ2 (1)= .001, p=.97) or the SW group (χ2 (1)=
0.185, p=.667). At 3 months post-treatment also, the NTx group‟s post-treatment PEG tube
dependence rate did not statistically significantly differ from that of the EX group (Fisher‟s exact
test, p=.455) or the SW group (χ2 (1)= 2.108, p=.146). However, the EX group exhibited
significantly higher PEG tube elimination rates as compared to the SW group at 3 months posttreatment (Fisher‟s exact test, p=.016*) (Figure 4.1).
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Table 4.11: PEG tube dependence outcomes between the exercise (EX) vs. swallow (SW) vs. no
treatment (NTx) groups at post-RT/C and 3 months post-treatment
GROUPS
PEG 

EX

SW

NTx

p value

Post-treatment

8/26
(31%)

13/24
(54%)

10/23
(43.5%)

Pearson chi square
NTx vs. EX, χ2 (1)= .001, p=.97
NTx vs. SW, χ2 (1)= 0.185, p=.667

3 month f/u

4/25
(16%)

12/24
(50%)

5/18
(28%)

1 Died

Fisher‟s exact test,
EX vs. SW, p=.016*
NTx vs. EX, p=.455

5 missing data

Pearson chi square
NTx vs. SW, χ2 (1)= 2.108, p=.146

EX: exercise group; SW: swallow group; NTx: no treatment group; PEG: feeding tube; f/u:
follow up

100

Post-treatment
nEX Group
nSW Group
nNTx Group

PEG %

80
54%

60
40

50%

43.5%
28%

31%

3 months posttreatment
EX Group
SW Group
NTx Group

16%

20
0

EX
(Post n=26;
3 mos n=25)

SW
(Post n=24;
3 mos n=24)

NTx
(Post n=23;
3 mos n=18)

GROUPS at post-RT/C vs. 3 months
EX vs. SW at 3 months post-treatment(p=.011*)
EX: exercise group; SW: swallow group; RT/C: radiation therapy with/without chemotherapy; mos: months

Figure 4.1: PEG tube dependence (%) in patients in the exercise (EX), swallow (SW), and NTx
groups at post-treatment and 3 months post-treatment
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Since, patients in the NTx group received ChT significantly less frequently, PEG
dependence rates were additionally compared at post-treatment and 3 months post-treatment only
in patients who received RT + ChT in the EX, SW and NTx groups (Table 4.12). At posttreatment, the EX group (RT+ChT) exhibited significantly lower PEG tube dependence rates as
compared to the SW group (RT+ChT) (χ2 (1)= 4.05, p=.044*) and the NTx group (χ2 (1)= 4.045,
p=.044*) . The SW group did not exhibit significantly different rates of PEG tube dependence as
compared to the NTx group (Fisher‟s exact test, p=1.0). At 3 months post-treatment, the EX
group continued to exhibit significantly lower PEG tube dependence rates as compared to the
SW group (Fisher‟s exact test, p=.011*) and the NTx group (Fisher‟s exact test, p=.009*).
There were no statistically significant differences between the SW and NTx group‟s PEG tube
dependence rates at 3 months post-treatment (Fisher‟s exact test, p=.679) (Figure 4.2)
Table 4.12: PEG tube dependence outcomes at post-treatment and 3 months post-treatment,
between patients in the exercise (EX) vs. swallow (SW) vs. no treatment (NTx) groups, who
received chemotherapy (ChT) in addition to radiation therapy (RT)
GROUPS

PEG

Post-treatment

EX
SW
NTx
(RT+ChT) (RT+ChT) (RT+ChT)
n=20
n=16
n=11
7/20
(35%)

11/16
(69%)

8/11
(73%)

p value

Pearson chi square
EX vs. SW, χ2 (1)= 4.05, p=.044*
EX vs. NTx, χ2 (1)= 4.045, p=.044*
Fisher‟s exact test
SW vs. NTx, p=1.0

3 month f/u

2/20
(10%)

8/16
(50%)

5/8
(62.5)

Fisher‟s exact test,

EX: exercise group; SW: swallow group; NTx: no treatment group; PEG: feeding tube
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EX vs. SW, p=.011*
EX vs. NTx, p=.009*
SW vs. NTx, p=.679

100

PEG %

73%

69%

80
60

62.5%

3 months posttreatment
EX Group
SW Group
NTx Group

50%
35%

40
20
0

Post-treatment
nEX Group
nSW Group
nNTx Group

10%

EX
(Post n=20;
3 mos n=20)

SW
(Post n=16;
3 mos n=16)

NTx
(Post n=11;
3 mos n=8)

GROUPS at post-RT+ChT vs. at 3 months
Post-treatment: EX vs. SW, p=.044*; EX vs. NTx, p=.044*; SW vs. NTx, p=1.0
At 3 months post-treatment: EX vs. SW, p=.011*; EX vs. NTx, p=.009* SW vs. NTx, p=.679
EX: exercise group; SW: swallow group; RT+C: radiation therapy with chemotherapy; mos: months

Figure 4.2: PEG tube dependence (%) at post-treatment and 3 months post-treatment between
patients in the exercise (EX), swallow (SW), and no treatment (NTx) groups, who received
radiation therapy + chemotherapy.
Additionally, during the data collection process, a higher rate of prophylactic PEG tube
placement was observed at the non-Baton Rouge MBPCC sites (23%) vs. MBPCC-Baton Rouge
(6%) (Table 4.13).
Hypothesis 3: Correlations between physiological swallowing outcomes, functional
swallowing outcomes, swallowing-related QOL outcomes and weight loss.
Only 42 of the total 50 patients enrolled in the study completed the post-treatment MBS
study, as described earlier. As is evident in Table 4.14, the phi correlation indicated a significant
relationship between aspiration at post-treatment and PEG tube dependence (p=.047*); however
the value 0.307 indicates only a weak positive relation. Patient-reported FOIS scores at posttreatment did not correlate with physiological outcomes (aspiration and PAS scores) in this
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Table 4.13: PEG tube placement patterns at MBPCC at three different timelines A) prospective
patient recruitment timeline, 12/1/10 to 1/31/12 at the Baton Rouge site and B) retrospective NTx
group recruitment timeline, 12/1/10 to 9/30/11 at the non-Baton Rouge sites
DATA COLLECTION SITES

PEG placements
Prophylactic
Reactive

MBPCC-Baton Rouge
(timeline of recruitment of EX & SW)
12/1/10 to 1/31/12
3/53 (6%)

MBPCC- Non Baton Rouge
(timeline of recruitment of NTx)
12/1/10 to 9/30/11
7/30 (23%)

21/50 (42%)

10/23 (43%)

EX: 31%; SW: 54%

None

29/50 (58%)

13/23 (57%)

Total PEG

24/53 (45%)

17/23 (74%)

MBPCC: Mary Bird Perkins Cancer Center; EX: exercise group; SW: swallow group; NTx: no treatment group

Table 4.14: Correlations between physiological swallowing outcomes i.e. aspiration and
Penetration Aspiration Scale (PAS) scores and functional outcomes i.e. PEG dependence,
Functional Oral Intake Scale (FOIS) scores reported by patients at post-treatment and FOIS
scores recommended by the clinician at the time of post-treatment Modified Barium Swallow
(MBS) study of patients in the treatment groups i.e. EX + SW.
Functional outcomes

Physiological
outcomes

n= 42

Aspiration

PAS scores

PEG dependence

FOIS scores (patient)

FOIS(clinician)

Phi correlation

Point biserial correlation

Point biserial correlation

Value= .307 (p=.047*)

r=.014 (p=.929)

r=-.432 (p=.004*)

Point biserial correlation

Kendall‟s correlation

Kendall‟s correlation

r=.015 (p=.925)

tau_b=-.075 (p=.552)

tab_b=-.468 (p=.000*)

EX: exercise group; SW: swallow group; PAS: Penetration Aspiration Scale; FOIS: Functional Oral Intake Scale

study. However, clinician reported FOIS scores (functional outcome) estimated from the MBS
study correlated with aspiration and PAS scores (physiological outcomes), as expected with a p
value of .004* and <.001* respectively. Similarly, changes in MDADI scores (QOL outcome)
and weight loss post-treatment did not correlate with aspiration or PAS scores (Table 4.15).
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Table 4.15: Correlation between physiological swallowing outcomes i.e. aspiration and
Penetration Aspiration Scale (PAS) scores and quality-of-life (QOL) outcomes i.e. MDADI
scores (overall and global) and weight outcomes i.e. weight loss post-treatment

Physiological
outcomes

n= 42

QOL and Weight outcomes
MDADI
Overall

MDADI
Global

MDADI
Emotional

MDADI
Functional

MDADI
Physical

Weight
loss

Aspiration

Point biserial
correlation
r=-.011
(p=.945)

Point biserial
correlation
r=.028
(p=.858)

Point biserial
correlation
r=-.179
(p=.256)

Point biserial
correlation
r=.170
(p=.283)

Point biserial
correlation
r=-.018
(p=.910)

Point biserial
correlation
r=.015
(p=.925)

PAS
scores

Kendall‟s
correlation
tau_b=-.056
(p=.637)

Kendall‟s
correlation
tau_b=-.119
(p=.356)

Kendall‟s
correlation
tau_b=-.184
(p=.124)

Kendall‟s
correlation
tau_b=.079
(p=.512)

Kendall‟s
correlation
tau_b=-.034
(p=.770)

Kendall‟s
correlation
tau_b=-.084
(p=.473)

QOL: quality-of-life; PAS: Penetration Aspiration Scale; FOIS: Functional Oral Intake Scale; MDADI: MD
Anderson Dysphagia Inventory Scale

4.3 Secondary Research Findings
Radiation Toxicities
Each week, when patients were seen in swallowing therapy, they were requested to rate
the severity of toxicities experienced on a scale of 1 to 5, 5 being the worst. Toxicities assessed
included, xerostomia, mucositis, pain, odynophagia, nausea/vomiting, dysgeusia, trismus and
reduced appetite. Figure 4.3 is a graphical presentation of the changes in individual toxicities
experienced by patients as a group, with RT advancement. Weekly changes in toxicities
appeared consistently similar in both EX and SW treatment groups; dysgeusia, reduced appetite
and xerostomia (in decreasing order) being the three most severe toxicities experienced
throughout the treatment weeks, in both groups.
Dysphagia Symptoms
Every week patients rated the symptoms, choking with solids and liquids, nasal and oral
regurgitation, reflux, difficulty initiating a swallow, globus sensation, foods sticking in the
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Figure 4.3: Proportions of severity of RT toxicities, including xerostomia, mucositis, pain, odynophagia, nausea/vomiting, dysgeusia,
trismus and reduced appetite reported by patients in the exercise (EX) vs. swallow (SW) groups, throughout radiation therapy (RT)
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(Figure 4.3 continued)
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(Figure 4.3 continued)
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throat, gagging, NPO status, hoarseness and wet/gurgly voice quality (1 to 5, 5 being the worst).
Figure 4.4 is a graphical presentation of the progressive changes in individual symptoms reported
by patients. The EX group reported hoarseness, globus sensation and difficulty initiating a swallow
(in decreasing order) as the three most severe dysphagia symptoms throughout RT; whereas for the
SW group these were hoarseness, difficulty initiating swallow, reflux, foods sticking in the throat
and globus sensation (in decreasing order).
Patient-Reported Compliance with Therapeutic Tasks
All patients in the study were requested to maintain a log of the number of sets of exercises
completed on a daily basis. At each therapy session, patients returned completed log sheets to the
attending speech pathologist. Figure 4.5 presents the group percentage of the number of sets of
exercises completed by patients in the EX and SW treatment groups. A progressively downward
trend in compliance with exercises was evident, indicating that compliance reduced as RT
advanced.
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Figure 4.4: Proportions of severity of dysphagia symptoms, including choking with solids and liquids, nasal and oral regurgitation,
reflux, difficulty initiating a swallow, globus sensation, foods sticking in the throat, gagging, NPO status, hoarseness and wet/gurgly
voice quality reported by patients in the exercise (EX) vs. swallow (SW) groups, throughout radiation therapy (RT)
77

(Figure 4.4 continued)
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(Figure 4.4 continued)
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Percentage of exercises completed (%)

EX Group
SW Group
EX Group
SW Group
Repetitive
Masako
Masako
Repe swallows
ve swallows
Pharyngeal
squeeze
Pharyngeal
squeeze
ShakerShaker
80
70
60
50
40
30
20
Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 7 ≥Week8
(EX 4.7, (EX 9.7,
(EX Weeks
(EX of RT
(EX
(EX
(EX
(EX
SW 3.9)EX:
SWexercise
8.1) group;
14.5, SW:19.3,
23.7,
27.8,
32.3,
35.1,
swallow group; RT: radiation therapy
SW
SW 18)
SW
SW
SW
SW
12.9)
22.4)
27.1)
31.4)
34.6)

Figure 4.5: Group percentages of exercises completed by patients in the exercise (EX) group:
Masako, pharyngeal squeeze and Shaker exercises and swallow (SW) group: repetitive swallows
over the course of radiation therapy with/without chemotherapy (RT/C)
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Percentage of exercises completed in EX Group (%)

EX
EX
EX
EX
EX
EX

100

No PEG: Masako
No PEG: Pharyngeal squeeze
No PEG: Shaker
PEG: Masako
PEG: Pharyngeal Squeeze
PEG: Shaker

90
80
70
60
50
40
30
20
10
Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 7 ≥Week8
Weeks of RT
EX: exercise group; RT: radiation therapy; PEG: feeding tube

Figure 4.6: Percentage of exercises completed by patients in the exercise (EX) group (Masako,
pharyngeal squeeze and Shaker exercises) with PEG tube placements and without PEG tubes.
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Percentage of exercises completed in SW Group (%)

SW No PEG: Swallows
SW PEG: Swallows

100
90
80
70
60
50
40
30
20
10
Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 7 ≥Week8
Weeks of RT
SW: swallow group; RT: radiation therapy; PEG: feeding tube

Figure 4.7: Percentage of repetitive swallows completed by patients in the swallow (SW) group
with PEG tube placements and without PEG tubes.
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CHAPTER 5: DISCUSSIONS
The purpose of the current study was to investigate the effects of two different behavioral
prophylactic swallowing exercise (PSE) protocols performed during radiation therapy (RT), on
swallowing physiology, function, quality-of-life (QOL) and weight outcomes following radiation
therapy with/without chemotherapy (RT/C) for head and neck cancers (HNC). The investigation
was conducted via a prospective study design including 26 patients in the „behavioral
swallowing exercise‟ or EX group and 24 patients in the „repetitive swallowing‟ or SW group.
Patients were alternately assigned to the treatment groups and every effort was made to match
the two groups for age, tumor site and tumor stage. Additionally, 23 patients were retrospectively
recruited to a „no treatment‟ (NTx) group within identical timelines of the prospective study.
There were no statistically significant differences between the EX and SW treatment groups at
pre-treatment in demographics, tumor characteristics, swallowing physiology, functional and
QOL, or cancer treatment-related characteristics. A significantly less number of patients in the
NTx group received combined modality treatments (i.e. both ChT and RT as opposed to RT
alone), as compared to the treatment groups. Therefore, PEG tube dependence outcomes were
also compared between the treatment and no treatment groups in patients who underwent both
RT and ChT.
In summary, data analyses revealed that there were no significant differences between the
EX and SW groups in terms of swallowing physiology (i.e. aspiration % and mean PAS scores),
function (i.e. PEG tube dependence % and mean FOIS scores), QOL (i.e. mean MDADI scores)
and weight loss at post-treatment. However, within each group, significantly worse scores were
evident in each of these domains: swallowing physiology, function and QOL, from pre-treatment
to post-treatment.
Additionally, the NTx group‟s PEG tube dependence rates were statistically similar to
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those of the EX and SW groups, both at post-treatment and 3 months post-treatment. However,
the EX group demonstrated significantly better rates of PEG tube elimination (16%) as compared
to the SW group (50%) at 3 months post-treatment. Among patients who specifically received
both RT and ChT, the EX group demonstrated significantly lower feeding tube dependence as
compared to the SW and NTx groups, at both timelines (i.e., post-treatment and 3 months posttreatment). The SW group and the NTx group did not differ from each other in PEG tube
dependence rates; yet, the SW group exhibited better outcomes than the NTx group. Majority of
PEG tube placements in patients occurred due to treatment-related toxicities, rather than the
presence of aspiration. In addition, significantly worse post-treatment MDADI overall scores and
emotional domain scores were reported by patients who received PEG tubes vs. those who did
not. A statistically significant, yet weak positive correlation was evident between swallowing
physiology (aspiration and PAS scores) and functional outcomes (clinician-assigned FOIS
scores) at the post-treatment MBS study.

However, patient-reported FOIS scores did not

correlate with PAS scores or the presence of aspiration.
The findings of this study indicated that performing PSE (i.e. Masako, pharyngeal
squeeze and Shaker exercises) resulted in improved swallowing function (determined by PEG
tube dependence) as compared to performing repetitive swallows as the therapeutic task or no
therapy. The following sections discuss the findings of this study in relation to the proposed
hypotheses and to the literature.
5.1. Physiological Outcomes
This study hypothesized that the EX group will exhibit significantly lower rates of
aspiration and lower Penetration Aspiration Scale (PAS) scores at post-treatment, as compared to
the SW group. This hypothesis was rejected based on data analyses. However, there were withingroup differences from pretreatment to post-RT/C. Both, the EX and SW treatment groups
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demonstrated significantly worse post-treatment PAS scores; yet only the SW group exhibited
significantly worse post-treatment aspiration rates. This particular finding encourages the current
clinical assumption that PSE may help patients to better retain swallowing physiology
determined by aspiration rates. 18% aspiration in the EX group appeared to be comparable to
that reported in other studies employing PSE (i.e. 14% to 18%), 89, 91 but lower than that reported
in studies not employing PSE (i.e. 23% to 65%).11, 85, 186-190 The SW group‟s aspiration rates on
the other hand, appeared to be at the lower end of the range reported in the literature not
employing PSE, but higher than that in other studies employing PSE regimens. Additionally, the
EX group‟s mean post-treatment PAS score also appeared to be lower than that reported in the
literature employing a PSE regimen.
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The worse PAS score in the current study was obtained

with thin liquids. PAS scores could not be compared with the van der Molen et al., (2011) study
89

as they reported mean PAS scores across consistencies; whereas the current study reported

only the worse PAS score obtained with any consistency. Patient demographics, tumor
characteristics and cancer treatment-related factors of the patients in this study appear quite
similar to those reported in the comparable studies; however methodological differences and
institutional factors affecting outcomes cannot be accounted for at this time.
This current finding along with findings from two other studies, 89, 91 confirm the positive
impacts of performing PSE in reducing physiological swallowing impairments post-RT/C,
determined by aspiration. The intense, salient task of repetitive swallowing appeared to have
produced insignificantly worse aspiration rates than performing an intense, biomechanical eventspecific exercise regimen focusing on tongue base retraction, hyolaryngeal excursion and upper
esophageal sphincter (UES) opening. Two of the three exercises (i.e. pharyngeal squeeze and
Shaker exercises) did not involve the act of swallowing i.e. they were not salient to swallowing,
but were salient to specific events within the act of swallowing. The results of this study
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encourage the use of exercises geared towards the specific events of swallowing physiology to
minimize the effects of RT/C, since they produced better outcomes in swallowing function. The
SW group‟s post-treatment aspiration rate (30%) appeared at the lower end of the range reported
in the literature not employing a PSE regimen. Additionally, since this rate was not statistically
different when compared to the rate of the EX group, the relative benefits of performing
repetitive swallows over behavioral exercises and no exercises cannot be ruled out. Repetitive
swallows in this study were performed either dry or with sips of water as needed. Altering the
regimen of repetitive swallows such as altering the consistency used during practice (nutritious
thickened liquid or pureed consistencies) or increasing the frequency/ intensity schedule, appears
to be worth investigating, to determine if outcomes may improve. The McNeill Dysphagia
Therapy Program (MDTP)-

155, 156

which is a 3 week intensive program employing hard

swallows with an increasing hierarchy of bolus consistency and volume modifications at a high
intensity,155, 156 has been shown to improve swallowing outcomes. Increasing the richness of
repetitive swallows employed in this study, either by adding effort to it or by further increasing
its saliency with the introduction of an appropriate bolus, appears important. The current study‟s
author‟s motivation of investigating these aspects emerges from the knowledge that patients
undergoing RT/C experience among several toxicities, pain, fatigue and even depression,191
which evidently result in a reduction in adherence to a complex, exercise program. Identifying
the value of a simple, more feasible, scientifically sound exercise program may significantly
reduce the burden of performing complex behavioral exercises in this fragile and overwhelmed
patient population undergoing RT/C in addition to decreasing swallowing impairments. The
current study‟s findings indicate that the employment of salient swallowing tasks with
alterations, may have the potential to meet this need.
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 Characteristics of Aspirating vs. Non-Aspirating Patients in the Treatment Groups
Since no significant differences in aspiration rates or PAS scores were revealed between
the EX and SW groups, they were combined to assess for patient and cancer-related factors
potentially contributing to the occurrence of aspiration. Of the 10 patients who aspirated in this
current study, only four patients exhibited significant aspiration, all four patients relied on PEG
tubes at post-treatment to meet their nutritional needs; two of them (in the EX group) eliminated
PEG tubes prior to the 3-month follow up consultation. Patients who underwent pre-RT/C
surgeries in this study exhibited significantly lower aspiration rates. However, this finding is
confounded by the large difference in the number of aspirating vs. non aspirating patients. PreRT/C surgeries have been previously reported to increase the risk of aspiration post-treatment;
192

this was not evident in the current study, possibly related to the small aspirating group of

patients. Patients who aspirated post-treatment, also had a prolonged duration/ course of RT (by
approximately 5 days) as compared to non-aspirating patients. Duration of RT, which was
defined as the number of days from the initiation to the completion of RT, is representative of a
patient‟s treatment schedule. Therefore slightly longer RT durations, may not necessarily
indicate that the patients received significantly higher dosages of RT, rather they imply the
length of planned therapy in addition to any missed days due to miscellaneous reasons. Longer
RT durations in some patients in this study (especially the ones who aspirated post-treatment)
were mainly caused by treatment breaks due to miscellaneous reasons including, technical
malfunctions of the radiation delivery machines; holidays; hospitalizations due to dehydration or
PEG tube placements and breaks from treatment due to altered laboratory values.
Post-treatment patient-reported FOIS scores did not significantly differ between the
aspirating and non-aspirating groups of patients. This finding indicates that patient-reported
FOIS scores may not truly represent the actual change in swallowing physiology. Both groups of
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patients reported lower scores than pre-treatment. However, at the post-treatment MBS study,
patients in the aspirating group were assigned significantly lower FOIS scores as compared to the
non-aspirating group of patients. This is expected considering that dietary restrictions or use of
compensatory strategies become necessary to prevent patients from developing aspiration
pneumonia. The fact that patients, who did not aspirate on the post-treatment MBS studies,
underestimated their ability to tolerate a variety of foods and liquids towards the end of RT/C,
explains the impact of RT/C toxicities on oral intake. Previous studies have reported the role of
reduced pharyngeal peristalsis in impairing transit of food and liquid boluses through the
pharynx into the UES, negatively impacting oral intake and eating ability during RT/C.

24

Despite absence of aspiration, RT toxicities (dysgeusia, reduced appetite and xerostomia)
impacting pharyngeal bolus transit appeared significant enough to hinder functional eating
ability among patients in the current study. The most severe dysphagia-related symptoms
reported by patients in this study included: hoarseness, globus sensation, difficulty initiating a
swallow, foods sticking in the throat and reflux. These are consistent with literature reports 24 and
were thought to relate to the low FOIS scores reported in both groups of patients, irrespective of
the presence/absence of aspiration.
The post-treatment MBS did not only identify patients who exhibited aspiration so that
appropriate dietary and compensatory strategy recommendations could be made; but it also
identified patients whose physiological swallowing abilities were near-intact and were
underestimating this function. The MBS study helped these patients realize their physiological
abilities to tolerate a variety of food and liquid consistencies. Inability to recognize this could
potentially have led to these patients continuing to restrict eating and drinking, which could have
resulted in true dysphagia from reduced use of swallowing muscles. Therefore irrespective of
patients‟ eating abilities at the completion of RT/C, MBS studies should be performed so that
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immediate appropriate dietary, exercise and compensatory recommendations can be made, prior
to the development of permanent radiation fibrosis.
Literature reveals factors associated with aspiration in patients with HNC, including
advanced age,
hypopharynx,
195

94, 192

193

long-term post-completion of treatment,

advanced tumors (i.e., T3 or T4),

192, 194

192

tumors of the larynx and/or

surgical procedures

192

and ChT. 28, 94,

A phase 3 clinical trial reported that risk factors for developing dysphagia in the acute phase

of RT/C include large tumors, lymph node disease involvements, pre-treatment swallowing
difficulties, six treatments per week and tumors located anywhere but the vocal cords.

196

Additionally, long-term dysphagia was associated with large tumor sizes, pre-treatment
swallowing problems and tumors located anywhere but the vocal cords.

196

Factors including

previous or concurrent comorbidities, age, social support, continued smoking and alcohol
consumption and additional surgical interventions to treat the cancer are all considered to affect
the manner in which patients recover after RT.

24

However, these factors are associated, but not

100% predictive of the occurrence of aspiration after RT/C. 24 No specific demographics, tumorrelated or cancer treatment related factors associated with occurrence of aspiration in this study,
again potentially related to the relatively small number of aspirating patients.
5.2. Functional Outcomes
Patients in the EX group of this study exhibited a statistically similar rate of PEG tube
dependence (31%) as compared to the SW (54%) and NTx (43.5%) groups at post-treatment.
Also, the EX group did not exhibit better post-treatment FOIS scores than the SW group,
resulting in the rejection of hypotheses 1b and 2. Further analyses of the data demonstrated that
the non-treatment group exhibited significantly less ChT utilization as compared to the treatment
groups of this study. Although the NTx group of this study did not initially exhibit statistically
significantly higher reactive PEG tube dependence as compared to the EX or SW treatment
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groups either at post-treatment or at 3 months post-treatment, the recognition of the impact of
including ChT in addition to RT in patients‟ cancer treatment protocol, altered this finding.
Therefore among patients who were treated with combined modalities (RT+ChT), the NTx group
exhibited worse PEG tube dependence rates as compared to the EX group, both at post-treatment
and 3 months post-treatment. At 3 months post-treatment, a significantly higher rate of PEG tube
elimination was noted in the EX group (10%) as compared to the SW group (50%) and the NTx
group (62%), among patients who received both RT and ChT. As a group, the EX group (16%)
still did significantly better, as compared to the SW group (50%) in terms of PEG tube
dependency. However, this difference was not apparent between the EX and NTx (28%) groups.
The SW and EX groups, exhibited post-treatment PEG tube dependence rates within the range
reported in other studies employing intense, evidence based PSE. Nguyen et al., (2009) reported
10% PEG dependence in their patient cohort at post-treatment, which is the lowest, reported in
the literature. More than half of the patients in that study had early stage tumors, influencing
these findings, as acknowledged by the authors.

187

16% is the lowest reported PEG tube

dependence (EX group) rate in the literature employing PSE regimens (i.e. 17% 91) and that not
employing PSE regimens (36 to 73%

30, 48, 50

). Carnaby-Mann et al., (2012) who employed a

different PSE regimen and recently reported the lowest PEG tube dependence rate at posttreatment (i.e. 25%), did not provide rates at 3 months post-treatment, but reported 17% PEG
dependence at 6 months post-treatment. 91
Literature reports that 18% to 79% patients consume ≤ 50% of their nutrition orally after
the completion of RT/C,10, 38, 44, 48, 89, 109, 188, 190, 197 As a group 30% and individually 23% patients
in the EX group of this study exhibited ≤ 50% oral intake in this study, both percentages along
the lower end of reported ranges. The finding that 77% patients in the EX group continued to
intake all of their required nutrition orally, is among the highest reported in the literature. PSE
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regimens are conducted to minimize the swallowing impairments known to occur, post-RT/C;
however, patients continue to exhibit the expected RT/C toxicities- reduced oral intake being one
of them, throughout RT, despite performing exercises. Therefore it is not surprising that this
study‟s findings in terms of oral intake abilities are not particularly better than literature reports;
yet scores are amongst the highest reported, despite the large percentage of patients with
advanced stage tumors, consistent with other studies.
The functional outcomes evident in this study are significant in promoting the exercise
regimen of the EX group. The combination of swallowing-specific Masako exercises and
biomechanical event-specific pharyngeal squeeze and Shaker exercises as hypothesized by the
study, appeared effective in reducing functional swallowing impairments, determined by PEG
tube dependence (at 3 months post-treatment) and FOIS scores (post-treatment). In comparing
16% PEG tube dependence of the EX group (3 months post-RT/C) in this study with 35%
reported by van der Molen et al., (2012)
al., (2012)

91

89

at 3 months and 17% reported by Carnaby-Mann et

at 6 months post-treatment, leads to several important inferences of the PSE

regimen of the EX group. Patients in the EX group of the current study performed 70 Masako, 70
pharyngeal squeeze and 3 sets of Shaker exercises daily as an ongoing home program and
attended therapy x1 per week. Such a unique combination of exercises addressing the
oropharyngeal and particularly the pharyngoesophageal biomechanical events of swallowing has
not been investigated previously. The intensity regimen of the recommended protocol appears
higher than that employed in other studies such as that by the van der Molen et al., (2011) 89 and
Carnaby-Mann et al., (2012) 91 studies. However, Carnaby-Mann et al., (2012) provided therapy
on a daily basis. Despite therapy once per week, patients in the EX group of the current study
achieved similar, if not better functional outcomes. Consulting patients once a week is clinically
more practical and feasible in terms of easier insurance approvals and lower costs to patients,
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easier availability of personnel with the expertise to provide these services and reduced burden
to the patient, who is already scheduled for several appointments on a daily basis. Additionally,
this schedule is better generalizable to a clinical setting. Findings of this study strongly suggest
the clinical utility and generalization of the EX group‟s PSE regimen.
Between-institution factors also appeared to have played a potential role in these
outcomes. The current clinical practice at the non-Baton Rouge sites of MBPCC favor
prophylactic PEG tube placements; one reason for which may be related to lack of swallowing
therapy services available for these patients, unless they agree to travel to outpatient centers for
the same. Percentages of reactive + prophylactic PEG tube placement in the NTx group were
much higher (74%) than in individual study groups or as a total group inclusive of three
additional prophylactic PEG tube dependent patients in the treatment group. It appears that
prophylactic PEG tube placements, potentially caused reduced use of the swallowing muscles
with subsequently worse functional outcomes in the NTx group‟s patients. The results of the
current study suggest that for some patients in the NTx group, worse swallowing outcomes could
possibly have been avoided, with either exercise regimen of this study. Addition of studies like
the current one to the literature will strengthen the need for PSE for HNC patients undergoing
RT/C, in improving post-treatment swallowing function outcomes.
Insignificant, yet better functional outcomes than the NTx group, further confirm the
argument for the need to continue to strengthen the SW group‟s exercise regimen to potentially
improve outcomes and achieve better compliance with exercise regimens necessary from
patients.
 Characteristics of PEG Tube Dependent vs. Non-PEG Tube Dependent Patients in the
Treatment Groups
In this study, 21 of 50 patients received reactive PEG tubes. As a group only 7 of these
patients exhibited any aspiration (33%). The role of treatment toxicities (67%) in resulting in a
92

need for alternative nutrition modalities, appeared quite substantial. 4-6 weeks post-treatment is
considered to be an acute healing period

24

when most patients experience gradual resolution of

treatment toxicities and therefore it is justifiable that patients who continue to require PEG tubes
beyond this point may have a true expression of dysphagia-related need for alternative feeding.
The EX group‟s PEG tube dependence rate at post-treatment along with the high rate of
elimination of PEG tubes at 3 months post-treatment indicate patients‟ ability to resume
swallowing and oral intake and eliminate tube feedings. This finding encourages the use of this
post-RT/C timeline for valid assessments of the true expression of dysphagia. This timeline may
also be suitable to perform MBS studies (4-6 weeks), after adequate healing time has been
allowed and true residual dysphagia and its impact on eating ability can be assessed.
Relatively lower percentages of pre-treatment surgeries, higher RT dosages and longer
durations of RT, differentiated PEG tube dependent patients from non-PEG tube dependent
patients in this study. These factors may have a potential role in the establishment of guidelines
for candidacy for prophylactic PEG tube placements; however it is noteworthy, that these factors
were not exclusive among the PEG tube dependent patients. Patients who underwent pretreatment surgeries or received lower dosages of RT over a short duration of time also received
PEG tubes. Alternatively, several patients with higher dosages of radiation and longer RT
durations completed treatment without the need for PEG tubes. The cause-effect relationship
between longer durations of RT and PEG tube placements were not clear in the current study.
Several PEG tube dependent patients appeared to have experienced an increase in RT duration
only because they missed treatments due to hospital admissions for PEG tube placements itself.
Longer RT durations did not cause patients to get PEG tubes, rather tube placements resulted in
lengthening of RT time. Patients who required PEG tubes in this study exhibited higher rates of
aspiration, higher PAS scores, worse FOIS scores reported at post-treatment and worse FOIS
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scores assigned by the clinician based on the post-treatment MBS results. This finding is
encouraging in that physiological swallowing impairments correlated with the need for
dysphagia-related PEG tube dependence.
Paleri and Patterson (2010)

52

recently reviewed the literature of feeding tube-use in the

HNC patient population. They identified factors, most associated with feeding tube placements
including: oropharyngeal/ hypopharyngeal tumors,
reconstructions,
dysphagia,

200

198

tracheotomy,

198

198, 199

ChT utilization,

198

stage III or IV tumors,

increased age,

pain on swallowing, aspiration or other dysphagia symptoms

dosage to the pharyngeal constrictor muscles.

201, 202

flap

malnutrition and
200

and higher RT

Factors least associated with feeding tube

placements included: nasopharyngeal tumors,203 laryngeal tumors
199

198

198

199

and tumors of the sinuses.

Less than 100% aspiration rates or PEG tube placement rates reported in the non-PSE

employing literature indicates that some patients certainly get through RT/C without severe
dysphagia and need for alternative feeding modalities. Several patient-demographic, tumor and
cancer treatment-related factors have been reported to be associated with reduced or increased
likelihood of significant physiological and functional swallowing impairments, as described
previously; however, a predictive model which would foresee a given patients‟ outcomes is not
available. This has led to vast advancements in the investigation of genetic biomarkers of
patients‟ response to cancer treatment and the severity of toxicities.

204

Cytokines have been

shown to contribute, as well as indicate tissue damage in irradiated patients.

205

Investigations to

assess the use of cytokine-studies at pre-treatment in identifying patients who may be expected to
have more than normal toxicity, are currently underway in the field. Such studies will hopefully
help significantly in characterizing patients who are at higher risks of developing dysphagia from
RT/C toxicities and availing them of intensive prophylactic regimens for swallowing,
lymphedema and nutrition rehabilitation, to maximize outcomes.
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Given that no conclusive guidelines regarding upfront gastrotomy tube placements exist
despite the vast literature attempting to classify patients that may likely benefit from such an
approach, the decision continues to be made based on individual physicians‟ or facilities‟
experiences with their cohort of patients.

52

Based on the known quality-of-life impairments of

PEG tubes, the cost of feeding through a PEG tube (as reviewed by the author‟s of this study in
Appendix E) and the risk of permanent dysphagia from muscle disuse, future studies
standardizing guidelines and criteria for PEG tube placements are warranted.
5.3. Quality-of-Life (QOL) Outcomes
Although no significant differences appeared in post-treatment MDADI scores (i.e.
overall scores, global, emotional, functional and physical domains) between the EX and SW
groups; within each group, significantly worse scores were evident in each of these domains,
from pre-treatment to post-treatment. This finding indicates the significant negative impacts of
RT/C on patients‟ QOL, via treatment induced-toxicities.
Wilson, Carding and Patterson, (2011) recently reported MDADI scores of 65.0 (SD=
17.6) at 3 months post-treatment, indicating significant deterioration in QOL.

206

This is

comparable to the post-treatment overall scores obtained in this study, i.e. 62.72. The Kulbersh
et al., (2006) study is the only study reporting post-treatment MDADI scores (percentages) in
patients who received PSE, starting 2 weeks prior to cancer-treatment (Global assessment 71.7,
Emotional 71.5, Functional 68.3, and Physical 65.1).
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Scores were obtained at a median of 9

months following treatment, hence are not comparable to the findings of this current study. They
also reported scores on a NTx group whose median follow-up time was 14 months posttreatment (Global 45, Emotional 57.5, Functional 61.3, and Physical 49), once again not
comparable, given the largely different timelines.
QOL impairments related to PEG tube placements have been described in the literature
95

previously.

52-63

Statistically significant negative impacts of having a PEG tube, on patients‟

QOL were revealed in this study, via the MDADI-overall and emotional scores. Patients who
received PEG tubes reported worse scores on these measures at post-treatment. Few studies have
even reported improved QOL with the prophylactic PEG tube placement practice.
Methodological differences, particularly varying assessment tools

207-209

207-209

and differing timelines

of PEG tube placements, resulted in inability to make direct comparisons. Other studies have
compared QOL in patients with prophylactic PEG tubes vs. nasogastric (NG) tubes using various
QOL questionnaires; the findings however, are not relevant for comparison with the current
study. 208
Whether PEG tube placements, particularly prophylactically, result in worse QOL cannot
be concluded at this time;

45

however, the current study‟s and literature‟s findings definitely

indicate worse QOL with PEG tubes placed in general. Future studies with larger patient cohorts
are recommended to evaluate the impact of alternative modalities of feeding, placed
prophylactically or reactively, on patients‟ QOL. The high cost associated with feeding via PEG
tubes and the significant negative QOL associated with PEG tubes are further encouraging in the
employment of PSE in HNC patients. This is supported by the results of the current and previous
studies employing PSE and demonstrate its benefits in reducing aspiration, PEG tube
dependence, and cost-effectiveness (vs. feeding via PEG tubes- Appendix E).
5.4. Weight Loss and PEG Tube Placements
Post-RT/C weight loss was not found to be statistically significantly different in the EX
vs. SW groups or between PEG tube dependent vs. non-PEG tube dependent patients. Weekly
weight loss between the EX and SW patient groups did not vary significantly at any point
through RT. In the current study, a mean weight loss of 7.5% was evident (combined EX+SW
groups), as compared to 7.8% weight loss reported in the most recent, van der Molen, et al.,
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(2011) study.

89

The Carnaby-Mann et al., (2012) study reported 6.69 kg (14.7 lbs) weight loss

comparable to 13.5 lbs weight loss in the EX group of this study.

91

Patients without PEG tubes

(EX+SW) experienced a mean weight loss of 6.5%, whereas patients with reactive PEG tubes
had lost on an average 9% weight. This is understandable to an extent, as patients who received
PEG tubes may have already experienced weight loss prior to tube placements. Yet, receiving
PEG tubes did not necessarily mean that patients continued to maintain or gain weight, due to the
known complications associated with tube feeding and complexities of learning the method of
feeding through this modality. 54
Ten percent weight loss is generally considered severe weight loss during RT/C in HNC
patients.

52, 210, 211

More than 10% weight loss is considered a risk for malnutrition and any

weight loss exceeding 20% has been associated with an increase in morbidity and mortality.
At least 10% weight loss post-RT/C is typically reported in the literature.
significant, the van der Molen et al., (2011) study,

89

44

110

Although not

Carnaby-Mann et al., (2012) study

91

and

this current study (particularly the EX group) do report lower weight loss percentages. This may
be related to methodological differences from other studies, however it could also reflect
improved nutrition intake by patients, related to the speech clinician‟s consistent delivery of the
importance of swallowing, eating and maintaining weight. This finding indicates yet another
advantage of providing prophylactic swallowing therapy to this patient population. Additionally,
like most radiation oncology centers, a full-time nutritionist at the MBPCC followed each of the
patients on the study on a weekly basis, to assist in nutritional needs.
Thus despite rejecting hypotheses 1a, 1b (entire cohort), 1c and 1d of this study, the
EX group showed a better trend over the SW group, NTx group, other PSE-employing literature
and non-PSE employing literature in physiological, functional, quality-of-life and weight
outcomes, beyond the acute post-treatment healing period. Particularly when accounted for
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patients who underwent both RT and ChT, the EX group exhibited significantly better PEG tube
outcomes than the SW and the NTx groups, both at post-treatment and 3 months post-treatment.
The SW group also showed improved outcomes as compared to the NTx group. Long-term
benefits of performing intense, swallowing exercises prophylactically were evident in this study,
potentially due to muscle preservation, as reported by Carnaby-Mann et al., (2012).155 PEG tube
dependence in the EX group of this study at post-treatment and 3 months post-treatment stood
out as a statistically and clinically significant finding.
5.5. Correlations Between Physiological, Functional, Quality-of-Life (QOL) and Weight
Outcomes Post-Radiation Therapy with/without Chemotherapy (RT/C) for Head and Neck
Cancers (HNC)
The current study abided by the recommendations of the World Health Organization‟s
(WHO)

International

Classification

of

Functioning,

Disability

and

Health

(ICF)-

recommendations, in assessing not just physiological outcomes, but functional and QOL
outcomes as well. 178, 179 Although an initial core set of structures and functions specific to HNC
has been provided, establishment of standardized outcomes measures to use with the ICF
framework is underway.

180, 181

The current study therefore employed valid and reliable tools to

measure physiology (PAS), function (FOIS) and QOL (MDADI) in patients.
There was a statistically significant; however weak correlation between aspiration and
PEG tube dependence at post-treatment in this study, leading to an inference that patients who
aspirated at post-treatment MBS studies were more likely to have PEG tubes placed reactively,
during or immediately post-treatment. However, this relationship was weak, probably
attributable to the fact that only 10 patients exhibited any aspiration in this study. Also, both
aspiration and PAS scores assigned to patients by SLPs based on their post-treatment MBS
studies, correlated significantly with the assigned FOIS scores. This is expected, as aspiration of
boluses plays a vital role in dietary and compensatory strategy recommendations made.
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Langmore (2010) has reported that aspiration is commonly known to result post-RT/C
particularly when the site of cancer is the larynx.

24

A major post-treatment impact of RT/C in

the form of tissue fibrosis, often results in reduced bolus transit and clearance through the
pharyngoesophageal pathway,

24

causing dysphagia characterized by feeling of foods sticking in

the throat and choking. The weaker relationships between aspiration and PEG tube dependence
are thus further justified, in that patients may not have aspirated, rather experienced significantly
reduced pharyngeal peristalsis and reduced pharyngeal clearance, increasing risk of aspiration
from pharyngeal residue, after the swallow. These were consistent with patient-reports of RT
toxicity-related dysphagia symptoms. No other significant correlations were revealed between
physiological swallowing outcomes (aspiration and PAS scores), QOL outcomes (MDADIoverall, global, emotional, functional and physical domain scores) and weight loss. Patients with
PEG tube dependence in this study, exhibited worse MDADI-overall and emotional scores posttreatment- a finding indicative of a relationship between functional and QOL life impairments.
5.6. Secondary Research Findings
Radiation Toxicities
Radiation toxicities occurring through treatment included but were not limited to
xerostomia, mucositis, soreness and pain associated with the mucositis, odynophagia, nausea/
vomiting, dysgeusia, trismus and reduced appetite. Of the 21 patients who received PEG tubes in
this study (EX+SW), only 7 of them (33%) exhibited any aspiration at the post-treatment MBS
study. All other PEG tubes were placed during treatment, due to induced toxicities (67%). The
three most important toxicities that prevailed and/or worsened throughout treatment were
dysgeusia, reduced appetite and xerostomia. These can therefore be most closely related to PEG
tube placements in patients. There is vast literature to support medical management of RT
toxicities (chapter 2). All patients in the current study were assessed by their radiation
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oncologists, at least once a week and were prescribed necessary treatments for RT toxicities;
despite which, toxicities caused a significant reason for PEG tube placements (67%).
Dysphagia Symptoms
Some of the common dysphagia symptoms occurring during RT/C included but were not
limited to, choking with solids and liquids, nasal and oral regurgitation, reflux, difficulty
initiating a swallow, globus sensation, foods sticking in the throat, gagging, NPO status,
hoarseness and wet/gurgly voice quality. Among the topmost severe dysphagia symptoms
reported by patients in the EX group were hoarseness, globus sensation and difficulty initiating
a swallow; whereas for the SW group these were hoarseness, difficulty initiating a swallow,
reflux, foods sticking in the throat and globus sensation. Patients in both the EX and SW
treatment groups performed one swallowing-salient exercise i.e. Masako and repetitive swallows
respectively. However, only the SW group of patients consistently reported the dysphagia
symptom, foods sticking in the throat. Clinically, this symptom is associated with reduced
pharyngeal peristalsis post-RT/C. It is speculated that the addition of the pharyngeal squeeze and
Shaker exercises to address pharyngoesophageal swallowing abilities, to the EX group‟s exercise
regimen, potentially benefited improved pharyngoesophageal bolus transit, and support its
generalization to the clinic.
Compliance with the Therapeutic Regimen
As elaborated earlier, every patient in the study met with the SLP/ study coordinator on a
weekly basis. During this visit, each patient was encouraged to perform at least 50% of the
therapeutic tasks assigned for that day, under the clinician‟s supervision. Additionally, each
patient filled out a log sheet provided to him/ her each day to indicate the number of sets of each
exercise that he/she had completed that day. Most patients were compliant with logging the
exercises, whereas for some patients, caregiver input to estimate the number of sets, sometimes
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on a daily basis was required.
As a group, patients in both, the EX and SW groups exhibited a gradual decrease in
compliance with exercises from over 60% during the first week of treatment, to below 35% in
the last week. Patients in the EX group appeared to be more compliant with the Masako and
pharyngeal squeeze exercises than the Shaker exercises. Through several weeks of RT, the SW
group appeared to be slightly more compliant with their therapeutic task than the EX group with
any of the exercises. Although a highly intensive exercise regimen was assigned to both groups,
at no point were patients more than 75% (mean) compliant with their exercises. Despite this,
patients, particularly in the EX group exhibited low aspiration rates and better abilities to
eliminate PEG tube dependence at 3 months post-treatment.
This finding could extend the future scope of research in several directions: could
reducing the intensity of exercises maintain the obtained outcomes, and potentially improve
patient compliance? Or could strengthening the repetitive swallowing exercise protocol either in
terms of intensity/frequency or saliency, result in improved outcomes? van der Molen et al.,
(2011) employed a different set of exercises at a relatively lower intensity, but also reported
higher PEG tube dependence rates at 3 months post-treatment.

89

On the other hand, Carnaby-

Mann et al (2012) employed the Masako and pharyngeal squeeze exercises with a few other
exercises, at a relatively lower intensity with daily therapy and reported outcomes comparable to
those obtained in the current study. 91 Future studies are therefore warranted to assess the optimal
intensity of exercises and frequency schedule of therapy, potentially based on the dosage of
radiation employed in cancer treatment. Therapy once a week was certainly as beneficial in this
study as was daily therapy in the Carnaby-Mann et al., (2012) study. 91
An interesting finding of this study, which may correlate with the clinical impressions of
many clinicians working with the HNC population was that patients in the EX group who ended
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up with PEG tube placements, evidently exhibited much reduced mean percent compliance with
exercises as compared to patients who did not end up with feeding tubes. This was true of the
SW group as well; however, in this group of patients, it appeared as if the mean compliance
percent dropped following the third week of RT, after most patients actually underwent PEG
tube placements and reduced the frequency of swallowing exercises. Patient non-compliance in
therapy has been previously reported by self-perceptions of exercises being too „strange‟ and
„annoying‟, they „forget‟ to do them and that it is difficult to „practice daily‟.

89

Patients stop

doing the exercises during RT because of pain in the mouth, nausea and fatigue.

89

van der

Molen et al., (2011) reported that only 7 of their 49 patients (14%) practiced exercises on a daily
basis, whereas on an average other patients did exercises 4 days per week (range 0 to 7 days).
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Additionally, other studies have reported that patients typically do not comply with swallowing
recommendations as they are not satisfied with dietary alterations recommended, lack of family
support and lack of resources. 212 Depression and fatigue at the beginning of RT/C have recently
been reported to have a negative effect on patient-compliance with a PSE regimen.

191

Other

studies have also described issues of patient compliance in therapy in various outpatient and
nursing home facilities as well;

213, 214

however these are not comparable to the current group of

patients who are physically quite fragile as they undergo toxic RT/C for HNC. Further studies
are warranted to investigate factors that could increase the compliance of PSE and its effects on
swallowing function.
5.7. Should the Prophylactic Swallowing Exercise (PSE) Regimen Employed by Patients in
the Exercise (EX) Group of This Study Be Generalized to Routine Clinical Practice?
Within the PSE regimens of the EX and SW groups of patients in this study, only the
Masako exercise which requires completion of the act of swallowing appeared salient to
swallowing. The pharyngeal squeeze and Shaker exercises although not salient to the act of
swallowing, were salient to specific biomechanical events of the act of swallowing. Repetitive
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swallows matched in intensity with the number of range-of-motions achieved by the EX group
from doing exercises, were thought to be as salient as could be with the act of swallowing since
they represent the function of swallowing itself.
This study hypothesized that performing less complex, simple repetitive swallows would
result in worse outcomes as compared to performing intense and complex, more difficult,
evidence-based exercises. Among patients treated with RT + ChT, better functional outcomes of
the EX group were evident. However, the premise and motivation of selecting repetitive
swallows as the therapeutic task in the first place, was the fact that treatment toxicities often
reduce patients‟ oral intake, resulting in PEG tube placements, which further reduce the use of
swallowing muscles, causing them to atrophy.
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Long-term superiority of complex,

biomechanical event-specific exercises over the act of swallowing as the therapeutic task, and no
therapy was evident in this study. Peck et al., (2010) have reported higher neural activation
levels with the effortful swallow and the Mendelsohn‟s maneuver, than with dry swallows.
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This report further justifies the superiority of complex, intense exercises over simple, repetitive
swallows in obtaining desired swallowing outcomes. Given that there were no statistically
significant differences in demographics, tumor characteristics, cancer treatment-related
characteristics and pre-treatment swallowing function, between the two groups of patients, the
therapeutic task itself was thought to be have played a significant role in the achieved outcomes.
It is difficult however, to determine if patients with specific tumor sites or smaller stages may
benefit from rather simple „repetitive swallows‟ vs. „complex exercises‟ as the therapeutic task in
maintaining swallowing physiology and function.
The unique combination of exercises employed in this study can be appreciated in terms
of its comprehensive focus on the oropharyngeal and pharyngoesophageal phases of
swallowing, encouraging the clinical utility of this regimen as a prophylactic program for
103

patients undergoing organ preservation treatments for HNC. Therapy provided once a week,
resulted in essentially similar if not better swallowing outcomes as compared to the CarnabyMann, et al., (2012) study which utilized daily therapy at a slightly lower intensity than this
study. 91 Results of this study appear worth future investigations with a larger cohort of subjects,
with more homogeneous, advanced tumor and cancer treatment characteristics. In particular, the
effects of this combination of exercise on muscle preservation is indicated, such as the
investigation conducted by Carnaby-Mann et al., (2012).
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Given its significant benefits, this

study proposes the employment of this protocol in patients undergoing RT/C for HNC. As
elaborated in detail earlier, the authors of this study continue to recommend future investigations
with alterations in the exercise regimen of the SW group since this group did not exhibit
statistically significantly worse post-treatment outcomes as compared to the EX group, and
exhibited slightly better outcomes than the NTx group. Intensity/ frequency and saliency
alterations to this protocol in future investigations are strongly recommended.
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CHAPTER 6: CONCLUSIONS
6.1. Conclusions and Clinical Implications
In conclusion, the prophylactic swallowing exercise (PSE) protocols performed by
patients in the EX group of this study undergoing RT/C for HNC resulted in better posttreatment swallowing outcomes. Benefits were characterized by improved swallowing
physiology (i.e. lower rates of aspiration and higher PAS scores), function (i.e. significantly
lower rates of PEG tube dependence, at post-treatment and particularly at 3 months posttreatment, and ability to maintain oral intake) and QOL (i.e. better overall and emotional domain
scores on the MDADI in the non-PEG tube dependent patients). Significantly lower PEG tube
dependence rates at post-treatment and 3 months post-treatment, as compared to the SW and
NTx groups were revealed in patients who underwent both ChT and RT. In particular, a
combination of the Masako, pharyngeal squeeze and Shaker exercises to address the
oropharyngeal and pharyngoesophageal phases of swallowing, provided a beneficial combination
to improve post-treatment swallowing outcomes, especially at 3 months post-treatment, by which
time most RT/C toxicities have significantly resolved. Clinical application of this protocol is
recommended in centers that already employ a prophylactic approach to swallowing as well as in
centers where such therapy is not employed at this time.
Although the long-term significance of behavioral exercises over repetitive swallows
were evident in this study, at post-treatment no significant differences emerged between groups
in physiological, functional, QOL or weight outcomes. The ease of performing simple, repetitive
swallows in these settings call for future investigations with alterations to this protocol. Impacts
of altering the consistency used when practicing these swallows, intensifying the task with effort
(i.e. hard repetitive swallows) or altering the frequency/ intensity of swallows itself, are
warranted to assess the relative benefits of this protocol, even if these may be limited to a
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subgroup of patients.
Compliance with the PSE regimen differentiated patients of the EX group who ended up
with PEG tubes vs. not. However, several patients with reduced compliance were also able to
quickly resume full oral diets and eliminate alternative feeding within 3 months post-treatment.
Compliance with the therapeutic task did not distinguish the SW group‟s patients with/ without
PEG tubes. Compliance in therapy is a key clinical issue and obtaining more objective insights
into patients‟ conformity with exercises will benefit the understanding of the optimal frequency
and intensity of exercises..
The current study was the first to investigate the differential impacts of performing
prophylactic swallowing exercises vs. encouraging patients to continue to swallowing through
RT/C, with a significantly high intensity. Findings proved the superiority of exercises in
preserving swallowing physiology and function. The practice of prophylactic swallowing
training is not common clinical practice in Cancer Centers at this time. Presumably, patients
undergoing treatments at these centers are probably only encouraged by the doctors and the
nutritionists to continue to swallow through treatment to maintain function. According to the
findings of the current study, this practice is certainly not as beneficial to patients and there is a
significant need for the establishment of prophylactic swallowing therapy as common practice
for HNC patients. Conducting this study has substantially impacted multidisciplinary patient care
at the MBPCC which currently lacks the services of a part-time/ full-time SLP.
Dysgeusia, reduced oral intake and xerostomia appeared to be the most prominent RT/Ctoxicities in patients enrolled in this study. Additionally, hoarseness, globus sensation, difficulty
initiating a swallow, reflux and foods sticking in the throat were among the more severe
dysphagia symptoms reported by patients during the course of RT. A high percentage of PEG
tubes in this study were placed due to treatment toxicities rather than aspiration. Placement and
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use of PEG tubes caused patients to reduce the use of swallowing muscles and in turn a need to
continue to rely on PEG tubes for a prolonged duration.
All patients, who reported no dysphagia or eating restrictions at pre-treatment, exhibited
functional swallowing abilities on pre-treatment MBS studies. Pre-treatment MBS studies proved
minimally beneficial in this study. Therefore it may be proposed that in the absence of
complaints of dysphagia by patients, pre-treatment MBS studies could be differed, reducing one
additional cost to patients going through the expensive course of RT/C. However, literature has
indicated the presence of dysphagia and aspiration at pre-treatment in patients with more
advanced stage cancers. MBS studies may be more beneficial in this sub-population.
Overall, it is hoped that continued future advances in the understanding of prophylactic
preservation of swallowing in HNC patients, will result in positive impacts on patients‟ QOL and
reduce the burden of dysphagia and related complications post-treatment. This study can be
considered a significant contribution to current literature striving to establish an optimal muscle
preservation regimen for patients undergoing RT/C for HNC.
6.2 Limitations of the Study
The no treatment group employed in this study included patients who were treated at cofacilities of the MBPCC-Baton Rouge, during identical timelines of prospective patient
recruitment. Retrospective recruitment of this group was the best possible option, given that
emerging evidence supports the employment of PSE. Prospective recruitment of a no treatment
group in this scenario would pose ethical concerns regarding denying therapy to patients who
might otherwise benefit significantly from a PSE regimen to maintain healthy swallowing
function following RT/C. This is a common challenge encountered in studies of this nature. 216
It is noteworthy that only five studies have previously investigated the impact of PSE on
swallowing outcomes, of which only three studies have included some type of a „control‟ group
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(i.e. 1 retrospective, 1 prospective non-randomized from a co-facility and 1 prospective
randomized). Therefore the employment of a no treatment group in determining if either exercise
protocols in this study would result in improved swallowing outcomes was considered necessary.
The drawbacks of the no treatment group in this study, considered prior to recruitment were:
between-institution differences (radiation delivery machines and physicians), physicians‟
opinions on prophylactic and reactive PEG tube placements potentially influenced by lack of
speech pathology services, and most importantly the inability to obtain pre-treatment and posttreatment MBS studies and vital information regarding patients‟ swallowing physiology,
function and QOL. The author of this investigation considered the possibility of alternatively
recruiting a within-institution comparison group retrospectively (of a previous timeline) to
represent the no treatment group in this study. This would potentially help to better interpret the
impact of PSE on swallowing outcomes in PEG tube dependence patterns within the institution.
However, the prime shortcoming of this approach again would be physicians‟ bias against PEG
tube placements in prospectively recrtuited patients due to the presence of the speech pathologist
on site, versus more readily placed PEG tubes in previously treated patients. Although, simply
comparing reactive PEG tube placements between the treatment groups and the within-institution
group, would compensate for this issue; yet the limitation of unmatched groups and inability to
control any subtle or extensive changes in HNC patient-care protocols evolving from differential
timelines, could still influence PEG tube outcomes. Additionally, since the no treatment group
was found to not match with the treatment groups in terms of utilization of ChT in this study,
analyses of PEG tube outcomes were difficult to interpret. Application of the criteria “treatment
with both RT and ChT” revealed the expected outcomes, yet doing so, further reduced the
number of subjects in each group.
Patient assessments in this study were not blinded to the study coordinator who was also
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the evaluating and treating speech pathologist. Although all measures reported are rather
objective, future measures to improve this aspect of the study are recommended.
The patient group employed in the current study was heterogeneous in terms of tumor
sites, tumor stage and cancer-treatment related characteristics. Such variances result in
limitations in performing valid statistical analyses. Future studies should focus on specific tumor
sites, stages and RT/C protocols to obtain more accurate and specific information regarding the
benefits of prophylactic swallowing therapy in multiple HNC centers to ensure an adequate
number of patients with the same tumor site and stage.
Although the intention was to obtain pre-treatment MBS studies prior to the initiation of
any RT and post-treatment MBS studies within 3 weeks after the completion of RT,
miscellaneous conflicts resulted in some variations between the timelines at which these were
obtained. Yet, all recruited patients exhibited pre-treatment MBS studies within functional limits
and all but 3 post-treatment studies were performed within 6 weeks of completion of RT.
Unfortunately, this is a common limitation of studies in related fields. Future studies should aim
to assess the impacts of PSE on post-treatment physiological outcomes at fixed timelines across
patients.
Compliance measurements in this study were patient-reported. Any inaccuracies in these
reports could not be controlled. Future studies are warranted to improve methods of assessment
of compliance with swallowing exercises. Potential development of mechanical devices to track
specific muscles movements in performing exercises, may provide better insights into patient
compliance issues and the optimal frequency/ intensity schedules of exercise recommendations.
6.3. Scope for Future Research
The current study continues to recruit additional patients to improve the sample size and
subsequent power of the results obtained. Additionally, appropriate IRB approvals have been
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obtained to investigate the long-term PEG tube and oral intake statuses of patients enrolled in the
current study (at 6 months and 12 months post-treatment).
Future investigations with unique combinations of exercises such as the one proposed in
this study on muscle physiology are recommended to further optimize prophylactic swallowing
rehabilitation in HNC patients.
Since post-treatment physiological, functional, QOL and weight outcomes did not differ
between patients in the EX and SW groups, receiving RT/C future investigations modifying the
repetitive swallowing exercise regimen, potentially with varied consistencies or frequency/
intensity are recommended, due to the relative ease of performing these over complex exercises.
Investigations of swallowing exercises with larger, more specific patient characteristics
are recommended. These will provide better insights into identifying specific groups of patients
for whom prophylactic nutrition and swallowing therapy may be warranted to improve
outcomes.
Investigations of the strength of genetic biomarkers to identify high-risk patients and
improved medical management of RT/C toxicities are also recommended in the field. These will
contribute to improving the care of high-risk patients with HNC.

110

REFERENCES
1. Spaulding MB, Fischer SG, Wolf GT. Tumor response, toxicity, and survival after
neoadjuvant organ-preserving chemotherapy for advanced laryngeal carcinoma. The Department
of Veterans Affairs Cooperative Laryngeal Cancer Study Group. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 1994;12(8): 1592-9.
2. Wolf GT. Induction chemotherapy plus radiation compared with surgery plus radiation in
patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer
Study Group. The New England journal of medicine 1991;324(24): 1685-90.
3. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for
organ preservation in advanced laryngeal cancer. The New England journal of medicine
2003;349(22): 2091-8.
4. Chang YC, Chen SY, Lui LT, et al. Dysphagia in patients with nasopharyngeal cancer after
radiation therapy: a videofluoroscopic swallowing study. Dysphagia 2003;18(2): 135-43.
5. Frowen JJ, Perry AR. Swallowing outcomes after radiotherapy for head and neck cancer: a
systematic review. Head & neck 2006;28(10): 932-44.
6. Gillespie MB, Brodsky MB, Day TA, Sharma AK, Lee FS, Martin-Harris B. Laryngeal
penetration and aspiration during swallowing after the treatment of advanced oropharyngeal
cancer. Archives of otolaryngology--head & neck surgery 2005;131(7): 615-9.
7. Greven KM, White DR, Browne JD, Williams DW, 3rd, McGuirt WF, Sr., D'Agostino RB, Jr.
Swallowing dysfunction is a common sequelae after chemoradiation for oropharynx carcinoma.
American journal of clinical oncology 2008;31(3): 209-12.
8. Hutcheson KA, Barringer DA, Rosenthal DI, May AH, Roberts DB, Lewin JS. Swallowing
outcomes after radiotherapy for laryngeal carcinoma. Archives of otolaryngology--head & neck
surgery 2008;134(2): 178-83.
9. Jensen K, Lambertsen K, Grau C. Late swallowing dysfunction and dysphagia after
radiotherapy for pharynx cancer: frequency, intensity and correlation with dose and volume
parameters. Radiotherapy and oncology : journal of the European Society for Therapeutic
Radiology and Oncology 2007;85(1): 74-82.
10. Logemann JA, Pauloski BR, Rademaker AW, et al. Swallowing disorders in the first year
after radiation and chemoradiation. Head & neck 2008;30(2): 148-58.
11. Nguyen NP, Frank C, Moltz CC, et al. Aspiration rate following chemoradiation for head and
neck cancer: an underreported occurrence. Radiotherapy and oncology : journal of the European
Society for Therapeutic Radiology and Oncology 2006;80(3): 302-6.
12. Nguyen NP, Moltz CC, Frank C, et al. Evolution of chronic dysphagia following treatment
for head and neck cancer. Oral oncology 2006;42(4): 374-80.

111

13. Colangelo LA, Logemann JA, Rademaker AW. Tumor size and pretreatment speech and
swallowing in patients with resectable tumors. Otolaryngology--head and neck surgery : official
journal of American Academy of Otolaryngology-Head and Neck Surgery 2000;122(5): 653-61.
14. McCabe D, Ashford J, Wheeler-Hegland K, et al. Evidence-based systematic review:
Oropharyngeal dysphagia behavioral treatments. Part IV--impact of dysphagia treatment on
individuals' postcancer treatments. Journal of rehabilitation research and development
2009;46(2): 205-14.
15. Pauloski BR, Rademaker AW, Logemann JA, et al. Pretreatment swallowing function in
patients with head and neck cancer. Head & neck 2000;22(5): 474-82.
16. Rosen A, Rhee TH, Kaufman R. Prediction of aspiration in patients with newly diagnosed
untreated advanced head and neck cancer. Archives of otolaryngology--head & neck surgery
2001;127(8): 975-9.
17. Stenson KM, MacCracken E, List M, et al. Swallowing function in patients with head and
neck cancer prior to treatment. Archives of otolaryngology--head & neck surgery 2000;126(3):
371-7.
18. van der Molen L, van Rossum MA, Ackerstaff AH, Smeele LE, Rasch CR, Hilgers FJ.
Pretreatment organ function in patients with advanced head and neck cancer: clinical outcome
measures and patients' views. BMC ear, nose, and throat disorders 2009;9: 10.
19. Armstrong E, Isman K, Dooley P, et al. An investigation into the quality of life of individuals
after laryngectomy. Head & neck 2001;23(1): 16-24.
20. Harrison LB, Zelefsky MJ, Pfister DG, et al. Detailed quality of life assessment in patients
treated with primary radiotherapy for squamous cell cancer of the base of the tongue. Head &
neck 1997;19(3): 169-75.
21. Logemann JA, Pauloski BR, Rademaker AW, Colangelo LA. Speech and swallowing
rehabilitation for head and neck cancer patients. Oncology 1997;11(5): 651-6, 59; discussion 59,
63-4.
22. Logemann JA, Pauloski BR, Rademaker AW, et al. Speech and swallow function after
tonsil/base of tongue resection with primary closure. Journal of speech and hearing research
1993;36(5): 918-26.
23. Myers SE, Carrel AL, Whitman BY, Allen DB. Physical effects of growth hormone
treatment in children with Prader-Willi syndrome. Acta paediatrica 1999;88(433): 112-4.
24. Langmore S. Dysphagia after radiotherapy for head and neck cancer: etiology, clinical
presentation, and efficacy of current treatments. Swallowing and Swallowing Disorders
(Dysphagia) 2010;19.
25. Pauloski BR, Logemann JA, Rademaker AW, et al. Speech and swallowing function after
oral and oropharyngeal resections: one-year follow-up. Head & neck 1994;16(4): 313-22.

112

26. Pauloski BR, Logemann JA, Rademaker AW, et al. Speech and swallowing function after
anterior tongue and floor of mouth resection with distal flap reconstruction. Journal of speech
and hearing research 1993;36(2): 267-76.
27. Garcia-Peris P, Paron L, Velasco C, et al. Long-term prevalence of oropharyngeal dysphagia
in head and neck cancer patients: Impact on quality of life. Clinical nutrition 2007;26(6): 710-7.
28. Gaziano JE. Evaluation and management of oropharyngeal Dysphagia in head and neck
cancer. Cancer control : journal of the Moffitt Cancer Center 2002;9(5): 400-9.
29. Langendijk JA, Doornaert P, Rietveld DH, Verdonck-de Leeuw IM, Leemans CR, Slotman
BJ. A predictive model for swallowing dysfunction after curative radiotherapy in head and neck
cancer. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology
and Oncology 2009;90(2): 189-95.
30. Goguen LA, Posner MR, Norris CM, et al. Dysphagia after sequential chemoradiation
therapy for advanced head and neck cancer. Otolaryngology--head and neck surgery : official
journal of American Academy of Otolaryngology-Head and Neck Surgery 2006;134(6): 916-22.
31. Nguyen NP, Moltz CC, Frank C, et al. Effectiveness of the cough reflex in patients with
aspiration following radiation for head and neck cancer. Lung 2007;185(5): 243-8.
32. Nguyen NP, Moltz CC, Frank C, et al. Dysphagia following chemoradiation for locally
advanced head and neck cancer. Annals of oncology : official journal of the European Society
for Medical Oncology / ESMO 2004;15(3): 383-8.
33. Rutten H, Pop LA, Janssens GO, et al. Long-term outcome and morbidity after treatment
with accelerated radiotherapy and weekly cisplatin for locally advanced head-and-neck cancer:
results of a multidisciplinary late morbidity clinic. International journal of radiation oncology,
biology, physics 2011;81(4): 923-9.
34. Tschiesner UM, Rogers SN, Harreus U, Berghaus A, Cieza A. Comparison of outcome
measures in head and neck cancer--literature review 2000-2006. Head & neck 2009;31(2): 251-9.
35. Rieger JM, Zalmanowitz JG, Wolfaardt JF. Functional outcomes after organ preservation
treatment in head and neck cancer: a critical review of the literature. International journal of oral
and maxillofacial surgery 2006;35(7): 581-7.
36. Haraf DJ, Rosen FR, Stenson K, et al. Induction chemotherapy followed by concomitant
TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research
2003;9(16 Pt 1): 5936-43.
37. Tishler RB, Busse PM, Norris CM, Jr., et al. An initial experience using concurrent paclitaxel
and radiation in the treatment of head and neck malignancies. International journal of radiation
oncology, biology, physics 1999;43(5): 1001-8.
38. Graner DE, Foote RL, Kasperbauer JL, et al. Swallow function in patients before and after
intra-arterial chemoradiation. The Laryngoscope 2003;113(3): 573-9.
113

39. Vokes EE, Stenson K, Rosen FR, et al. Weekly carboplatin and paclitaxel followed by
concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organpreserving therapy for advanced head and neck cancer. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2003;21(2): 320-6.
40. Kies MS, Haraf DJ, Rosen F, et al. Concomitant infusional paclitaxel and fluorouracil, oral
hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck
cancer. Journal of clinical oncology : official journal of the American Society of Clinical
Oncology 2001;19(7): 1961-9.
41. Smith RV, Kotz T, Beitler JJ, Wadler S. Long-term swallowing problems after organ
preservation therapy with concomitant radiation therapy and intravenous hydroxyurea: initial
results. Archives of otolaryngology--head & neck surgery 2000;126(3): 384-9.
42. Vokes EE, Kies MS, Haraf DJ, et al. Concomitant chemoradiotherapy as primary therapy for
locoregionally advanced head and neck cancer. Journal of clinical oncology : official journal of
the American Society of Clinical Oncology 2000;18(8): 1652-61.
43. Koch WM, Lee DJ, Eisele DW, et al. Chemoradiotherapy for organ preservation in oral and
pharyngeal carcinoma. Archives of otolaryngology--head & neck surgery 1995;121(9): 974-80.
44. Newman LA, Vieira F, Schwiezer V, et al. Eating and weight changes following
chemoradiation therapy for advanced head and neck cancer. Archives of otolaryngology--head &
neck surgery 1998;124(5): 589-92.
45. Locher JL, Bonner JA, Carroll WR, et al. Prophylactic percutaneous endoscopic gastrostomy
tube placement in treatment of head and neck cancer: a comprehensive review and call for
evidence-based medicine. JPEN. Journal of parenteral and enteral nutrition 2011;35(3): 365-74.
46. Ackerstaff AH, Tan IB, Rasch CR, et al. Quality-of-life assessment after supradose selective
intra-arterial cisplatin and concomitant radiation (RADPLAT) for inoperable stage IV head and
neck squamous cell carcinoma. Archives of otolaryngology--head & neck surgery 2002;128(10):
1185-90.
47. Murphy BA, Chen A, Curran WJ, Jr., et al. Longitudinal oncology registry of head and neck
carcinoma (LORHAN): initial supportive care findings. Supportive care in cancer : official
journal of the Multinational Association of Supportive Care in Cancer 2009;17(11): 1393-401.
48. Rademaker AW, Vonesh EF, Logemann JA, et al. Eating ability in head and neck cancer
patients after treatment with chemoradiation: a 12-month follow-up study accounting for
dropout. Head & neck 2003;25(12): 1034-41.
49. Samant S, Kumar P, Wan J, et al. Concomitant radiation therapy and targeted cisplatin
chemotherapy for the treatment of advanced pyriform sinus carcinoma: disease control and
preservation of organ function. Head & neck 1999;21(7): 595-601.
50. Shiley SG, Hargunani CA, Skoner JM, Holland JM, Wax MK. Swallowing function after
chemoradiation for advanced stage oropharyngeal cancer. Otolaryngology--head and neck
114

surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
2006;134(3): 455-9.
51. Staton J, Robbins KT, Newman L, Samant S, Sebelik M, Vieira F. Factors predictive of poor
functional outcome after chemoradiation for advanced laryngeal cancer. Otolaryngology--head
and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck
Surgery 2002;127(1): 43-7.
52. Paleri V, Patterson J. Use of gastrostomy in head and neck cancer: a systematic review to
identify areas for future research. Clinical otolaryngology : official journal of ENT-UK ; official
journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery
2010;35(3): 177-89.
53. El-Deiry MW, Futran ND, McDowell JA, Weymuller EA, Jr., Yueh B. Influences and
predictors of long-term quality of life in head and neck cancer survivors. Archives of
otolaryngology--head & neck surgery 2009;135(4): 380-4.
54. Merrick S, Farrell D. Head and neck cancer patients' experiences of percutaneous endoscopic
gastrostomy feeding: a Q-methodology study. European journal of cancer care 2012.
55. Roberge C, Tran M, Massoud C, et al. Quality of life and home enteral tube feeding: a
French prospective study in patients with head and neck or oesophageal cancer. British journal of
cancer 2000;82(2): 263-9.
56. Ringash J, Lockwood G, O'Sullivan B, et al. Hyperfractionated, accelerated radiotherapy for
locally advanced head and neck cancer: quality of life in a prospective phase I/II trial.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and
Oncology 2008;87(2): 181-7.
57. Terrell JE, Ronis DL, Fowler KE, et al. Clinical predictors of quality of life in patients with
head and neck cancer. Archives of otolaryngology--head & neck surgery 2004;130(4): 401-8.
58. Gurney TA, Eisele DW, Orloff LA, Wang SJ. Predictors of quality of life after treatment for
oral cavity and oropharyngeal carcinoma. Otolaryngology--head and neck surgery : official
journal of American Academy of Otolaryngology-Head and Neck Surgery 2008;139(2): 262-7.
59. Rogers SN, Thomson R, O'Toole P, Lowe D. Patients experience with long-term
percutaneous endoscopic gastrostomy feeding following primary surgery for oral and
oropharyngeal cancer. Oral oncology 2007;43(5): 499-507.
60. Jordan S, Philpin S, Warring J, Cheung WY, Williams J. Percutaneous endoscopic
gastrostomies: the burden of treatment from a patient perspective. Journal of advanced nursing
2006;56(3): 270-81.
61. Morton RP, Crowder VL, Mawdsley R, Ong E, Izzard M. Elective gastrostomy, nutritional
status and quality of life in advanced head and neck cancer patients receiving
chemoradiotherapy. ANZ journal of surgery 2009;79(10): 713-8.

115

62. Verhoef MJ, Van Rosendaal GM. Patient outcomes related to percutaneous endoscopic
gastrostomy placement. Journal of clinical gastroenterology 2001;32(1): 49-53.
63. Anis MK, Abid S, Jafri W, et al. Acceptability and outcomes of the Percutaneous Endoscopic
Gastrostomy (PEG) tube placement--patients' and care givers' perspectives. BMC
gastroenterology 2006;6: 37.
64. Bundgaard T, Tandrup O, Elbrond O. A functional evaluation of patients treated for oral
cancer. A prospective study. International journal of oral and maxillofacial surgery 1993;22(1):
28-34.
65. Hammerlid E, Mercke C, Sullivan M, Westin T. A prospective quality of life study of
patients with oral or pharyngeal carcinoma treated with external beam irradiation with or without
brachytherapy. Oral oncology 1997;33(3): 189-96.
66. Huguenin PU, Taussky D, Moe K, et al. Quality of life in patients cured from a carcinoma of
the head and neck by radiotherapy: the importance of the target volume. International journal of
radiation oncology, biology, physics 1999;45(1): 47-52.
67. List MA, Siston A, Haraf D, et al. Quality of life and performance in advanced head and
neck cancer patients on concomitant chemoradiotherapy: a prospective examination. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(3):
1020-8.
68. Pauloski BR, Rademaker AW, Logemann JA, et al. Swallow function and perception of
dysphagia in patients with head and neck cancer. Head & neck 2002;24(6): 555-65.
69. Tschudi D, Stoeckli S, Schmid S. Quality of life after different treatment modalities for
carcinoma of the oropharynx. The Laryngoscope 2003;113(11): 1949-54.
70. List MA, Mumby P, Haraf D, et al. Performance and quality of life outcome in patients
completing concomitant chemoradiotherapy protocols for head and neck cancer. Quality of life
research : an international journal of quality of life aspects of treatment, care and rehabilitation
1997;6(3): 274-84.
71. Barringer DA, Hutcheson KA, Sturgis EM, Kies MS, Lewin JS. Effect of induction
chemotherapy on speech and swallowing function in patients with oral tongue cancer. Head &
neck 2009;31(5): 611-7.
72. Epstein JB, Tsang AH, Warkentin D, Ship JA. The role of salivary function in modulating
chemotherapy-induced oropharyngeal mucositis: a review of the literature. Oral surgery, oral
medicine, oral pathology, oral radiology, and endodontics 2002;94(1): 39-44.
73. Logemann JA, Rademaker AW, Pauloski BR, Kahrilas PJ. Effects of postural change on
aspiration in head and neck surgical patients. Otolaryngology--head and neck surgery : official
journal of American Academy of Otolaryngology-Head and Neck Surgery 1994;110(2): 222-7.

116

74. Rasley A, Logemann JA, Kahrilas PJ, Rademaker AW, Pauloski BR, Dodds WJ. Prevention
of barium aspiration during videofluoroscopic swallowing studies: value of change in posture.
AJR. American journal of roentgenology 1993;160(5): 1005-9.
75. Lazarus CL, Logemann JA, Rademaker AW, et al. Effects of bolus volume, viscosity, and
repeated swallows in nonstroke subjects and stroke patients. Archives of physical medicine and
rehabilitation 1993;74(10): 1066-70.
76. Kahrilas PJ, Logemann JA, Krugler C, Flanagan E. Volitional augmentation of upper
esophageal sphincter opening during swallowing. The American journal of physiology
1991;260(3 Pt 1): G450-6.
77. Lazarus C, Logemann JA, Gibbons P. Effects of maneuvers on swallowing function in a
dysphagic oral cancer patient. Head & neck 1993;15(5): 419-24.
78. Logemann JA. Behavioral management for oropharyngeal dysphagia. Folia phoniatrica et
logopaedica : official organ of the International Association of Logopedics and Phoniatrics
1999;51(4-5): 199-212.
79. Martin BJ, Logemann JA, Shaker R, Dodds WJ. Normal laryngeal valving patterns during
three breath-hold maneuvers: a pilot investigation. Dysphagia 1993;8(1): 11-20.
80. Mittal BB, Pauloski BR, Haraf DJ, et al. Swallowing dysfunction--preventative and
rehabilitation strategies in patients with head-and-neck cancers treated with surgery,
radiotherapy, and chemotherapy: a critical review. International journal of radiation oncology,
biology, physics 2003;57(5): 1219-30.
81. Veis S, Logemann JA, Colangelo L. Effects of three techniques on maximum posterior
movement of the tongue base. Dysphagia 2000;15(3): 142-5.
82. Logemann JA. Evaluation and treatment of swallowing disorders. 2nd ed. Austin, TX: ProEd, 1998.
83. Pauloski BR. Rehabilitation of dysphagia following head and neck cancer. Physical medicine
and rehabilitation clinics of North America 2008;19(4): 889-928, x.
84. Sullivan CA, Jaklitsch MT, Haddad R, et al. Endoscopic management of hypopharyngeal
stenosis after organ sparing therapy for head and neck cancer. The Laryngoscope 2004;114(11):
1924-31.
85. Eisbruch A, Schwartz M, Rasch C, et al. Dysphagia and aspiration after chemoradiotherapy
for head-and-neck cancer: which anatomic structures are affected and can they be spared by
IMRT? International journal of radiation oncology, biology, physics 2004;60(5): 1425-39.
86. Carroll WR, Locher JL, Canon CL, Bohannon IA, McColloch NL, Magnuson JS.
Pretreatment swallowing exercises improve swallow function after chemoradiation. The
Laryngoscope 2008;118(1): 39-43.

117

87. Cavalot AL, Ricci E, Schindler A, et al. The importance of preoperative swallowing therapy
in subtotal laryngectomies. Otolaryngology--head and neck surgery : official journal of
American Academy of Otolaryngology-Head and Neck Surgery 2009;140(6): 822-5.
88. Kulbersh BD, Rosenthal EL, McGrew BM, et al. Pretreatment, preoperative swallowing
exercises may improve dysphagia quality of life. The Laryngoscope 2006;116(6): 883-6.
89. van der Molen L, van Rossum MA, Burkhead LM, Smeele LE, Rasch CR, Hilgers FJ. A
randomized preventive rehabilitation trial in advanced head and neck cancer patients treated with
chemoradiotherapy: feasibility, compliance, and short-term effects. Dysphagia 2011;26(2): 15570.
90. Ahlberg A, Engstrom T, Nikolaidis P, et al. Early self-care rehabilitation of head and neck
cancer patients. Acta oto-laryngologica 2011;131(5): 552-61.
91. Carnaby-Mann G, Crary MA, Schmalfuss I, Amdur R. "Pharyngocise": Randomized
Controlled Trial of Preventative Exercises to Maintain Muscle Structure and Swallowing
Function During Head-and-Neck Chemoradiotherapy. International journal of radiation
oncology, biology, physics 2011.
92. Demir N, Serel, S., Karaduman, A., Hosal, A.S., Suslu, N. & Sozeri, B. Swallowing therapy !
Early or Late ? Dysphagia Research Society. Toronto, Ontario, Canada, 2012.
93. Burkhead LM, Sapienza CM, Rosenbek JC. Strength-training exercise in dysphagia
rehabilitation: principles, procedures, and directions for future research. Dysphagia 2007;22(3):
251-65.
94. Caudell JJ, Schaner PE, Meredith RF, et al. Factors associated with long-term dysphagia
after definitive radiotherapy for locally advanced head-and-neck cancer. International journal of
radiation oncology, biology, physics 2009;73(2): 410-5.
95. Lewin JS. Dysphagia after chemoradiation: prevention and treatment. International journal of
radiation oncology, biology, physics 2007;69(2 Suppl): S86-7.
96. Rosenthal DI, Lewin JS, Eisbruch A. Prevention and treatment of dysphagia and aspiration
after chemoradiation for head and neck cancer. Journal of clinical oncology : official journal of
the American Society of Clinical Oncology 2006;24(17): 2636-43.
97. Langmore S, Krisciunas GP, Miloro KV, Evans SR, Cheng DM. Does PEG Use Cause
Dysphagia in Head and Neck Cancer Patients? Dysphagia 2011.
98. Hutchinson F. The molecular basis for radiation effects on cells. Cancer research 1966;26(9):
2045-52.
99. Hauer-Jensen M, Fink LM, Wang J. Radiation injury and the protein C pathway. Critical care
medicine 2004;32(5 Suppl): S325-30.
100. Libshitz HI, DuBrow RA, Loyer EM, Charnsangavej C. Radiation change in normal organs:
an overview of body imaging. European radiology 1996;6(6): 786-95.
118

101. Stubblefield MD. Radiation fibrosis syndrome: neuromuscular and musculoskeletal
complications in cancer survivors. PM & R : the journal of injury, function, and rehabilitation
2011;3(11): 1041-54.
102. Busch DB. Radiation and chemotherapy injury: pathophysiology, diagnosis, and treatment.
Critical reviews in oncology/hematology 1993;15(1): 49-89.
103. Lazarus CL. Effects of chemoradiotherapy on voice and swallowing. Current opinion in
otolaryngology & head and neck surgery 2009;17(3): 172-8.
104. Rodriguez-Caballero A, Torres-Lagares D, Robles-Garcia M, Pachon-Ibanez J, GonzalezPadilla D, Gutierrez-Perez JL. Cancer treatment-induced oral mucositis: a critical review.
International journal of oral and maxillofacial surgery 2011.
105. Baker PD, Morzorati SL, Ellett ML. The pathophysiology of chemotherapy-induced nausea
and vomiting. Gastroenterology nursing : the official journal of the Society of Gastroenterology
Nurses and Associates 2005;28(6): 469-80.
106. Sullivan CA, Haddad RI, Tishler RB, Mahadevan A, Krane JF. Chemoradiation-induced
cell loss in human submandibular glands. The Laryngoscope 2005;115(6): 958-64.
107. Hammerlid E, Mercke C, Sullivan M, Westin T. A prospective quality of life study of
patients with laryngeal carcinoma by tumor stage and different radiation therapy schedules. The
Laryngoscope 1998;108(5): 747-59.
108. de Graeff A, de Leeuw RJ, Ros WJ, et al. A prospective study on quality of life of laryngeal
cancer patients treated with radiotherapy. Head & neck 1999;21(4): 291-6.
109. Oates JE, Clark JR, Read J, et al. Prospective evaluation of quality of life and nutrition
before and after treatment for nasopharyngeal carcinoma. Archives of otolaryngology--head &
neck surgery 2007;133(6): 533-40.
110. Goodwin WJ, Jr., Byers PM. Nutritional management of the head and neck cancer patient.
Med Clin North Am 1993;77(3): 597-610.
111. Eilers J, Million R. Clinical update: prevention and management of oral mucositis in
patients with cancer. Seminars in oncology nursing 2011;27(4): e1-16.
112. Shenoy VK, Shenoy KK, Rodrigues S, Shetty P. Management of oral health in patients
irradiated for head and neck cancer: a review. Kathmandu University medical journal 2007;5(1):
117-20.
113. Delanian S, Lefaix JL. Current management for late normal tissue injury: radiation-induced
fibrosis and necrosis. Seminars in radiation oncology 2007;17(2): 99-107.
114. O'Sullivan B, Levin W. Late radiation-related fibrosis: pathogenesis, manifestations, and
current management. Seminars in radiation oncology 2003;13(3): 274-89.

119

115. Lazarus CL, Logemann JA, Pauloski BR, et al. Swallowing and tongue function following
treatment for oral and oropharyngeal cancer. Journal of speech, language, and hearing research :
JSLHR 2000;43(4): 1011-23.
116. Lazarus C, Logemann JA, Pauloski BR, et al. Effects of radiotherapy with or without
chemotherapy on tongue strength and swallowing in patients with oral cancer. Head & neck
2007;29(7): 632-7.
117. Farwell DG, Rees CJ, Mouadeb DA, et al. Esophageal pathology in patients after treatment
for head and neck cancer. Otolaryngology--head and neck surgery : official journal of American
Academy of Otolaryngology-Head and Neck Surgery 2010;143(3): 375-8.
118. Mallick I, Waldron JN. Radiation therapy for head and neck cancers. Seminars in oncology
nursing 2009;25(3): 193-202.
119. Bentzen SM, Overgaard M, Thames HD. Fractionation sensitivity of a functional endpoint:
impaired shoulder movement after post-mastectomy radiotherapy. International journal of
radiation oncology, biology, physics 1989;17(3): 531-7.
120. Box RC, Reul-Hirche HM, Bullock-Saxton JE, Furnival CM. Shoulder movement after
breast cancer surgery: results of a randomised controlled study of postoperative physiotherapy.
Breast cancer research and treatment 2002;75(1): 35-50.
121. Box RC, Reul-Hirche HM, Bullock-Saxton JE, Furnival CM. Physiotherapy after breast
cancer surgery: results of a randomised controlled study to minimise lymphoedema. Breast
cancer research and treatment 2002;75(1): 51-64.
122. Balou M, McCullough, G., Stack, B., Aduli, F. & Snoddy, P. Videomanometric
measurements of head rotation and chin tuck in head and neck cancer patients. Dysphagia
Research Society. Toronto, Ontario, Canada, 2012.
123. Waters TM, Logemann JA, Pauloski BR, et al. Beyond efficacy and effectiveness:
conducting economic analyses during clinical trials. Dysphagia 2004;19(2): 109-19.
124. Steelman R, Sokol J. Quantification of trismus following irradiation of the
temporomandibular joint. Missouri dental journal 1986;66(6): 21-3.
125. Cohen EG, Deschler DG, Walsh K, Hayden RE. Early use of a mechanical stretching device
to improve mandibular mobility after composite resection: a pilot study. Archives of physical
medicine and rehabilitation 2005;86(7): 1416-9.
126. Dijkstra PU, Sterken MW, Pater R, Spijkervet FK, Roodenburg JL. Exercise therapy for
trismus in head and neck cancer. Oral oncology 2007;43(4): 389-94.
127. Buchbinder D, Currivan RB, Kaplan AJ, Urken ML. Mobilization regimens for the
prevention of jaw hypomobility in the radiated patient: a comparison of three techniques. Journal
of oral and maxillofacial surgery : official journal of the American Association of Oral and
Maxillofacial Surgeons 1993;51(8): 863-7.

120

128. Wada S, Tohara, H., lida, T., Inoue, M., Sato, M., Sanpei, R., Nakayama, E. & Ueda K.
Effect of jaw opening exercise on strength of suprahyoid muscles in healthy elderly. Dysphagia
Research Society. Tonronto, Ontario, Canada, 2012.
129. White R, Cotton SM, Hind J, Robbins J, Perry A. A comparison of the reliability and
stability of oro-lingual swallowing pressures in patients with head and neck cancer and healthy
adults. Dysphagia 2009;24(2): 137-44.
130. Robbins J, Gangnon RE, Theis SM, Kays SA, Hewitt AL, Hind JA. The effects of lingual
exercise on swallowing in older adults. Journal of the American Geriatrics Society 2005;53(9):
1483-9.
131. Robbins J, Kays SA, Gangnon RE, et al. The effects of lingual exercise in stroke patients
with dysphagia. Archives of physical medicine and rehabilitation 2007;88(2): 150-8.
132. Van Nuffelen G, Vanderwegen, J., Guns, C., Van den Steen, L. & De Bodt, M. Effect of
tongue strength training in head and neck cancer (HNC) patients treated with chemoradiation
(CRT) or radiotherapy (RT). Dysphagia Research Society. Toronto, Ontario, Canada, 2012.
133. Robin DA, Goel A, Somodi LB, Luschei ES. Tongue strength and endurance: relation to
highly skilled movements. Journal of speech and hearing research 1992;35(6): 1239-45.
134. Lazarus C, Logemann JA, Huang CF, Rademaker AW. Effects of two types of tongue
strengthening exercises in young normals. Folia phoniatrica et logopaedica : official organ of the
International Association of Logopedics and Phoniatrics 2003;55(4): 199-205.
135. Steele CM, Bailey, G.L., Molfenter, S.M. & Yeates, E.M. Rationale for strength and skill
goals in tongue resistance: A review. Perspectives on swallowing and swallowing disorders
(Dysphagia) 2009;18.
136. Steele CM, Bailey GL, Molfenter SM, Yeates EM, Grace-Martin K. Pressure profile
similarities between tongue resistance training tasks and liquid swallows. Journal of
rehabilitation research and development 2010;47(7): 651-60.
137. Nicosia MA, Hind JA, Roecker EB, et al. Age effects on the temporal evolution of
isometric and swallowing pressure. J Gerontol A Biol Sci Med Sci 2000;55(11): M634-40.
138. Robbins J, Levine R, Wood J, Roecker EB, Luschei E. Age effects on lingual pressure
generation as a risk factor for dysphagia. J Gerontol A Biol Sci Med Sci 1995;50(5): M257-62.
139. Stierwalt JA, Youmans SR. Tongue measures in individuals with normal and impaired
swallowing. Am J Speech Lang Pathol 2007;16(2): 148-56.
140. Bond SM, Dietrich MS, Murphy BA. Association of age and symptom burden in patients
with head and neck cancer. ORL-head and neck nursing : official journal of the Society of
Otorhinolaryngology and Head-Neck Nurses 2011;29(1): 8-14.
141. Rodriguez KH, Roth CR, Rees CJ, Belafsky PC. Reliability of the pharyngeal squeeze
maneuver. The Annals of otology, rhinology, and laryngology 2007;116(6): 399-401.
121

142. Fuller SC, Leonard R, Aminpour S, Belafsky PC. Validation of the pharyngeal squeeze
maneuver. Otolaryngology--head and neck surgery : official journal of American Academy of
Otolaryngology-Head and Neck Surgery 2009;140(3): 391-4.
143. Setzen M, Cohen MA, Perlman PW, et al. The association between laryngopharyngeal
sensory deficits, pharyngeal motor function, and the prevalence of aspiration with thin liquids.
Otolaryngology--head and neck surgery : official journal of American Academy of
Otolaryngology-Head and Neck Surgery 2003;128(1): 99-102.
144. Aviv JE, Spitzer J, Cohen M, Ma G, Belafsky P, Close LG. Laryngeal adductor reflex and
pharyngeal squeeze as predictors of laryngeal penetration and aspiration. The Laryngoscope
2002;112(2): 338-41.
145. Shaker R, Easterling C, Kern M, et al. Rehabilitation of swallowing by exercise in tube-fed
patients with pharyngeal dysphagia secondary to abnormal UES opening. Gastroenterology
2002;122(5): 1314-21.
146. Easterling C, Grande B, Kern M, Sears K, Shaker R. Attaining and maintaining isometric
and isokinetic goals of the Shaker exercise. Dysphagia 2005;20(2): 133-8.
147. Shaker R, Kern M, Bardan E, et al. Augmentation of deglutitive upper esophageal sphincter
opening in the elderly by exercise. The American journal of physiology 1997;272(6 Pt 1):
G1518-22.
148. Logemann JA, Rademaker A, Pauloski BR, et al. A randomized study comparing the
Shaker exercise with traditional therapy: a preliminary study. Dysphagia 2009;24(4): 403-11.
149. Lazarus C, Logemann JA, Song CW, Rademaker AW, Kahrilas PJ. Effects of voluntary
maneuvers on tongue base function for swallowing. Folia phoniatrica et logopaedica : official
organ of the International Association of Logopedics and Phoniatrics 2002;54(4): 171-6.
150. Fujiu ML, J.A. Effect of a tongue holding maneuver on posterior pharyngeal wall
movement during deglutition. Am J Speech Lang Path 1996;5: 23-30.
151. Ohmae Y, Logemann JA, Kaiser P, Hanson DG, Kahrilas PJ. Effects of two breath-holding
maneuvers on oropharyngeal swallow. The Annals of otology, rhinology, and laryngology
1996;105(2): 123-31.
152. Hind JA, Nicosia MA, Roecker EB, Carnes ML, Robbins J. Comparison of effortful and
noneffortful swallows in healthy middle-aged and older adults. Archives of physical medicine
and rehabilitation 2001;82(12): 1661-5.
153. Hiss SG, Huckabee ML. Timing of pharyngeal and upper esophageal sphincter pressures as
a function of normal and effortful swallowing in young healthy adults. Dysphagia 2005;20(2):
149-56.
154. Lever TE, Cox KT, Holbert D, Shahrier M, Hough M, Kelley-Salamon K. The effect of an
effortful swallow on the normal adult esophagus. Dysphagia 2007;22(4): 312-25.

122

155. Crary MA, Carnaby GD, Lagorio LA, Carvajal PJ. Functional and Physiological Outcomes
from an Exercise-Based Dysphagia Therapy: A Pilot Investigation of the McNeill Dysphagia
Therapy Program. Archives of physical medicine and rehabilitation 2012.
156. Carnaby-Mann GD, Crary MA. McNeill dysphagia therapy program: a case-control study.
Archives of physical medicine and rehabilitation 2010;91(5): 743-9.
157. Wheeler-Hegland K, Ashford J, Frymark T, et al. Evidence-based systematic review:
Oropharyngeal dysphagia behavioral treatments. Part II--impact of dysphagia treatment on
normal swallow function. Journal of rehabilitation research and development 2009;46(2): 18594.
158. Lazarus CL. Management of swallowing disorders in head and neck cancer patients:
optimal patterns of care. Seminars in speech and language 2000;21(4): 293-309.
159. Retel VP, van der Molen L, Hilgers FJ, et al. A cost-effectiveness analysis of a preventive
exercise program for patients with advanced head and neck cancer treated with concomitant
chemo-radiotherapy. BMC Cancer 2011;11: 475.
160. Tyml K, Mathieu-Costello O. Structural and functional changes in the microvasculature of
disused skeletal muscle. Front Biosci 2001;6: D45-52.
161. Kent RD. The uniqueness of speech among motor systems. Clinical linguistics & phonetics
2004;18(6-8): 495-505.
162. Kent RD, Robbins J. Introduction to the special issue, Integrative neural systems underlying
vital aerodigestive tract functions. Head & neck 2011;33 Suppl 1: S1-4.
163. Sokoloff AJ. Localization and contractile properties of intrinsic longitudinal motor units of
the rat tongue. Journal of neurophysiology 2000;84(2): 827-35.
164. Stal PS, Lindman R. Characterisation of human soft palate muscles with respect to fibre
types, myosins and capillary supply. Journal of anatomy 2000;197 ( Pt 2): 275-90.
165. Powers SKH, E.T. Exercise Physiology. 4th ed. New York: McGraw Hill, 2001.
166. Robbins J, Butler SG, Daniels SK, et al. Swallowing and dysphagia rehabilitation:
translating principles of neural plasticity into clinically oriented evidence. Journal of speech,
language, and hearing research : JSLHR 2008;51(1): S276-300.
167. Cohen LG, Ziemann U, Chen R, et al. Studies of neuroplasticity with transcranial magnetic
stimulation. Journal of clinical neurophysiology : official publication of the American
Electroencephalographic Society 1998;15(4): 305-24.
168. Kleim JA, Jones TA. Principles of experience-dependent neural plasticity: implications for
rehabilitation after brain damage. Journal of speech, language, and hearing research : JSLHR
2008;51(1): S225-39.

123

169. Pollock ML, Gaeser, G.A., Butcher, J.D., Despres, J., Dishman, R.K., Franklin, B.A., &
Garber, C.E. American College of Sports Medicine Position Stand. The recommended quantity
and quality of exercise for developing and maintaining cardiorespiratory and muscular fitness,
and flexibility in healthy adults. Medicine and science in sports and exercise 1998;30(6): 975-91.
170. Sapienza C, Wheeler-Hegland, K., Stewart, k. & Nocera, J. Exercise prescription for
dysphagia: Intensity and duration manipulation. Perspectives on swallowing and swallowing
disorders (Dysphagia) 2008;17: 50-8.
171. El Sharkawi A, Ramig L, Logemann JA, et al. Swallowing and voice effects of Lee
Silverman Voice Treatment (LSVT): a pilot study. Journal of neurology, neurosurgery, and
psychiatry 2002;72(1): 31-6.
172. Pitts T, Bolser D, Rosenbek J, Troche M, Okun MS, Sapienza C. Impact of expiratory
muscle strength training on voluntary cough and swallow function in Parkinson disease. Chest
2009;135(5): 1301-8.
173. Robbins J. Cutting edge sensory and motor innervation. Dysphagia Research Society.
Toronto, Ontario, Canada, 2012.
174. Lazarus CL, Logemann JA, Pauloski BR, et al. Swallowing disorders in head and neck
cancer patients treated with radiotherapy and adjuvant chemotherapy. The Laryngoscope
1996;106(9 Pt 1): 1157-66.
175. Lear CS, Flanagan JB, Jr., Moorrees CF. The Frequency of Deglutition in Man. Archives of
oral biology 1965;10: 83-100.
176. Sato K, Nakashima T. Human adult deglutition during sleep. The Annals of otology,
rhinology, and laryngology 2006;115(5): 334-9.
177. Estelle P, Threats, T.T. & Worall, L.E. An introduction to the International Classification of
Functioning, Disability and Health (ICF) for speech-language pathology: Its past, present and
future. International journal of speech-language pathology 2008;10(1-2): 2-8.
178. World Health Organization. Internatinational Classificaiton of Functioning DaHI. Geneva:
World Health Organization, 2001.
179. McCormack JW, L. The ICF Body Functions and Structures related to speech-language
pathology. International journal of speech-language pathology 2008;10(1-2): 9-17.
180. Tschiesner U, Rogers S, Dietz A, Yueh B, Cieza A. Development of ICF core sets for head
and neck cancer. Head & neck 2010;32(2): 210-20.
181. Tschiesner U, Becker S, Cieza A. Health professional perspective on disability in head and
neck cancer. Archives of otolaryngology--head & neck surgery 2010;136(6): 576-83.
182. Rosenbek JC, Robbins JA, Roecker EB, Coyle JL, Wood JL. A penetration-aspiration scale.
Dysphagia 1996;11(2): 93-8.

124

183. Crary MA, Mann GD, Groher ME. Initial psychometric assessment of a functional oral
intake scale for dysphagia in stroke patients. Archives of physical medicine and rehabilitation
2005;86(8): 1516-20.
184. Chen AY, Frankowski R, Bishop-Leone J, et al. The development and validation of a
dysphagia-specific quality-of-life questionnaire for patients with head and neck cancer: the M. D.
Anderson dysphagia inventory. Archives of otolaryngology--head & neck surgery 2001;127(7):
870-6.
185. Hill TLP. Statistics Methods and Applications- A comprehensive reference for science,
industry and data mining. 1st ed. Tulsa, OK: StatSoft, Inc., 2005.
186. Agarwal J, Palwe V, Dutta D, et al. Objective assessment of swallowing function after
definitive concurrent (chemo)radiotherapy in patients with head and neck cancer. Dysphagia
2011;26(4): 399-406.
187. Nguyen NP, Frank C, Moltz CC, et al. Aspiration risk and postoperative radiation for head
and neck cancer. Cancer investigation 2009;27(1): 47-51.
188. Logemann JA, Rademaker AW, Pauloski BR, et al. Site of disease and treatment protocol as
correlates of swallowing function in patients with head and neck cancer treated with
chemoradiation. Head & neck 2006;28(1): 64-73.
189. Kotz T, Costello R, Li Y, Posner MR. Swallowing dysfunction after chemoradiation for
advanced squamous cell carcinoma of the head and neck. Head & neck 2004;26(4): 365-72.
190. Newman LA, Robbins KT, Logemann JA, et al. Swallowing and speech ability after
treatment for head and neck cancer with targeted intraarterial versus intravenous chemoradiation.
Head & neck 2002;24(1): 68-77.
191. LaGorio LC, G. Impact of baseline factors on adherence to a preventative swallowing
exercise (pharyngocise) during CRT in head and neck cancer (HNC) patients. Dysphagia
Research Society. Toronto, Ontario, Canada, 2012.
192. Jung SJ, Kim, D.Y. & Joo, S.Y. Risk factors associated with aspiration in patients with head
and neck cancer. Ann Rehabil Med 2011;35(6): 781-90.
193. Starmer H, Gourin C, Lua LL, Burkhead L. Pretreatment swallowing assessment in head
and neck cancer patients. The Laryngoscope 2011;121(6): 1208-11.
194. Nguyen NP, Frank C, Moltz CC, et al. Analysis of factors influencing aspiration risk
following chemoradiation for oropharyngeal cancer. Br J Radiol 2009;82(980): 675-80.
195. Nguyen NP, Moltz CC, Frank C, et al. Dysphagia severity following chemoradiation and
postoperative radiation for head and neck cancer. Eur J Radiol 2006;59(3): 453-9.
196. Hardon-Villard C. Following head and neck cancer treatment, a new way to identify
patients at risk of dysphagia. Medical News Today 2011, February 28.

125

197. Ackerstaff AH, Balm AJ, Rasch CR, et al. First-year quality of life assessment of an intraarterial (RADPLAT) versus intravenous chemoradiation phase III trial. Head & neck 2009;31(1):
77-84.
198. Cheng SS, Terrell JE, Bradford CR, et al. Variables associated with feeding tube placement
in head and neck cancer. Archives of otolaryngology--head & neck surgery 2006;132(6): 655-61.
199. Ahmed KA, Samant S, Vieira F. Gastrostomy tubes in patients with advanced head and
neck cancer. The Laryngoscope 2005;115(1): 44-7.
200. Riera L, Sandiumenge A, Calvo C, et al. Percutaneous endoscopic gastrostomy in head and
neck cancer patients. ORL; journal for oto-rhino-laryngology and its related specialties
2002;64(1): 32-4.
201. Feng FY, Kim HM, Lyden TH, et al. Intensity-modulated radiotherapy of head and neck
cancer aiming to reduce dysphagia: early dose-effect relationships for the swallowing structures.
International journal of radiation oncology, biology, physics 2007;68(5): 1289-98.
202. Mavroidis P, Laurell G, Kraepelien T, Fernberg JO, Lind BK, Brahme A. Determination
and clinical verification of dose-response parameters for esophageal stricture from head and neck
radiotherapy. Acta oncologica 2003;42(8): 865-81.
203. Beaver ME, Matheny KE, Roberts DB, Myers JN. Predictors of weight loss during radiation
therapy. Otolaryngology--head and neck surgery : official journal of American Academy of
Otolaryngology-Head and Neck Surgery 2001;125(6): 645-8.
204. Okunieff P, Chen Y, Maguire DJ, Huser AK. Molecular markers of radiation-related normal
tissue toxicity. Cancer Metastasis Rev 2008;27(3): 363-74.
205. Okunieff P, Chen Y, Maguire DJ, Huser AK. Molecular markers of radiation-related normal
tissue toxicity. Cancer metastasis reviews 2008;27(3): 363-74.
206. Wilson JA, Carding PN, Patterson JM. Dysphagia after nonsurgical head and neck cancer
treatment: patients' perspectives. Otolaryngology--head and neck surgery : official journal of
American Academy of Otolaryngology-Head and Neck Surgery 2011;145(5): 767-71.
207. Silander E, Nyman J, Bove M, Johansson L, Larsson S, Hammerlid E. Impact of
prophylactic percutaneous endoscopic gastrostomy on malnutrition and quality of life in patients
with head and neck cancer: a randomized study. Head & neck 2012;34(1): 1-9.
208. Magne N, Marcy PY, Foa C, et al. Comparison between nasogastric tube feeding and
percutaneous fluoroscopic gastrostomy in advanced head and neck cancer patients. European
archives of oto-rhino-laryngology : official journal of the European Federation of Oto-RhinoLaryngological Societies 2001;258(2): 89-92.
209. Senft M, Fietkau R, Iro H, Sailer D, Sauer R. The influence of supportive nutritional
therapy via percutaneous endoscopically guided gastrostomy on the quality of life of cancer
patients. Supportive care in cancer : official journal of the Multinational Association of
Supportive Care in Cancer 1993;1(5): 272-5.
126

210. Beeken L, Calman F. A return to "normal eating" after curative treatment for oral cancer.
What are the long-term prospects? Eur J Cancer B Oral Oncol 1994;30B(6): 387-92.
211. Johnston CA, Keane TJ, Prudo SM. Weight loss in patients receiving radical radiation
therapy for head and neck cancer: a prospective study. JPEN. Journal of parenteral and enteral
nutrition 1982;6(5): 399-402.
212. King JML, K. Patient noncompliance with swallowing recommendations: Reports from
speech-language pathologists. Contemporary issues in communication science and disorders
2011;38: 53-60.
213. Low J, Wyles, C., Wilkinson, T., & Sainsbury, R. The effect of compliance on clinical
outcomes for patients with dysphagia on videofluoroscopy. Dysphagia 2001;16: 4-13.
214. Sharp HM. When patients refuse recommendations for dysphagia treatment. Perspectives on
swallowing and swallowing disorders (Dysphagia) 2005;14(3): 3-7.
215. Peck KK, Branski RC, Lazarus C, et al. Cortical activation during swallowing rehabilitation
maneuvers: a functional MRI study of healthy controls. The Laryngoscope 2010;120(11): 21539.
216. Callahan CM, Buchanan NN, Stump TE. Healthcare costs associated with percutaneous
endoscopic gastrostomy among older adults in a defined community. Journal of the American
Geriatrics Society 2001;49(11): 1525-9.
217. Raykher A, Correa L, Russo L, et al. The role of pretreatment percutaneous endoscopic
gastrostomy in facilitating therapy of head and neck cancer and optimizing the body mass index
of the obese patient. JPEN. Journal of parenteral and enteral nutrition 2009;33(4): 404-10.
218. Lawson JD, Gaultney J, Saba N, Grist W, Davis L, Johnstone PA. Percutaneous feeding
tubes in patients with head and neck cancer: rethinking prophylactic placement for patients
undergoing chemoradiation. American journal of otolaryngology 2009;30(4): 244-9.
219. Lee JH, Machtay M, Unger LD, et al. Prophylactic gastrostomy tubes in patients
undergoing intensive irradiation for cancer of the head and neck. Archives of otolaryngology-head & neck surgery 1998;124(8): 871-5.

127

APPENDIX A
Modified Barium Swallow (MBS) Study Protocol Employed at the OLOL-VC to Evaluate
Patients’ Baseline and Post-treatment Swallowing Function

Site: Radiology unit of the OLOL Regional Medical Center
Performed by: Speech Pathologist, assisted by radiologist or a physician‟s assistant and a
radiation technician
Planes assessed: Lateral- to view the oral cavity anteriorly, the soft palate and the nasal cavity
superiorly, the posterior pharyngeal wall and cervical vertebrae posteriorly and
the UES inferiorly.
Anterior-posterior (AP)- to assess symmetry of swallowed bolus/ impairments
Products administered: E-Z-EM‟s Varibar® and E-Z- Paque®
Trials: Thin liquid: 3 ml (x1), 5 ml (x2), 10 ml (x2) and spontaneous 3 ounces
Paste: ½ tspn
Graham cracker: ¼ piece
Nectar- thick, honey-thin and honey-thick liquids: as needed
Procedures & Instructions: Measured liquids and paste: “Take this and swallow it at once”
Spontaneous size thin liquid: “Sip and swallow continuously in one breath”
Graham cracker: “Chew well and swallow”
Postural maneuvers, compensatory strategies and behavioral maneuvers were employed
promptly as deemed necessary.
Vocalize /i/ three times by taking breaths in between to allow recording of vocal fold
motion under fluoroscopy.
Documentation: Report generated. Results and recommendations reviewed with the patient
and/or caregiver
Standardized scales scored: Penetration Aspiration Scale (PAS) and Functional Oral Intake
Scale (FOIS)
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APPENDIX B
Informed Consent Form
STUDY TITLE:

Effects of Behavioral Swallowing Therapy during
Radiation Therapy on Swallowing Physiology, Function,
Quality-of-life and Weight Outcomes Following OrganPreservation Treatments for Oral, Pharyngeal and/or
Laryngeal Cancers

PERFORMANCE SITE (S):

Mary Bird Perkins Cancer Center &
Our Lady of the Lake Regional Medical Center

PRINCIPAL INVESTIGATOR:

Andrew J. McWhorter, MD
7777 Hennessy Blvd., Suite 408
Baton Rouge, Louisiana 70808
United States
Phone: 225-765-5335
24-hour number: 225-202-0155

CO-INVESTIGATORS:

Melda Kunduk, PhD
&
Aneesha Virani, ABD CCC-SLP
7777 Hennessy Blvd., Suite 408
Baton Rouge, Louisiana 70808
United States
Phone: 225-765-5335

You may take home an unsigned copy of this consent form to think about or discuss with family
or friends before making your decision. This consent form may contain words that are not clear
to you. Please ask the co-investigator to explain any words or information that you do not
understand clearly. Once you sign this consent form, you will be enrolled in this study.
PURPOSE OF THE STUDY
The purpose of this research study is to determine if performing swallowing exercises during
radiation therapy with or without chemotherapy will result in reduced aspiration (i.e., choking),
reduced feeding-tube dependence and better swallowing-related quality-of-life at the completion
of cancer treatment. Cancer treatments may result in swallowing problems as side effects and
subsequent feeding-tube dependence. A proactive approach to swallowing therapy is currently
starting to emerge nationwide to offset these undesirable side effects of cancer treatment
modalities. However, there is limited research data to understand specifics of its benefits. Since
you will be undergoing radiation therapy with or without chemotherapy for your cancer
diagnosis, you are eligible to participate in this study.
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DESCRIPTION OF THE STUDY

Length of Study and Number of Participants
This study will be conducted during the entire course of your cancer treatment at the Mary Bird
Perkins Cancer Center. Radiation treatments typically last for five to seven weeks. Sixty
participants will be enrolled in this study.
Procedures
You are eligible to participate in this study based on your nature of cancer and results of the
baseline Modified Barium Swallow Study.
Your speech pathologist will give you a swallowing exercise protocol that you will perform
everyday. Throughout your radiation treatments, your speech pathologist will visit with you at
the Mary Bird Perkins Cancer Center twice per week to provide swallowing therapy either just
before or after your radiation treatment. You will not be required to make an extra visit to the
Mary Bird Perkins Cancer Center. During each visit with the speech pathologist, you will
perform half of your exercises so that she can monitor your progress and identify any problems
with the performance of exercises. She will also be able to answer any swallowing-related
questions you may have. Any swallowing problems that may arise during this period will also be
identified so that they can be managed appropriately and in a timely manner. You will be
provided with log sheets to record exercises that you complete everyday to be returned to the
check-in personnel, the following day when you return for radiation treatment. Each week, your
weight and diet will be recorded. In addition, you will fill out a quality-of-life questionnaire,
which asks twenty questions related to your swallowing.
At the completion of radiation treatment with or without chemotherapy, your radiation
oncologist will refer you for another routine Modified Barium Swallow Study, which will be
performed by your speech pathologist, to identify any problems with the structure and function
of swallowing. Your study-related swallowing therapy will end at this time. However, if you do
suffer any swallowing problems, the speech pathologist will refer you to the Our Lady of the
Lake Regional Medical Center- Voice Center for continuation of swallowing therapy.
To assess the long term effects of swallowing therapy on swallowing function, you will be
requested to fill a quality-of-life questionnaire and a swallowing status questionnaire when you
return to Mary Bird Perkins for your 3 month, 6 month and 12 month follow up appointments.
These questionnaires along with the doctor‟s notes from your consultation visit, will be reviewed
to obtain additional long-term information regarding your swallowing function.
BENEFITS TO SUBJECTS
Performing swallowing exercises during radiation treatments may result in the following
benefits:
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a) Prevention or reduction in swallowing impairments and subsequent lung complications of
aspiration during and following cancer treatments
b) Reduction in feeding-tube dependence during and following cancer treatments
c) Improvement in swallowing-related quality-of-life during and following cancer
treatments
RISKS TO SUBJECTS
There are no known risks of swallowing therapy.
However, when you perform exercises you may run the risk of biting your tongue, straining the
neck or feeling tired.
In addition, filling out the M D Anderson Dysphagia Inventory questionnaire may upset you
because it may make you realize your swallowing-related limitations. You may be referred for
counseling services if you or your doctor indicates a need for the same.
ALTERNATIVES TO PARTICIPATION IN THE STUDY
The alternative is to not participate in this study. In addition, if you develop dysphagia during
cancer treatment, you may be referred for speech pathology services, which are available at the
Our Lady of the Lake Regional Medical Center- Voice Center.
SUBJECT REMOVAL
The co-investigator may stop you from taking part in this study if at any time if it is believed to
be in your best interest; if you do not follow the study procedures; or if the study is stopped. You
could be taken off the study if your health worsens; if another treatment option appears to be
appropriate; or for any other cause which prevents your continuing in the study as per your
radiation oncologist.
SUBJECT’S RIGHT TO REFUSE TO PARTICIPATE OR WITHDRAW
Participation is voluntary. Refusal to participate will involve no penalty or loss of benefits to
which you are otherwise entitled, and you may discontinue participation at any time without
penalty or loss of benefits to which you are otherwise entitled. You may refuse to participate or
withdraw from the study at any time without jeopardizing, in any way, your medical treatment at
this institution in the present or future. Tell the researcher if you are thinking about withdrawing
from the study so that you may do so safely. If you decide not to continue participation in the
study you should seek medical advice for alternatives. Should significant new findings take place
during the course of the research that may relate to your willingness to continue participation,
that information will be provided to you.
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SUBJECT’S RIGHT TO PRIVACY
If the results of the study are published, the privacy of subjects will be protected and they will
not be identified in any way. Your personal information may be disclosed if required by law.
RELEASE OF INFORMATION
Organizations that may inspect and/or copy your study-related medical records for quality
assurance and data analysis include:







Primary investigator and co-investigators listed on page 1 of this consent form and their
staff
Staff at Mary Bird Perkins Cancer Center, Baton Rouge
Institutional Review Board at Our Lady of the Lake Regional Medical Center- Voice
Center, Baton Rouge
Institutional Review Board at Louisiana State University Health Sciences Center, New
Orleans
Institutional Review Board at Louisiana State University, Baton Rouge
The Western Institutional Review Board® (WIRB®)

While every effort will be made to maintain your privacy, absolute confidentiality cannot be
guaranteed. Records will be kept private to the extent allowed by law.
FINANCIAL INFORMATION
The swallowing therapy is part of the study and there is no charge for this. You will not be paid
for your participation in this research study
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SIGNATURES
The study has been discussed with me and all my questions have been answered. Additional
questions regarding the study should be directed to Aneesha Virani at the number listed on page
1 of this consent form. If I have questions about subject‟s rights, or other concerns, I can contact
the Chancellor of the LSU Health Sciences Center New Orleans at (504) 568-4801. I agree with
the terms above, acknowledge I have been given a copy of the consent form, and agree to
participate in this study. I have not waived any of my legal rights by signing this consent form.

_____________________________________
Signature of Subject

________________________
Date

_____________________________________
Signature of Principal Investigator

________________________
Date

_____________________________________
Consent Administered by

________________________
Date

The study subject has indicated to me that the subject is unable to read. I certify that I have read
this consent form to the subject and explained that by completing the signature line above the
subject has agreed to take part.

Signature of Reader

Date

Signature of Witness

Date
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APPENDIX C
Progress Note Employed During Weekly Consultations with Patients in the EX and SW
Treatment Groups
Speech Pathology- Swallowing Therapy Weekly Progress Note
Subjective:
Session # ____________
Diet Recommended from the baseline MBS Study ____________________________
Diet Tolerated as of today ________________________________________________
Number of RAD Completed ____________
Dose of RAD received as of last Radiation Treatment ____________
MDADI Obtained and Reviewed today
Yes/No
Feeding tube placed
Yes [Date] ________/No

Objective:
Weight today ____________
Therapeutic tasks performed in the session today:
1. Swallows ____________ repetitions ____________ sets
2. Masako exercises ____________ repetitions ____________ sets
3. Pharyngeal squeeze exercises ____________ repetitions ____________ sets
4. Shaker exercises Part I: ____________ repetitions ____________ sets
Part II: ____________ repetitions ____________ sets
5. Postural Maneuvers ________________________________________________
6. Behavioral Strategies _______________________________________________
7. Swallow Maneuvers ________________________________________________
8. Home Program Compliance since last session ____________________________

Assessment:

None =1

Minimal=2

Mild=3

Radiation Toxicities
Xerostomia
Mucositis
Soreness/ Pain
Odynophagia
Nausea/Vomiting
Dysgeusia
Trismus
Reduced appetite

Moderate=4

Severe=5

Dysphagia Symptoms
1
1
1
1
1
1
1
1

2
2
2
2
2
2
2
2

3
3
3
3
3
3
3
3

4
4
4
4
4
4
4
4

5
5
5
5
5
5
5
5

Choking with solids
Choking with liquids
Nasal regurgitation
Oral regurgitation
Reflux
Difficulty initiating swallowing
Globus sensation
Foods sticking
Gagging
NPO status
Hoarseness
Wet, gurgly voice

Plan: Next Appointment ____________
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2
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3
3
3
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3
3
3
3
3

4
4
4
4
4
4
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5
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5
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Appendix D
Standardized Assessment Tools
D1: Penetration Aspiration Scale 182
Score

ASPIRATION

PENETRATION

Category

Description

1

Contrast does not enter the airway

2

Contrast enters the airway; remains above vocal folds; no residue

3

Contrast remains above vocal folds; visible residue remains

4

Contrast contacts vocal folds; no residue

5

Contrast contacts vocal folds; visible residue remains

6

Contrast passes glottis; no subglottic residue visible

7

Contrast passes glottis; visible subglottic residue despite patient‟s response

8

Contrast passes glottis; visible subglottic residue; absent patient response

D2: Functional Oral Intake Scale (FOIS) 183

FULL-ORAL

NON-ORAL

Category

Level

Description

1

Nothing by mouth (NPO)

2

Tube dependent with minimal attempts of food or liquid

3

Tube dependent with consistent intake of liquid or food

4

Total oral diet of a single consistency

5

Total oral diet with multiple consistencies but requiring special preparation
or compensations

6

Total oral diet with multiple consistencies without special preparation, but
with specific food limitations

7

Total oral diet with no restriction
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D3: M D Anderson Dysphagia Inventory (MDADI) 184
THE M.D. ANDERSON DYSPHAGIA INVENTORY
VOICE CENTER
This questionnaire asks for your views about your swallowing ability. This information will help us understand how
you feel about swallowing. The following statements have been made by people who have problems with their
swallowing. Some of the statements may apply to you. Please read each statement and circle the response which
best reflects your experience in the past week.
My swallowing ability limits my day-to-day
activities

Strongly Agree

Agree

No opinion

Disagree

Strongly Disagree

E2. I am embarrassed by my eating habits.

Strongly Agree

Agree

No opinion

Disagree

Strongly Disagree

F1. People have difficulty cooking for me.

Strongly Agree

Agree

No opinion

Disagree

Strongly Disagree

P2. Swallowing is more difficult at the end of the
day.

Strongly Agree

Agree

No opinion

Disagree

Strongly Disagree

E7. I do not feel self-conscious when I eat.

Strongly Agree

Agree

No opinion

Disagree

Strongly Disagree

E4. I am upset by my swallowing problem.

Strongly Agree

Agree

No opinion

Disagree

Strongly Disagree

P6. Swallowing takes great effort.

Strongly Agree

Agree

No opinion

Disagree

Strongly Disagree

E5. I do not go out because of my swallowing
problem.

Strongly Agree

Agree

No opinion

Disagree

Strongly Disagree

F5. My swallowing difficulty has caused me to
lose income.

Strongly Agree

Agree

No opinion

Disagree

Strongly Disagree

P7. It takes me longer to eat because of my
swallowing problem.

Strongly Agree

Agree

No opinion

Disagree

Strongly Disagree

P3. People ask me, “Why can‟t you eat that?”

Strongly Agree

Agree

No opinion

Disagree

Strongly Disagree

E3. Other people are irritated by my eating
problem.

Strongly Agree

Agree

No opinion

Disagree

Strongly Disagree

P8. I cough when I try to drink thin liquids.

Strongly Agree

Agree

No opinion

Disagree

Strongly Disagree

F3. My swallowing problems limit my social and
personal life.

Strongly Agree

Agree

No opinion

Disagree

Strongly Disagree

F2. I feel free to go out to eat with my friends,
neighbors, and relatives.

Strongly Agree

Agree

No opinion

Disagree

Strongly Disagree

P5. I limit my food intake because of my
swallowing difficulty.

Strongly Agree

Agree

No opinion

Disagree

Strongly Disagree

P1. I cannot maintain my weight because of my
swallowing problem.

Strongly Agree

Agree

No opinion

Disagree

Strongly Disagree

E6. I have low self-esteem because of my
swallowing problem.

Strongly Agree

Agree

No opinion

Disagree

Strongly Disagree

P4. I feel that I am swallowing a huge amount of
food.

Strongly Agree

Agree

No opinion

Disagree

Strongly Disagree

F4. I feel excluded because of my eating habits.

Strongly Agree

Agree

No opinion

Disagree

Strongly Disagree

Thank you for completing this questionnaire!
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APPENDIX E
Cost of Feeding Through a PEG Tube
Callahan, Buchanan and Stump (2001) have reported highly conservative costs of PEG
tubes in their cohort of 105 patients with various diagnoses. 216 Their investigation suggested that
the total cost of feeding/ patient/ year was $ 31,832. For the purposes of this study, an estimation
of the basic costs of a PEG tube for 3 months can be made from the cost-guidelines provided by
Callahan et al., (2001): cost of the initial placement procedure $ 2200 (including hospital and
physician‟s charges); cost of enteral formula per day $ 8.52; cost of one physician visit for any
PEG tube related problems $ 56.95 and cost of one minor PEG tube related complication $ 288.
Costs of fluoroscopic studies that may be required prior to or following PEG placement, PEG
replacement costs, costs of major complications and cost of labor to feed patients are being
ignored for the purposes of this study‟s argument. Additionally, a higher cost of enteral feeding
due to higher nutritional needs of patients under active treatment is also being ignored for this
explanation. With the included costs, 100 days of feeding via PEG, amounts to $ 3,396.95 per
patient. So, the cost of feeding 8 additional PEG tube dependent patients in the SW group as
compared to 4 patients in the EX group (at 3 months post-treatment), would sum up to $
27,175.6. If these patients are unable to eliminate their PEG tubes at 6 months, then the cost will
rise to $ 53,983.6 which includes an additional cost of a major PEG tube related complication.
The current study‟s inclusion criteria was that patients should not have received prophylactic
PEG tubes, in order to determine the need for alternative feeding as a true result of RT toxicities.
It is not uncommon for PEG tubes to be placed prophylactically in patients who are to undergo
RT/C for HNC, and in fact this is the new standard of practice at some centers, sometimes 100%
of the times.

45, 217-219

During the timeline of this current study, 3 patients underwent PEG tube

placements prophylactically and hence were not recruited in this study. Cost of PEG tubes for
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these additional 3 patients for 10 weeks (7 weeks of RT + approximately 3 weeks of post-RT
healing) would sum up to $ 8,912.85, increasing the originally estimated PEG feeding cost to $
62,896.45 (8 patients from the SW group + 3 prophylactic tube feeders). If these patients are
unable to eliminate dependence at 3 months, a further significant increase in this cost would
occur. Not to mention, the cost of potentially losing swallowing ability from underuse would be
irreparable. Again, this study estimates a very conservative cost of feeding since the true costs of
PEG feedings in this group of patients were not directly estimated, as this was not the aim of the
study.
This conservative cost is higher than the salary of a part-time/ full-time SLP at a
Radiation Oncology Center, such as the MBPCC. Considering that the MBPCC does not have an
on-site SLP, such a position is highly recommended. We hypothesize that this is justifiable,
given the study‟s findings of improved physiological, functional, QOL and weight outcomes and
also in terms of reducing healthcare costs to patients. During this study period, the study
coordinators experienced the benefits of having an on-site SLP at this center allowing: weekly
monitoring of patients‟ swallowing abilities and making appropriate dietary, exercise and
compensatory strategy recommendations; eliminating the need for patients to travel to outpatient
centers for therapy, while being occupied with daily RT appointments; clarifying patients‟
questions, concerns and myths regarding swallowing in the presence of toxicities, and
encouraging patients to continue to swallow and eat orally despite expected RT toxicities.
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